U.S. patent application number 15/225271 was filed with the patent office on 2017-06-15 for substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals.
The applicant listed for this patent is SANOFI. Invention is credited to Petra ARNDT, Werngard CZECHTIZKY, Heinz GOEGELEIN, Volker KRAFT, Nils RACKELMANN, Olaf RITZELER, John WESTON, Klaus WIRTH.
Application Number | 20170166548 15/225271 |
Document ID | / |
Family ID | 47901924 |
Filed Date | 2017-06-15 |
United States Patent
Application |
20170166548 |
Kind Code |
A1 |
CZECHTIZKY; Werngard ; et
al. |
June 15, 2017 |
Substituted chroman-6-yloxy-cycloalkanes and their use as
pharmaceuticals
Abstract
The present invention relates to substituted
chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to
R4, p and q are as defined in the claims. The compounds of the
formula (I) are inhibitors of the sodium-calcium exchanger (NCX),
especially of the sodium-calcium exchanger of subtype 1 (NCX1), and
are suitable for the treatment of diverse disorders in which
intracellular calcium homeostasis is disturbed, such as
arrhythmias, heart failure and stroke. The invention furthermore
relates to processes for the preparation of the compounds of the
formula (I), their use in pharmaceuticals, and pharmaceutical
compositions comprising them. ##STR00001##
Inventors: |
CZECHTIZKY; Werngard;
(Frankfurt am Main, DE) ; WESTON; John; (Frankfurt
am Main, DE) ; RACKELMANN; Nils; (Frankfurt am Main,
DE) ; KRAFT; Volker; (Frankfurt am Main, DE) ;
ARNDT; Petra; (Frankfurt am Main, DE) ; WIRTH;
Klaus; (Frankfurt am Main, DE) ; GOEGELEIN;
Heinz; (Frankfurt am Main, DE) ; RITZELER; Olaf;
(Frankfurt am Main, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SANOFI |
Paris |
|
FR |
|
|
Family ID: |
47901924 |
Appl. No.: |
15/225271 |
Filed: |
March 8, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14772375 |
Sep 2, 2015 |
9440941 |
|
|
PCT/EP2014/054417 |
Mar 7, 2014 |
|
|
|
15225271 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 9/12 20180101; C07D
409/12 20130101; C07D 417/14 20130101; C07D 407/14 20130101; A61P
9/00 20180101; C07F 9/65522 20130101; C07D 417/12 20130101; C07D
413/12 20130101; C07D 311/60 20130101; A61P 13/12 20180101; A61P
43/00 20180101; A61P 25/28 20180101; A61P 9/10 20180101; A61P 9/06
20180101; A61P 9/04 20180101; C07D 405/12 20130101; C07D 407/12
20130101 |
International
Class: |
C07D 311/60 20060101
C07D311/60; C07D 413/12 20060101 C07D413/12; C07D 417/12 20060101
C07D417/12; C07D 407/12 20060101 C07D407/12; C07D 405/12 20060101
C07D405/12; C07D 409/12 20060101 C07D409/12 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 8, 2013 |
EP |
13305263.9 |
Claims
1. A compound of structure (IVb), ##STR00046## in any of its
stereoisomeric forms or a mixture of stereoisomeric forms in any
ratio, or a pharmaceutically acceptable salt thereof, wherein Ar is
phenyl which is unsubstituted or substituted by one or more
identical or different substituents R.sub.0; R.sub.0 is selected
from the series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O--, and two
groups R.sub.0 bonded to adjacent ring carbon atoms in Ar, together
with the carbon atoms carrying them, can form a 5-membered to
7-membered mono-unsaturated ring which comprises 0, 1 or 2
identical or different ring heteroatoms selected from the series
consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl; R.sub.1 is hydrogen or one or more
identical or different substituents selected from the series
consisting of fluorine and (C.sub.1-C.sub.4)-alkyl; R.sub.3 is
selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein (C.sub.1-C.sub.6)-alkyl is
unsubstituted or substituted by one or two identical or different
substituents selected from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl, phenyl, HO-- and
(C.sub.1-C.sub.4)-alkyl-O--; R.sub.4 is hydrogen or one or more
identical or different substituents selected from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--; wherein all phenyl groups are
unsubstituted or substituted by one or more identical or different
substituents selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--, unless
specified otherwise; wherein all cycloalkyl bicycloalkyl groups,
independently of any other substituents which can be present on a
cycloalkyl group can be substituted by one or more identical or
different substituents selected from the series consisting of
fluorine and (C.sub.1-C.sub.4)-alkyl; wherein all alkyl groups,
independently of any other substituents which can be present on an
alkyl group, can be substituted by one or more fluorine
substituents.
2. A compound of the formula (IVb) according to claim 1 in any of
its stereoisomeric forms or a mixture of stereoisomeric forms in
any ratio, or a pharmaceutically acceptable salt thereof, wherein
Ar is phenyl which is unsubstituted or substituted by one or more
identical or different substituents R.sub.0; R.sub.0 is selected
from the series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O; R.sub.1 is
hydrogen or one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl; R.sub.3 is selected from the series
consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl, wherein
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
two identical or different substituents selected from the series
consisting of (C.sub.3-C.sub.7)-cycloalkyl and phenyl; R.sub.4 is
hydrogen or one or more identical or different substituents
selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--; wherein
all phenyl groups are unsubstituted or substituted by one or more
identical or different substituents selected from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise; wherein
all cycloalkyl groups, independently of any other substituents
which can be present on a cycloalkyl group, can be substituted by
one or more identical or different substituents selected from the
series consisting of fluorine and (C.sub.1-C.sub.4)-alkyl; wherein
all alkyl groups, independently of any other substituents which can
be present on an alkyl group, can be substituted by one or more
fluorine substituents.
3. A compound of the formula (IVb) according to claim 1 in any of
its stereoisomeric forms or a mixture of stereoisomeric forms in
any ratio, or a pharmaceutically acceptable salt thereof, wherein
Ar is phenyl which is unsubstituted or substituted by one or more
identical or different substituents R.sub.0; R.sub.0 is selected
from the series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O--; R.sub.1
is hydrogen or one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl; R.sub.3 is selected from the series
consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl, wherein
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
two identical or different substituents selected from the series
consisting of (C.sub.3-C.sub.7)-cycloalkyl and phenyl; R.sub.4 is
hydrogen or one or more identical or different substituents
selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--; wherein
all phenyl groups are unsubstituted or substituted by one or more
identical or different substituents selected from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise; wherein
all cycloalkyl groups, independently of any other substituents
which can be present on a cycloalkyl group, can be substituted by
one or more identical or different substituents selected from the
series consisting of fluorine and (C.sub.1-C.sub.4)-alkyl; wherein
all alkyl groups, independently of any other substituents which can
be present on an alkyl group, can be substituted by one or more
fluorine substituents.
4. A compound of the formula (IVb) according to claim 1 in any of
its stereoisomeric forms or a mixture of stereoisomeric forms in
any ratio, or a pharmaceutically acceptable salt thereof, wherein
Ar is phenyl which is unsubstituted or substituted by one or more
identical or different substituents R.sub.0; R.sub.0 is selected
from the series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.1-C.sub.6)-alkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-O--; R.sub.1 is hydrogen or one or
more identical or different substituents selected from the series
consisting of fluorine and (C.sub.1-C.sub.4)-alkyl; R.sub.3 is
hydrogen; R.sub.4 is hydrogen or one or more identical or different
substituents selected from the series consisting of halogen and
(C.sub.1-C.sub.4)-alkyl; wherein all cycloalkyl groups,
independently of any other substituents which can be present on a
cycloalkyl group, can be substituted by one or more identical or
different substituents selected from the series consisting of
fluorine and (C.sub.1-C.sub.4)-alkyl; wherein all alkyl groups,
independently of any other substituents which can be present on an
alkyl group, can be substituted by one or more fluorine
substituents.
Description
[0001] The present invention relates to substituted
chroman-6-yloxy-cycloalkanes of the formula I,
##STR00002##
in which Ar, R1 to R4, p and q are as defined below. The compounds
of the formula I are inhibitors of the sodium-calcium exchanger
(NCX), especially of the sodium-calcium exchanger of subtype 1
(NCX1), and are suitable for the treatment of diverse disorders in
which intracellular calcium homeostasis is disturbed, such as
arrhythmias, heart failure and stroke. The invention furthermore
relates to processes for the preparation of the compounds of the
formula I, their use as pharmaceuticals, and pharmaceutical
compositions comprising them.
[0002] Over the last decade major pharmacologic advances have been
realized in the management of heart failure (HF), or congestive
heart failure (CHF). Beta-blockers and inhibitors of the
renin-angiotensin-aldosterone system have been found to have a
favorable effect in CHF with regard to mortality and improvement of
symptoms (K. Dickstein et al., Eur. J. Heart Fail. 10 (2008):
933-989). Nevertheless, morbidity and mortality have remained
unacceptably high. The number of patients with CHF, and in
particular more severe forms of CHF, is even growing, in part
paradoxically because of the success of these treatment approaches.
Thus, there is still a need for agents that can help improve CHF
outcome and enhance quality of life. Blockers of the sodium-calcium
exchanger (NCX), a transport protein which is involved in the
regulation of cellular calcium and sodium levels, have the
potential to improve the prognosis of CHF and quality of life.
[0003] The function of the NCX is to extrude calcium in
cardiomyocytes and other cell types such as neurons. In CHF, the
NCX was shown to be upregulated, thus unloading the cell from
calcium and further decreasing myocardial contractility (M. Flesch
et al., Circulation 94 (1996): 992-1002; G. Hasenfuss et al.,
Circulation 99 (1999): 641-648). Pump failure in CHF is not only
due to irreversible structural changes and loss of myocardium, but
also due to adverse functional changes including a disturbance of
the intracellular calcium homeostasis. The latter can be treated by
inhibition of the NCX. Three subtypes of the NCX have been
described. In the heart, predominantly subtype 1 is expressed.
[0004] Through the NCX, calcium is exchanged for sodium, and
extracellular sodium is the driving force for the exchanger. The
stoichiometry of the exchanger is that three sodium ions enter the
cell for the extrusion of one calcium ion. This stoichiometry
causes a positive inward current which is depolarizing in nature.
The depolarizing current, if of a sufficient size, could induce
afterdepolarizations of the ventricular and atrial action
potential. Afterdepolarizations are oscillations of the electric
membrane potential and can occur during (early
afterdepolarizations, EADs) or after (delayed afterdepolarizations,
DADs) the cardiac action potential. The occurrence of EADs is
associated with a prolonged ventricular action potential (visible
as prolonged QT interval in the electrocardiogram (ECG)), which is
a common feature of the failing heart. Afterdepolarizations are
believed to be the major trigger of cardiac arrhythmias, which
therefore are also called triggered activity (D. M. Bers et al.,
Ann. N. Y. Acad. Sci. 1080 (2006): 165-177; K. R. Sipido et al.,
Pflugers Arch. 430 (1995): 871-878; A. O. Verkerk et al.,
Circulation 104 (2001): 2728-2733; C. Pott et al., Current Drug
Targets 12 (2011): 737-747; G. Antoons et al., Pharmacol. Ther. 134
(2012): 26-42). The premature beats arising from the NCX-induced
depolarizing currents can cause more complex and irreversible
arrhythmias such as episodes of tachycardia, ventricular flutter or
ventricular fibrillation.
[0005] Patients with pump failure, or heart failure, typically
suffer from arrhythmias and arrhythmic death. About 50% of the
cardiac mortality in CHF is due to arrhythmic death. NCX blockade
is therefore a means of improving pump failure and associated
symptoms as well as of reducing arrhythmic death. Current positive
inotropic drugs are associated with proarrhythmic effects that
either increase mortality, such as in the case of phosphodiesterase
inhibitors, or annihilate the positive effects achieved by an
improvement of pump failure by the positive inotropic effect (J. T.
Parissis et al., Curr. Opin. Crit. Care 16 (2010): 432-441). On the
other hand, a number of clinically useful antiarrhythmic drugs have
a negative inotropic effect on the heart worsening the symptoms of
heart failure. NCX blockers are therapeutically unique in that they
can address the two major problems of CHF, pump failure and
arrhythmias.
[0006] NCX blockade is particularly interesting for advanced stages
of CHF, like NYHA Classes III and IV according to the New York
Heart Association Functional Classification of heart failure, in
which the therapeutic options, i.e. beta-blockers, inhibitors of
the renin angiotensin-aldosterone system, diuretics and
vasodilators, already are fully exploited. Elderly patients
progressing to end-stage HF present a new emerging population. In
this late stage a vasodilator effect is no more desirable in a
considerable part of the patients because blood pressure is already
lowered as a consequence of pump failure. Phosphodiesterase
inhibitors as positive inotropic drugs not only suffer from the
drawback of being proarrhythmic, but also from a vasodilator
effect.
[0007] Atrial fibrillation (AF) is the most frequent arrhythmia. AF
affects about 6.8 million patients in the US and the European
Union, and its prevalence is strongly rising because of the aging
of the population and of the successful treatment of myocardial
infarction, coronary artery disease and congestive heart failure.
AF causes about 25% of all strokes, and increases mortality. Also
in AF, upregulation of the NCX has been demonstrated (U. Schotten
et al., Cardiovasc. Res. 53 (2002): 192-201). Upregulation of the
NCX can be involved in the induction of AF by the arrhythmogenic
activity of the NCX and in its maintenance, and hence NCX blockers
have therapeutically favorable effects in the therapy and
prevention of AF. Since AF is an increasing disease in the aging
population and is frequently associated with heart failure in up to
about 45% of patients (I. Savelieva et al., Europace 5 Suppl 1
(2004): S5-S19), NCX blockers would be particularly favorable in
patients with AF and CHF.
[0008] Since NCX blockers also exert a positive inotropic effect in
the atria, they may be particularly favorable in diastolic heart
failure where ventricular filling is the major problem as a
consequence of ventricular stiffening. A more vigorous atrial
contraction would improve ventricular filling in diastolic heart
failure.
[0009] Since a reduced cardiac output has deleterious effects on
the perfusion of organs such as the kidney, brain and heart,
inhibition of the NCX, which increases the contractility of the
heart, is able to improve perfusion of the brain, heart and kidney
for a therapy or prevention of stroke, dementia and Alzheimer's
disease, renal failure and cardiac ischemia. Since the NCX is also
involved in salt sensitive hypertension, its inhibition is also
suited for the treatment of hypertension.
[0010] Inhibitors of the NCX are also suited for the therapy and
prevention of life threatening conditions in which inotropic
support is required to maintain a sufficient level of blood supply.
This includes all forms of shock, hemodynamic shock, cardiogenic
shock and septic shock. Inhibitors of the NCX are particularly
suited to treat these conditions because they are neutral on heart
rate and lack the proarrhythmic or vasodilator or vasoconstrictor
properties of other inotropic drugs.
[0011] In stroke, NCX blockers have the potential of improving the
outcome since in neuronal hypoxia, as occurs in stroke, the NCX
reverses its transport direction to reverse mode, and loads the
cells with calcium leading to a calcium overload. This leads to
accelerated cell death due to excessive intracellular calcium
concentrations. Moreover, a low cardiac output can lead to brain
ischemia favoring stroke. NCX blockers will increase cardiac output
and raise brain perfusion. Hence, NCX blockers have a potential in
the therapy and prevention of stroke (T. Matsuda et al., J.
Pharmacol. Exp. Ther. 298 (2001): 249-256).
[0012] Certain compounds capable of inhibiting the NCX have already
been described, e.g. in EP 0978506, JP 2008/189592, WO 2004/000813,
WO 2004/063191, WO 03/006452, WO 02/32883, WO 97/09306. However,
there still is a need for further compounds which inhibit the NCX
and are suitable for use as pharmaceuticals in the treatment of the
mentioned disease states. It has now been found that the compounds
of the formula I are excellent inhibitors of the sodium-calcium
exchanger (NCX), especially of the sodium-calcium exchanger of
subtype 1 (NCX1), and have a favorable property profile for such
use.
[0013] Thus, a subject of the present invention are the compounds
of the formula I, in any of their stereoisomeric forms and mixtures
of stereoisomeric forms in any ratio, and the pharmaceutically
acceptable salts thereof,
##STR00003##
[0014] wherein
[0015] Ar is phenyl which is unsubstituted or substituted by one or
more identical or different substituents R0;
[0016] R0 is selected from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O--, and two
groups R0 bonded to adjacent ring carbon atoms in Ar, together with
the carbon atoms carrying them, can form a 5-membered to 7-membered
mono-unsaturated ring which comprises 0, 1 or 2 identical or
different ring heteroatoms selected from the series consisting of
nitrogen, oxygen and sulfur, and which is unsubstituted or
substituted by one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0017] R1 is hydrogen or one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0018] R2 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, phenyl-C(O)--O--,
Het1-C(O)--O--, R5-N(R6)-, R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)-,
R9-N(R10)-C(O)--N(R8)- and R5-N(R6)-C(O)--, wherein
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
more identical or different substituents R20;
[0019] R3 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein (C.sub.1-C.sub.6)-alkyl is
unsubstituted or substituted by one or two identical or different
substituents selected from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl, phenyl, HO-- and
(C.sub.1-C.sub.4)-alkyl-O--;
[0020] or the groups R2 and R3 together are oxo;
[0021] R4 is hydrogen or one or more identical or different
substituents selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--;
[0022] R5 and R6 are independently of one another selected from the
series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, phenyl, Het1 and Het2, wherein
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
more identical or different substituents R20, and
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl and
Het2 all are unsubstituted or substituted by one or more identical
or different substituents R21, and phenyl and Het1 all are
unsubstituted or substituted by one or more identical or different
substituents R22,
[0023] or the groups R5 and R6, together with the nitrogen atom
carrying them, form a 4-membered to 7-membered, monocyclic,
saturated or partially unsaturated heterocycle which, in addition
to the nitrogen atom carrying R5 and R6, comprises 0 or 1 further
ring heteroatom selected from the series consisting of nitrogen,
oxygen and sulfur, and which is unsubstituted or substituted by one
or more identical or different substituents R21;
[0024] R7 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, phenyl, Het1
and Het2, wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted or
substituted by one or more identical or different substituents R20,
and (C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and phenyl and Het1 all are unsubstituted or substituted by one or
more identical or different substituents R22;
[0025] R8 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.4)-alkyl;
[0026] R9 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-;
[0027] R10 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-;
[0028] R20 is selected from the series consisting of R24, fluorine,
HO--, oxo, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, R30-C(O)--O--, R30-NH--C(O)--O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
(C.sub.3-C.sub.7)-cycloalkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--;
[0029] R21 is selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-, R24, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
(C.sub.3-C.sub.7)-cycloalkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--;
[0030] R22 is selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
(C.sub.3-C.sub.7)-cycloalkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, R33-O--C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, NC--, R33-C(O)--,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--;
[0031] R24 is a 3-membered to 10-membered, monocyclic or bicyclic
ring which is saturated, partially unsaturated or aromatic and
comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms
selected from the series consisting of nitrogen, oxygen and sulfur,
and which is unsubstituted or substituted by one or more identical
or different substituents R22;
[0032] R30 and R33 are independently of one another selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-;
[0033] R31 and R32 are independently of one another selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-,
[0034] or the groups R31 and R32, together with the nitrogen atom
carrying them, form a 4-membered to 7-membered, monocyclic
saturated heterocycle which, in addition to the nitrogen atom
carrying R31 and R32, comprises 0 or 1 further ring heteroatom
selected from the series consisting of nitrogen, oxygen and sulfur,
and which is unsubstituted or substituted by one or more identical
or different substituents selected from the series consisting of
fluorine and (C.sub.1-C.sub.4)-alkyl;
[0035] R34 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-;
[0036] Het1 is a 5-membered or 6-membered, monocyclic, aromatic
heterocycle which comprises 1, 2 or 3 identical or different ring
heteroatoms selected from the series consisting of nitrogen, oxygen
and sulfur, and which is unsubstituted or substituted by one or
more identical or different substituents selected from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise;
[0037] Het2 is a 4-membered to 10-membered, monocyclic or bicyclic,
saturated or partially unsaturated heterocycle which comprises 1 or
2 identical or different ring heteroatoms selected from the series
consisting of nitrogen, oxygen and sulfur;
[0038] n is selected from the series consisting of 0, 1 and 2,
wherein all numbers n are independent of one another;
[0039] p and q are independently of one another selected from the
series consisting of 0 and 1;
[0040] wherein all phenyl groups are unsubstituted or substituted
by one or more identical or different substituents selected from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise;
[0041] wherein all cycloalkyl and bicycloalkyl groups,
independently of any other substituents which can be present on a
cycloalkyl or bicycloalkyl group, can be substituted by one or more
identical or different substituents selected from the series
consisting of fluorine and (C.sub.1-C.sub.4)-alkyl;
[0042] wherein all alkyl groups, independently of any other
substituents which can be present on an alkyl group, can be
substituted by one or more fluorine substituents.
[0043] If the group R1 is hydrogen, the carbon atoms of the
cycloalkane ring in the compounds of the formula I and all other
compounds in which R1 occurs, carry hydrogen atoms only, apart from
the groups R2 and R3 and the oxygen atom linking the cycloalkane
ring to the chroman ring. Groups R1 in the compounds of the formula
I and all other compounds in which R1 occurs, which are different
from hydrogen, i.e. fluorine and (C.sub.1-C.sub.4)-alkyl
substituents representing R1, can be bonded to any of the ring
carbon atoms of the cycloalkane ring depicted in formula I which
has a free binding site, i.e. to any ring carbon atom of the
cycloalkane ring except for the ring carbon atom carrying the
groups R2 and R3, as is indicated by the bond originating at R1
which is not directed to a specific carbon atom. Likewise, if the
group R4 is hydrogen, the chroman ring in the compounds of the
formula I and all other compounds in which R4 occurs, carries
hydrogen atoms only, apart from the group Ar and the oxygen atom
linking the chroman ring to the cycloalkane ring. Groups R4 in the
compounds of the formula I and all other compounds in which R4
occurs, which are different from hydrogen, i.e. halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--
substituents representing R4, can be bonded to any of the carbon
atoms of the chroman ring depicted in formula I which have a free
binding site, i.e. to the carbon atoms in ring positions 2, 3, 4,
5, 7 and 8 of the chroman ring as identified in formula I', as is
indicated by the bond originating at R4 which is not directed to a
specific carbon atom of the chroman ring.
##STR00004##
[0044] In all free binding sites of the carbon atoms in ring
positions 2, 3, 4, 5, 7 and 8 of the chroman ring which are not
occupied by groups R4 different from hydrogen, as well as in all
free binding sites of the cycloalkane ring which are not occupied
by groups R1 different from hydrogen, hydrogen atoms are present.
I.e., if in a compound of the formula I no group R4 is present
which is different from hydrogen, the carbon atoms in ring
positions 2, 5, 7 and 8 of the chroman ring carry one hydrogen
atom, and the carbon atoms in ring positions 3 and 4 of the chroman
ring carry two hydrogen atoms. If in a compound of the formula I no
group R1 is present which is different from hydrogen, the ring
carbon atom of the cycloalkane ring which carries the oxygen atom
linked to the chroman ring, carries one hydrogen atom, and the
other ring carbon atoms apart from the atom carrying R2 and R3
carry two hydrogen atoms. Compounds of the formula I in which no
group R4 and/or no group R1 is present which is different from
hydrogen, may alternatively be represented by a modified formula I
in which R4 and/or R1 and the bond originating at them are omitted.
If substituents R4 and/or R1 are present, i.e. atoms or groups
representing R4 and/or R1 which are different from hydrogen, one or
more of the said hydrogen atoms are replaced by the
substituents.
[0045] If structural elements such as groups, substituents or
numbers, for example, can occur several times in the compounds of
the formula I, they are all independent of each other and can in
each case have any of the indicated meanings, and they can in each
case be identical to or different from any other such element. In a
dialkylamino group, for example, the alkyl groups can be identical
or different.
[0046] Alkyl groups, i.e. saturated hydrocarbon residues, can be
linear (straight-chain) or branched. This also applies if these
groups are substituted or are part of another group, for example an
alkyl-O-- group (alkyloxy group, alkoxy group) or an HO-substituted
alkyl group (HO-alkyl-, hydroxyalkyl group). Depending on the
respective definition, the number of carbon atoms in an alkyl group
can be 1, 2, 3, 4, 5 or 6, or 1, 2, 3 or 4, or 1, 2 or 3, or 1 or
2, or 1. Examples of alkyl are methyl, ethyl, propyl including
n-propyl and isopropyl, butyl including n-butyl, sec-butyl,
isobutyl and tert-butyl, pentyl including n-pentyl, 1-methylbutyl,
isopentyl, neopentyl and tert-pentyl, and hexyl including n-hexyl,
3,3-dimethylbutyl and isohexyl. Examples of alkyl-O-- groups are
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy,
tert-butoxy, n-pentoxy. Examples of alkyl-S(O).sub.n-- are
methylsulfanyl- (CH.sub.3--S--), methanesulfinyl-
(CH.sub.3--S(O)--), methanesulfonyl (CH.sub.3--S(O).sub.2--),
ethylsulfanyl-(CH.sub.3--CH.sub.2--S--), ethanesulfinyl-
(CH.sub.3--CH.sub.2--S(O)--), ethanesulfonyl
(CH.sub.3--CH.sub.2--S(O).sub.2--), 1-methylethylsulfanyl-
((CH.sub.3).sub.2CH--S--), 1-methylethanesulfinyl-
((CH.sub.3).sub.2CH--S(O)--), 1-methylethanesulfonyl
((CH.sub.3).sub.2CH--S(O).sub.2--). In one embodiment of the
invention, the number n is selected from the series consisting of 0
and 2, wherein all numbers n are independent of each other and can
be identical or different. In another embodiment the number n in
any of its occurrences, independent of its meaning in other
occurrences, is 0. In another embodiment the number n in any of its
occurrences, independent of its meaning in other occurrences, is
2.
[0047] A substituted alkyl group can be substituted in any
positions, provided that the respective compound is sufficiently
stable and is suitable as a pharmaceutical active compound. The
prerequisite that a specific group and a compound of the formula I
are sufficiently stable and suitable as a pharmaceutical active
compound, applies in general with respect to the definitions of all
groups in the compounds of the formula I. As examples of
substituted alkyl groups, specifically of
HO--(C.sub.1-C.sub.4)-alkyl- groups, for example, hydroxymethyl,
1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl,
3-hydroxypropyl, 1-hydroxy-1-methylethyl, 2-hydroxy-1-methylethyl,
1-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl or
2-hydroxy-1-methylpropyl may be mentioned.
[0048] Independently of any other substituents which can be present
on an alkyl group, and unless specified otherwise, alkyl groups can
be substituted by one or more fluorine substituents, for example by
1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 fluorine substituents, or by 1,
2, 3, 4 or 5 fluorine substituents, or by 1, 2 or 3 fluorine
substituents, which can be located in any positions. I.e.,
independently of any other substituents which can be present on an
alkyl group, an alkyl group can be unsubstituted by fluorine
substituents, i.e. not carry fluorine substituents, or substituted
by fluorine substituents, wherein all alkyl groups in the compounds
of the formula I are independent of one another with regard to the
optional substitution by fluorine substituents. For example, in a
fluoro-substituted alkyl group one or more methyl groups can carry
three fluorine substituents each and be present as trifluoromethyl
groups, and/or one or more methylene groups (CH.sub.2) can carry
two fluorine substituents each and be present as difluoromethylene
groups. The explanations with respect to the substitution of a
group by fluorine also apply if the group additionally carries
other substituents and/or is part of another group, for example of
an alkyl-O-- group. Examples of fluoro-substituted alkyl groups are
trifluoromethyl, 2-fluoroethyl, 1-fluoroethyl, 1,1-difluoroethyl,
2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl,
2,2,3,3,3-pentafluoropropyl, 4,4,4-trifluorobutyl and
heptafluoroisopropyl. Examples of fluoro-substituted alkyl-O--
groups are trifluoromethoxy, 2,2,2-trifluoroethoxy,
pentafluoroethoxy and 3,3,3-trifluoropropoxy. Examples of
fluoro-substituted alkyl-S(O).sub.n-- groups are
trifluoromethylsulfanyl- (CF.sub.3--S--),
trifluoromethanesulfinyl-(CF.sub.3--S(O)--) and
trifluoromethanesulfonyl (CF.sub.3--S(O).sub.2--). With respect to
all groups or substituents in the compounds of the formula I which
can be an alkyl group which can generally contain one or more
fluorine substituents, as an example of groups or substituents
containing fluorine-substituted alkyl which may be included in the
definition of the group or substituent, the group CF.sub.3
(trifluoromethyl), or respective groups such as CF.sub.3--O-- or
CF.sub.3--S--, may be mentioned.
[0049] The above explanations with respect to alkyl groups apply
correspondingly to alkyl groups which in the definition of a group
in the compounds of the formula I are bonded to two adjacent
groups, or linked to two groups, and may be regarded as divalent
alkyl groups (alkanediyl groups), like in the case of the alkyl
part of a substituted alkyl group. Thus, such groups can also be
linear or branched, the bonds to the adjacent groups can be located
in any positions and can start from the same carbon atom or from
different carbon atoms, and they can be unsubstituted or
substituted by fluorine substituents independently of any other
substituents. Examples of such divalent alkyl groups are
--CH.sub.2--, --CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--, --CH(CH.sub.3)--,
--C(CH.sub.3).sub.2--, --CH(CH.sub.3)--CH--,
--CH.sub.2--CH(CH.sub.3)--, --C(CH.sub.3).sub.2CH.sub.2--,
--CH.sub.2--C(CH.sub.3).sub.2--. Examples of fluoro-substituted
alkanediyl groups, which can contain 1, 2, 3, 4, 5 or 6 fluorine
substituents, for example, are --CHF--, --CF.sub.2--,
--CF.sub.2--CH.sub.2--, --CH.sub.2--CF.sub.2--,
--CF.sub.2--CF.sub.2--, --CF(CH)--, --C(CF.sub.3).sub.2--,
--C(CH.sub.3).sub.2--CF.sub.2--,
--CF.sub.2--C(CH.sub.3).sub.2--.
[0050] The above explanations with respect to alkyl groups apply
correspondingly to unsaturated hydrocarbon residues, i.e. alkenyl
groups, which in one embodiment of the invention contain one double
bond. Thus, for example, alkenyl groups can likewise be linear or
branched. Double bonds can be present in any positions. The number
of carbon atoms in an alkenyl group can be 2, 3, 4, 5 or 6, or 2,
3, 4 or 5, or 3, 4 or 5, for example. Examples of alkenyl are
ethenyl (vinyl), prop-1-enyl, prop-2-enyl (allyl), but-2-enyl,
but-3-enyl, 2-methylprop-2-enyl, 3-methylbut-2-enyl, hex-3-enyl,
hex-4-enyl, 4-methylpent-3-enyl. In one embodiment of the
invention, an alkenyl group contains at least three carbon atoms
and is bonded to the remainder of the molecule via a carbon atom
which is not part of a double bond.
[0051] The number of ring carbon atoms in a
(C.sub.3-C.sub.7)-cycloalkyl group can be 3, 4, 5, 6 or 7. Examples
of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl
and cycloheptyl. The number of ring carbon atoms in a
(C.sub.6-C.sub.10)-bicycloalkyl group can be 6, 7, 8, 9 or 10. The
two cycles in a bicycloalkyl group can have one, two or more ring
carbon atoms in common and can be fused or form a bridged bicycle
or a spirocycle. Examples of bicycloalkyl are bicyclo[2.1.1]hexyl,
bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl,
bicyclo[3.2.1]octyl, bicyclo[3.2.2]nonyl and bicyclo[4.4.0]decyl.
Bicycloalkyl groups can be bonded via any ring carbon atom.
Independently of any other substituents which can be present on a
cycloalkyl group or bicycloalkyl group, and unless specified
otherwise, cycloalkyl groups and bicycloalkyl groups can be
substituted by one or more (C.sub.1-C.sub.4)-alkyl substituents,
for example by 1, 2, 3 or 4 identical or different
(C.sub.1-C.sub.4)-alkyl substituents, for example by methyl groups,
which can be located in any positions. I.e., independently of any
other substituents which can be present on a cycloalkyl group or
bicycloalkyl group, cycloalkyl groups and bicycloalkyl groups can
be unsubstituted by (C.sub.1-C.sub.4)-alkyl substituents, i.e. not
carry (C.sub.1-C.sub.4)-alkyl substituents, or substituted by
(C.sub.1-C.sub.4)-alkyl substituents, wherein all cycloalkyl groups
and bicycloalkyl groups in the compounds of the formula I are
independent of one another with regard to the optional substitution
by (C.sub.1-C.sub.4)-alkyl substituents. Examples of such
alkyl-substituted cycloalkyl groups and bicycloalkyl groups are
1-methylcyclopropyl, 2,2-dimethylcyclopropyl, 1-methylcyclopentyl,
2,3-dimethylcyclopentyl, 1-methylcyclohexyl, 4-methylcyclohexyl,
4-isopropylcyclohexyl, 4-tert-butylcyclohexyl,
3,3,5,5-tetramethylcyclohexyl, 7,7-dimethylbicyclo[2.2.1]heptyl,
6,6-dimethylbicyclo[3.1.1]heptyl and
1,7,7-trimethylbicyclo[2.2.1]heptyl.
[0052] Independently of any other substituents including
(C.sub.1-C.sub.4)-alkyl substituents which can be present on a
cycloalkyl group or bicycloalkyl group, and unless specified
otherwise, cycloalkyl groups and bicycloalkyl groups can further be
substituted by one or more fluorine substituents, for example by 1,
2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 fluorine substituents, or by 1, 2,
3, 4 or 5 fluorine substituents, or by 1, 2 or 3 fluorine
substituents, which can be located in any positions and can also be
present in a (C.sub.1-C.sub.4)-alkyl substituent. I.e.,
independently of any other substituents which can be present on a
cycloalkyl group or bicycloalkyl group, cycloalkyl groups and
bicycloalkyl groups can be unsubstituted by fluorine substituents,
i.e. not carry fluorine substituents, or substituted by fluorine
substituents, wherein all cycloalkyl groups and bicycloalkyl groups
in the compounds of the formula I are independent of one another
with regard to the optional substitution by fluorine substituents.
Examples of fluoro-substituted cycloalkyl groups and bicycloalkyl
groups are 1-fluorocyclopropyl, 2,2-difluorocyclopropyl,
3,3-difluorocyclobutyl, 1-fluorocyclohexyl, 4,4-difluorocyclohexyl,
3,3,4,4,5,5-hexafluorocyclohexyl, 1-fluorobicyclo[2.2.2]octyl and
1,4-difluorobicyclo[2.2.2]octyl. Cycloalkyl groups can also be
substituted simultaneously by fluorine and alkyl. Examples of the
group (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- are
cyclopropylmethyl-, cyclobutylmethyl-, cyclopentylmethyl-,
cyclohexylmethyl-, cycloheptylmethyl-, 1-cyclopropylethyl-,
2-cyclopropylethyl-, 1-cyclobutylethyl-, 2-cyclobutylethyl-,
1-cyclopentylethyl-, 2-cyclopentylethyl-, 1-cyclohexylethyl-,
2-cyclohexylethyl-, 1-cycloheptylethyl-, 2-cycloheptylethyl-. In
one embodiment of the invention, a
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- group in any
one or more occurrences of such a group, independently of any other
occurrences, is a
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.2)-alkyl- group, in
another embodiment a (C.sub.3-C.sub.7)-cycloalkyl-CH.sub.2-- group.
In the group (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
and likewise in all other groups, the terminal hyphen denotes the
free bond via which the group is bonded, and thus indicates via
which subgroup a group composed of subgroups is bonded.
[0053] In substituted phenyl groups, including phenyl groups
representing Ar and R24, the substituents can be located in any
positions. In monosubstituted phenyl groups, the substituent can be
located in position 2, in position 3 or in position 4. In
disubstituted phenyl groups, the substituents can be located in
positions 2 and 3, in positions 2 and 4, in positions 2 and 5, in
positions 2 and 6, in positions 3 and 4, or in positions 3 and 5.
In trisubstituted phenyl groups, the substituents can be located in
positions 2, 3 and 4, in positions 2, 3 and 5, in positions 2, 3
and 6, in positions 2, 4 and 5, in positions 2, 4 and 6, or in
positions 3, 4 and 5. If a phenyl group carries four substituents,
some of which can be fluorine atoms, for example, the substituents
can be located in positions 2, 3, 4 and 5, in positions 2, 3, 4 and
6, or in positions 2, 3, 5 and 6. If a polysubstituted phenyl group
or any other polysubstituted group carries different substituents,
each substituent can be located in any suitable position, and the
present invention comprises all positional isomers. The number of
substituents in a substituted phenyl group can be 1, 2, 3, 4 or 5.
In one embodiment of the invention, the number of substituents in a
substituted phenyl group, and likewise in other embodiments the
number of substituents in any other substituted group which can
carry one or more substituents, is 1, 2, 3 or 4, in another
embodiment 1, 2 or 3, in another embodiment 1 or 2, in another
embodiment 1, wherein the number of substituents in any occurrence
of such a substituted group is independent of the number of
substituents in other occurrences.
[0054] In heterocyclic groups, including the groups Het1 and Het2
and heterocyclic groups R24, and other heterocyclic rings which can
be present in the compounds of the formula I, such as rings formed
by two groups together with the atom or atoms carrying them, the
hetero ring members can be present in any combination and located
in any suitable ring positions, provided that the resulting group
and the compound of the formula I are suitable and sufficiently
stable as a pharmaceutical active compound. In one embodiment of
the invention, two oxygen atoms in any heterocyclic ring in the
compounds of the formula I cannot be present in adjacent ring
positions. In another embodiment of the invention, two hetero ring
members selected from the series consisting of oxygen atoms and
sulfur atoms cannot be present in adjacent ring positions in any
heterocyclic ring in the compounds of the formula I. In another
embodiment of the invention, two hetero ring members selected from
the series consisting of nitrogen atoms carrying an exocyclic group
like a hydrogen atom or a substituent, sulfur atoms and oxygen
atoms cannot be present in adjacent ring positions in any
heterocyclic ring in the compounds of the formula I. In an aromatic
heterocyclic ring the choice of hetero ring members is limited by
the prerequisite that the ring is aromatic, i.e. it comprises a
cyclic system of six delocalized pi electrons. Monocyclic aromatic
heterocycles are 5-membered or 6-membered rings and, in the case of
a 5-membered ring, comprise one ring heteroatom selected from the
series consisting of oxygen, sulfur and nitrogen, wherein this ring
nitrogen carries an exocyclic group like a hydrogen atom or a
substituent, and optionally one or more further ring nitrogen
atoms, and, in the case of a 6-membered ring, comprise one or more
nitrogen atoms as ring heteroatoms, but no oxygen atoms and sulfur
atoms as ring heteroatoms. Unless specified otherwise in the
definition of the group, heterocyclic groups can be bonded via any
suitable ring atom, i.e. any ring atom which carries a hydrogen
atom or a substituent, including ring carbon atoms and ring
nitrogen atoms. In one embodiment of the invention, any of the
heterocyclic groups occurring in the compounds of the formula I in
any of its occurrences, is independently of its other occurrences
and independently of any other heterocyclic group, bonded via a
ring carbon atom, and in another embodiment via a ring nitrogen
atom, if applicable. In substituted heterocyclic groups, the
substituents can be located in any positions.
[0055] The number of ring heteroatoms which can be present in a
heterocyclic group in the compounds of the formula I, the number of
cycles, i.e. whether the heterocyclic group can be monocyclic
and/or bicyclic, the number of ring members which can be present,
and the degree of saturation, i.e. whether the heterocyclic group
is saturated and does not contain a double bond within the ring, or
whether it is partially unsaturated and contains one or more, for
example one or two, double bonds within the ring but is not
aromatic, or whether it is aromatic and thus contains two double
bonds within the ring in the case of a 5-membered monocyclic
aromatic heterocycle, three double bonds within the ring in the
case of a 6-membered monocyclic aromatic heterocycle, four double
bonds within the ring in the case of 9-membered bicyclic aromatic
heterocycle, and five double bonds within the ring in the case of
10-membered aromatic heterocycle, is specified in the definitions
of the individual groups in the compounds of the formula I. The two
cycles in a bicyclic heterocyclic group can have one, two or more
ring atoms in common and can be fused or form a bridged bicycle or
a spirocycle. As examples of heterocyclic ring systems, from which
heterocyclic groups in the compounds of the formula I can be
derived, and from any one or more of which any of the heterocyclic
groups in the compounds of the formula I, independently of any
other heterocyclic group, is selected in one embodiment of the
invention, provided that the ring system is comprised by the
definition of the group, oxetane, thietane, azetidine, furan,
tetrahydrofuran, thiophene, tetrahydrothiophene, pyrrole,
pyrroline, pyrrolidine, 1,3-dioxole, 1,3-dioxolane, isoxazole
([1,2]oxazole), isoxazoline, isoxazolidine, oxazole ([1,3]oxazole),
oxazoline, oxazolidine, isothiazole ([1,2]thiazole), isothiazoline,
isothiazolidine, thiazole ([1,3]thiazole), thiazoline,
thiazolidine, pyrazole, pyrazoline, pyrazolidine, imidazole,
imidazoline, imidazolidine, [1,2,3]triazole, [1,2,4]triazole,
[1,2,4]oxadiazole, [1,3,4]oxadiazole, [1,2,5]oxadiazole,
[1,2,4]thiadiazole, 1H-tetrazole, pyran, tetrahydropyran,
thiopyran, tetrahydrothiopyran, 2,3-dihydro[1,4]dioxine,
1,4-dioxane, pyridine, 1,2,5,6-tetrahydropyridine, piperidine,
morpholine, thiomorpholine, piperazine, pyridazine, pyrimidine,
pyrazine, [1,2,4]triazine, oxepane, thiepane, azepane,
[1,3]diazepane, [1,4]diazepane, [1,4]oxazepane, [1,4]thiazepane,
azocane, 3-azabicyclo[3.1.0]hexane, octahydrocyclopenta[b]pyrrole,
octahydrocyclopenta[c]pyrrole, 2-azaspiro[4.4]nonane,
7-azabicyclo[2.2.1]heptane, 2,7-diazaspiro[4.4]nonane,
octahydropyrrolo[3,4-b]pyrrole,
6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole,
imidazo[2,1-b]thiazole, 6,7-dihydro-5H-thiazolo[3,2-a]pyrimidine,
benzofuran, isobenzofuran, benzothiophene (benzo[b]thiophene),
1H-indole, 2,3-dihydro-1H-indole, octahydroindole, 2H-isoindole,
octahydroisoindole, benzo[1,3]dioxole, benzoxazole, benzthiazole,
1H-benzimidazole, imidazo[1,2-a]pyridine,
[1,2,4]triazolo[4,3-a]pyridine, chroman, isochroman, thiochroman,
benzo[1,4]dioxane, 3,4-dihydro-2H-benzo[1,4]oxazine,
3,4-dihydro-2H-benzo[1,4]thiazine, 2-azaspiro[4.5]decane,
3-azabicyclo[3.2.2]nonane, quinoline, 1,2,3,4-tetrahydroquinoline,
5,6,7,8-tetrahydroquinoline, isoquinoline,
1,2,3,4-tetrahydroisoquinoline, 5,6,7,8-tetrahydroisoquinoline,
2,7-diazaspiro[4.5]decane, 2,8-diazaspiro[4.5]decane, cinnoline,
quinazoline, quinoxaline, phthalazine and [1,8]naphthyridine may be
mentioned, which can all be unsubstituted or substituted in any
suitable positions as specified in the definition of the respective
group in the compounds of the formula I, wherein the given degree
of unsaturation is by way of example only, and in the individual
groups also ring systems with a higher or lower degree of
saturation, or hydrogenation, or of unsaturation can be present as
specified in the definition of the group.
[0056] As mentioned, the heterocyclic groups can be bonded via any
suitable ring atom. For example, among others can an oxetane and a
thietane ring be bonded via positions 2 and 3, an azetidine ring
via positions 1, 2 and 3, a furan ring, a tetrahydrofuran ring, a
thiophene ring and a tetrahydrothiophene via positions 2 and 3, a
pyrrole ring and a pyrrolidine ring via positions 1, 2 and 3, an
isoxazole ring and an isothiazole ring via positions 3, 4 and 5, a
pyrazole ring via positions 1, 3, 4 and 5, an oxazole ring and a
thiazole ring via positions 2, 4 and 5, an imidazole ring and an
imidazolidine ring via positions 1, 2, 4 and 5, a 1H-tetrazole ring
via positions 1 and 5, a tetrahydropyran and a tetrahydrothiopyran
ring via positions 2, 3 and 4, a 1,4-dioxane ring via position 2, a
pyridine ring via positions 2, 3 and 4, a piperidine ring via
positions 1, 2, 3 and 4, a morpholine ring and a thiomorpholine
ring via positions 2, 3 and 4, a piperazine ring via positions 1
and 2, a pyrimidine ring via positions 2, 4 and 5, a pyrazine ring
via position 2, an azepane ring via positions 1, 2, 3 and 4, a
3-azabicyclo[3.1.0]hexane ring via positions 3 and 6, an
octahydrocyclopenta[b]pyrrole and an octahydrocyclopenta[c]pyrrole
ring via position 1, a 2-azaspiro[4.4]nonane ring via position 2, a
7-azabicyclo[2.2.1]heptane ring via position 7, an
octahydropyrrolo[3,4-b]pyrrole ring via positions 1 and 5, a
6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazole ring via position 3,
an imidazo[2,1-b]thiazole ring via positions 2, 5 and 6, a
6,7-dihydro-5H-thiazolo[3,2-a]pyrimidine via position 3, a
benzofuran ring and a benzothiophene ring via positions 2, 3, 4, 5,
6 and 7, a 1H-indole ring, a 2,3-dihydro-1H-indole and an
octahydroindole ring via positions 1, 2, 3, 4, 5, 6 and 7, a
benzo[1,3]dioxole ring via positions 4, 5, 6 and 7, a benzoxazole
ring and a benzthiazole ring via positions 2, 4, 5, 6 and 7, a
1H-benzimidazole ring via positions 1, 2, 4, 5, 6 and 7, an
imidazo[1,2-a]pyridine ring via positions 2 and 3, a
[1,2,4]triazolo[4,3-a]pyridine ring via position 3, a
benzo[1,4]dioxane ring via positions 5, 6, 7 and 8, a
3-azabicyclo[3.2.2]nonane ring via position 3, a quinoline ring via
positions 2, 3, 4, 5, 6, 7 and 8, a 1,2,3,4-tetrahydroquinoline
ring via positions 1, 5, 6, 7 and 8, a 5,6,7,8-tetrahydroquinoline
via positions 2, 3 and 4, an isoquinoline ring via positions 1, 3,
4, 5, 6, 7 and 8, a 1,2,3,4-tetrahydroisoquinoline ring via
positions 2, 5, 6, 7 and 8, a 5,6,7,8-tetrahydroisoquinoline ring
via positions 1, 3, 4 and 5, a 2,7-diazaspiro[4.5]decane ring via
positions 2 and 7, a 2,8-diazaspiro[4.5]decane ring via positions 2
and 8, for example, wherein the resulting residues of the
heterocyclic groups can all be unsubstituted or substituted in any
suitable positions as specified for the respective group in the
definition of the compounds of the formula I.
[0057] Halogen is fluorine, chlorine, bromine or iodine. In one
embodiment of the invention, in any of its occurrences halogen is
fluorine, chlorine or bromine, in another embodiment fluorine or
chlorine, in another embodiment fluorine, in another embodiment
chlorine, wherein all occurrences of halogen are independent of
each other.
[0058] An oxo group, i.e. a doubly bonded oxygen atom, when
occurring as a substituent on a carbon atom, replaces two hydrogen
atoms on a carbon atom of the parent system. Thus, if a CH.sub.2
group is substituted by oxo, it becomes a carbonyl group (C(O),
C.dbd.O). Just so, if the groups R2 and R3 together are oxo, the
group C(R2)-R3 in the cycloalkane ring depicted in formula I
becomes a carbonyl group. Oxo groups can also occur on sulfur
atoms, such as on ring sulfur atoms in saturated and partially
unsaturated heterocycles in which generally, besides a ring sulfur
atom, also an S(O) group (S(.dbd.O)) and an S(O).sub.2 group
(S(.dbd.O).sub.2) can be present as hetero ring members. An oxo
group cannot occur as a substituent on a carbon atom in an aromatic
ring such as in a phenyl group.
[0059] The present invention comprises all stereoisomeric forms of
the compounds of the formula I, for example all enantiomers and
diastereomers including cis/trans isomers. The invention likewise
comprises mixtures of two or more stereoisomeric forms, for example
mixtures of enantiomers and/or diastereomers including cis/trans
isomers, in all ratios. Asymmetric centers contained in the
compounds of the formula I, for example the carbon atom in position
2 of the chroman ring or in unsubstituted or substituted alkyl
groups, can all independently of each other have S configuration or
R configuration. The invention relates to enantiomers, both the
levorotatory and the dextrorotatory antipode, in enantiomerically
pure form and essentially enantiomerically pure form, for example
with a molar ratio of the two enantiomers of 98:2, or 99:1, or
greater, and in the form of their racemate, i.e. a mixture of the
two enantiomers in molar ratio of 1:1, and in the form of mixtures
of the two enantiomers in all ratios. The invention likewise
relates to diastereomers in the form of pure and essentially pure
diastereomers and in the form of mixtures of two or more
diastereomers in all ratios. The invention also comprises all
cis/trans isomers of the compounds of the formula I in pure form
and essentially pure form, for example with a molar ratio of the
cis/trans isomers of 98:2, or 99:1, or greater, and in the form of
mixtures of the cis isomer and the trans isomer in all ratios.
Cis/trans isomerism can occur in substituted rings, for example.
The preparation of individual stereoisomers, if desired, can be
carried out by resolution of a mixture according to customary
methods, for example, by chromatography or crystallization, or by
use of stereochemically uniform starting compounds in the
synthesis, or by stereoselective reactions. Optionally, before a
separation of stereoisomers a derivatization can be carried out.
The separation of a mixture of stereoisomers can be carried out at
the stage of the compound of the formula I or at the stage of an
intermediate in the course of the synthesis. For example, in the
case of a compound of the formula I containing an asymmetric center
the individual enantiomers can be prepared by preparing the
racemate of the compound of the formula I and resolving it into the
enantiomers by high pressure liquid chromatography on a chiral
phase according to standard procedures, or resolving the racemate
of any intermediate in the course of its synthesis by such
chromatography or by crystallization of a salt thereof with an
optically active amine or acid and converting the enantiomers of
the intermediate into the enantiomeric forms of the final compound
of the formula I, or by performing an enantioselective reaction in
the course of the synthesis. The invention also comprises all
tautomeric forms of the compounds of the formula I.
[0060] Besides the free compounds of the formula I, i.e. compounds
in which acidic and basic groups are not present in the form of a
salt, the present invention comprises also salts of the compounds
of the formula I, in particular their physiologically acceptable
salts, or toxicologically acceptable salts, or pharmaceutically
acceptable salts, which can be formed on one or more acidic or
basic groups in the compounds of the formula I, for example on
basic heterocyclic moieties. The compounds of the formula I may
thus be deprotonated on an acidic group and be used for example as
alkali metal salts, for example sodium or potassium salts, or as
ammonium salts, for example as salts with ammonia or organic amines
or amino acids. Compounds of the formula I comprising at least one
basic group may also be prepared and used in the form of their acid
addition salts, for example in the form of pharmaceutically
acceptable salts with inorganic acids and organic acids, such as
salts with hydrochloric acid and thus be present in the form of the
hydrochlorides, for example. Salts can in general be prepared from
acidic and basic compounds of the formula I by reaction with an
acid or base in a solvent or diluent according to customary
procedures. If the compounds of the formula I simultaneously
contain an acidic and a basic group in the molecule, the invention
also includes internal salts (betaines, zwitterions) in addition to
the salt forms mentioned. The present invention also comprises all
salts of the compounds of the formula I which, because of low
physiological tolerability, are not directly suitable for use as a
pharmaceutical, but are suitable as intermediates for chemical
reactions or for the preparation of physiologically acceptable
salts, for example by means of anion exchange or cation
exchange.
[0061] In one embodiment of the invention, the group Ar is phenyl
which is unsubstituted or substituted by 1, 2, 3 or 4, in another
embodiment by 1, 2 or 3, in another embodiment by 1 or 2 identical
or different substituents R0. In another embodiment, Ar is phenyl
which is unsubstituted or substituted by 1 substituent R0. In
another embodiment Ar is unsubstituted phenyl. In another
embodiment, Ar is phenyl which is substituted by 1, 2, 3 or 4, in
another embodiment by 1, 2 or 3, in another embodiment by 1 or 2
identical or different substituents R0. In another embodiment, Ar
is phenyl which is substituted by 1 substituent R0. If one
substituent R0 is present in Ar, in one embodiment it is located in
position 2, in another embodiment in position 3, in another
embodiment in position 4 of the phenyl group. If two substituents
R0 are present which do not form a ring together with the carbon
atoms carrying them, in one embodiment they are located in
positions 2 and 3, in another embodiment in positions 2 and 4, in
another embodiment in positions 2 and 5, in another embodiment in
positions 2 and 6, in another embodiment in positions 3 and 4, and
in another embodiment in positions 3 and 5 of the phenyl group.
[0062] The double bond which is present in the mono-unsaturated
ring which can be formed by two substituents R0 bonded to adjacent
ring carbon atoms in Ar together with the carbon atoms carrying
them, is present between the said two adjacent ring carbon in the
aromatic ring Ar which are common to the ring Ar and the ring
formed by the two groups R0, and because of the rules of
nomenclature for fused rings is regarded as a double bond present
in both rings. The case that two groups R0 bonded to adjacent
carbon atoms in Ar together with the carbon atoms carrying them
form a 5-membered to 7-membered mono-unsaturated ring, which is a
monocyclic ring, can in other words be regarded as two groups R0
together forming a divalent residue comprising a chain of 3 to 5
atoms of which 0, 1 or 2 are identical or different heteroatoms
selected from the series consisting of nitrogen, oxygen and sulfur,
the terminal atoms of which, which are bonded to the two adjacent
ring carbon atoms in Ar, are separated from each other by 1 to 3
atoms. Examples of such divalent residues, from any one or more of
which two groups R0 bonded to adjacent ring carbon atoms in Ar are
selected in one embodiment of the invention, are the residues
--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--CH.sub.2--,
--O--CH.sub.2--CH.sub.2--, --CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--CH.sub.2--O--,
--NH--CH.sub.2--CH.sub.2--O--, --O--CH.sub.2--CH.sub.2--NH--,
--S--CH.sub.2--CH.sub.2--NH-- and --NH--CH.sub.2--CH.sub.2--S--,
which can all be substituted on carbon atoms and nitrogen atoms by
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl, for example fluorine and methyl, and can
thus also be present, for example, as the divalent residues
--O--CF.sub.2--O--, --O--C(CH.sub.3).sub.2--O--,
--N(CH.sub.3)--CH.sub.2--CH.sub.2--O--,
--O--CH.sub.2--CH.sub.2--N(CH.sub.3)--,
--S--CH.sub.2--CH.sub.2--N(CH.sub.3)-- and
--N(CH.sub.3)--CH.sub.2--CH.sub.2--S--. In one embodiment of the
invention, the ring which can be formed by two groups R0 bonded to
adjacent ring carbon atoms in Ar together with the carbon atoms
carrying them, is a 5-membered or 6-membered, in another embodiment
a 5-membered, in another embodiment a 6-membered ring. In one
embodiment of the invention, the number of substituents selected
from the series consisting of fluorine and (C.sub.1-C.sub.4)-alkyl,
which can be present in a ring formed by two groups R0 bonded to
adjacent ring carbon atoms in Ar together with the carbon atoms
carrying them, is 1, 2 or 3, in another embodiment 1 or 2, in
another embodiment 1. In one embodiment of the invention,
substituents which can be present in a ring formed by two groups R0
bonded to adjacent ring carbon atoms in Ar together with the carbon
atoms carrying them, are fluorine substituents, and in another
embodiment they are (C.sub.1-C.sub.4)-alkyl substituents, for
example methyl substituents, and in another embodiment are
substituents in such a ring bonded to a ring nitrogen atom selected
from the series consisting of (C.sub.1-C.sub.4)-alkyl.
[0063] In one embodiment of the invention, the group R0 is selected
from the series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO-- and
(C.sub.1-C.sub.6)-alkyl-O--, in another embodiment from the series
consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, HO-- and (C.sub.1-C.sub.6)-alkyl-O--,
in another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- and
(C.sub.1-C.sub.6)-alkyl-O--, in another embodiment from the series
consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.1-C.sub.6)-alkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-O--, in another embodiment from the
series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and (C.sub.1-C.sub.6)-alkyl-O--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, HO-- and (C.sub.1-C.sub.6)-alkyl-O--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.1-C.sub.6)-alkyl-O--, in another
embodiment from the series consisting of halogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of halogen, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl, and in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl-O--, and in
all these embodiments two groups R1 bonded to adjacent carbon atoms
in Ar, together with the carbon atoms carrying them, can form a
5-membered to 7-membered mono-unsaturated ring which comprises 0, 1
or 2 identical or different ring heteroatoms selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl.
[0064] In one embodiment, R0 is selected from the series consisting
of halogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO-- and
(C.sub.1-C.sub.6)-alkyl-O--, in another embodiment from the series
consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, HO-- and (C.sub.1-C.sub.6)-alkyl-O--,
in another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- and
(C.sub.1-C.sub.6)-alkyl-O--, in another embodiment from the series
consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.1-C.sub.6)-alkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-O--, in another embodiment from the
series consisting of halogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and (C.sub.1-C.sub.6)-alkyl-O--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, HO-- and (C.sub.1-C.sub.6)-alkyl-O--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.1-C.sub.6)-alkyl-O--, in another
embodiment from the series consisting of halogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of halogen, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl, and in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl-O--.
[0065] In one embodiment, a (C.sub.1-C.sub.6)-alkyl group which
represents R0 or is present in the group
(C.sub.1-C.sub.6)-alkyl-O-- representing R0, is a
(C.sub.1-C.sub.4)-alkyl group, in another embodiment a
(C.sub.1-C.sub.3)-alkyl group, in another embodiment a
(C.sub.1-C.sub.2)-alkyl group, in another embodiment a methyl
group. In one embodiment of the invention, a
(C.sub.3-C.sub.7)-cycloalkyl group which represents R0 or is
present in R0, is a (C.sub.3-C.sub.6)-cycloalkyl group, in another
embodiment a (C.sub.3-C.sub.4)-cycloalkyl group, in another
embodiment a cyclopropyl group. In one embodiment, halogen
representing R0 is selected from the series consisting of fluorine
and chlorine, in another embodiment it is fluorine.
[0066] Examples of groups Ar including the optional substituents
R0, from any one or more of which Ar is selected in one embodiment
of the invention, are phenyl, i.e. unsubstituted phenyl,
2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 2-chloro-phenyl,
3-chloro-phenyl, 4-chloro-phenyl, 2-methyl-phenyl (o-tolyl),
3-methyl-phenyl (m-tolyl), 4-methyl-phenyl (p-tolyl),
2-ethylphenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 2-methoxy-phenyl,
3-methoxy-phenyl, 4-methoxy-phenyl, 2-ethoxy-phenyl,
3-ethoxy-phenyl, 4-ethoxy-phenyl, 2-propoxy-phenyl,
3-propoxy-phenyl, 4-propoxy-phenyl, 2-isopropoxy-phenyl,
3-isopropoxy-phenyl, 4-isopropoxy-phenyl, 2,3-difluoro-phenyl,
2,4-difluoro-phenyl, 2,5-difluoro-phenyl, 2,6-difluoro-phenyl,
3,4-difluoro-phenyl, 3,5-difluoro-phenyl, 2,3-dichloro-phenyl,
2,4-dichloro-phenyl, 2,5-dichloro-phenyl, 2,6-dichloro-phenyl,
3,4-dichloro-phenyl, 3,5-dichloro-phenyl, 2-chloro-3-fluoro-phenyl,
2-chloro-4-fluoro-phenyl, 2-chloro-5-fluoro-phenyl,
2-chloro-6-fluoro-phenyl, 3-chloro-2-fluoro-phenyl,
3-chloro-4-fluoro-phenyl, 3-chloro-5-fluoro-phenyl,
4-chloro-2-fluoro-phenyl, 4-chloro-3-fluoro-phenyl,
5-chloro-2-fluoro-phenyl, 2,3-dimethyl-phenyl, 2,4-dimethyl-phenyl,
2,5-dimethyl-phenyl, 2,6-dimethyl-phenyl, 3,4-dimethyl-phenyl,
3,5-dimethyl-phenyl, 2-fluoro-3-methyl-phenyl,
2-fluoro-4-methyl-phenyl, 2-fluoro-5-methyl-phenyl,
2-fluoro-6-methyl-phenyl, 3-fluoro-2-methyl-phenyl,
3-fluoro-4-methyl-phenyl, 3-fluoro-5-methyl-phenyl,
4-fluoro-2-methyl-phenyl, 4-fluoro-3-methyl-phenyl,
5-fluoro-2-methyl-phenyl, 2-chloro-3-methyl-phenyl,
2-chloro-4-methyl-phenyl, 2-chloro-5-methyl-phenyl,
2-chloro-6-methyl-phenyl, 3-chloro-2-methyl-phenyl,
3-chloro-4-methyl-phenyl, 3-chloro-5-methyl-phenyl,
4-chloro-2-methyl-phenyl, 4-chloro-3-methyl-phenyl,
5-chloro-2-methyl-phenyl, 2-fluoro-3-methoxy-phenyl,
2-fluoro-4-methoxy-phenyl, 2-fluoro-5-methoxy-phenyl,
2-fluoro-6-methoxy-phenyl, 3-fluoro-2-methoxy-phenyl,
3-fluoro-4-methoxy-phenyl, 3-fluoro-5-methoxy-phenyl,
4-fluoro-2-methoxy-phenyl, 4-fluoro-3-methoxy-phenyl,
5-fluoro-2-methoxy-phenyl, 2-methoxy-3-methyl-phenyl,
2-methoxy-4-methyl-phenyl, 2-methoxy-5-methyl-phenyl,
2-methoxy-6-methyl-phenyl, 3-methoxy-2-methyl-phenyl,
3-methoxy-4-methyl-phenyl, 3-methoxy-5-methyl-phenyl,
4-methoxy-2-methyl-phenyl, 4-methoxy-3-methyl-phenyl,
5-methoxy-2-methyl-phenyl.
[0067] In one embodiment of the invention, the group R1 is hydrogen
or one or more fluorine substituents. I.e., in this embodiment the
cycloalkane ring depicted in formula I is unsubstituted or
substituted by one or more fluorine substituents, apart from the
groups R2 and R3 and the oxygen atom linking the cycloalkane ring
to the chroman ring. In another embodiment, the group R1 is
hydrogen or one or more (C.sub.1-C.sub.4)-alkyl substituents. I.e.,
in this embodiment the cycloalkane ring depicted in formula I is
unsubstituted or substituted by one or more (C.sub.1-C.sub.4)-alkyl
substituents, apart from the groups R2 and R3 and the oxygen atom
linking the cycloalkane ring to the chroman ring. In another
embodiment, the group R1 is hydrogen. I.e., in this embodiment the
cycloalkane ring depicted in formula I is unsubstituted, or in
other words carries hydrogen atoms only, apart from the groups R2
and R3 and the oxygen atom linking the cycloalkane ring to the
chroman ring. In one embodiment, the number of fluorine atoms
and/or (C.sub.1-C.sub.4)-alkyl groups representing R1 is 1, 2, 3 or
4, in another embodiment 1, 2 or 3, in another embodiment 1 or 2,
in another embodiment 1. In one embodiment, (C.sub.1-C.sub.4)-alkyl
representing R1 is (C.sub.1-C.sub.6)-alkyl, in another embodiment
(C.sub.1-C.sub.2)-alkyl, in another embodiment methyl. In one
embodiment, the ring carbon atom of the cycloalkane ring depicted
in formula I which carries the oxygen atom linking the ring to the
chroman ring, does not carry a group R1 which is fluorine or
(C.sub.1-C.sub.4)-alkyl, i.e. this embodiment the said ring carbon
atom carries a hydrogen atom.
[0068] In one embodiment of the invention, the group R2 is selected
from the series consisting of (C.sub.1-C.sub.6)-alkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.1-C.sub.6)-alkyl-C(O)--O--,
phenyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O).sub.2--N(R8)-, R9-N(R10)-C(O)--N(R8)- and R5-N(R6)-C(O)--,
in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O).sub.2--N(R8)-, R9-N(R10)-C(O)--N(R8)- and R5-N(R6)-C(O)--,
in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
R5-N(R6)-, R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
R5-N(R6)-, R7-C(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl, HO--,
R5-N(R6)-, R7-C(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl, R5-N(R6)-,
R7-C(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and R5-N(R6)-C(O)--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, R5-N(R6)-, R7-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, phenyl-C(O)--O-- and
Het1-C(O)--O--, in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-C(O)--O and
Het1-C(O)--O--, in another embodiment from the series consisting of
HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O-- and Het1-C(O)--O--, in another
embodiment from the series consisting of HO--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O-- and Het1-C(O)--O--, wherein in
all these embodiments (C.sub.1-C.sub.6)-alkyl is unsubstituted or
substituted by one or more identical or different substituents R20,
or in all these embodiments R2 and R3 together are oxo.
[0069] In one embodiment, R2 is selected from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, HO--, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and R5-N(R6)-C(O)--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-C(O)--O--,
Het1-C(O)--O--, R5-N(R6)-, R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)-
and R5-N(R6)-C(O)--, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl, HO--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl, HO--,
R5-N(R6)-, R7-C(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.6)-alkyl, R5-N(R6)-, R7-C(O)--N(R8)-,
R7-S(O).sub.2--N(R8)- and R5-N(R6)-C(O)--, in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl, R5-N(R6)-,
R7-C(O)--N(R8)- and R5-N(R6)-C(O)--, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl, R5-N(R6)- and
R5-N(R6)-C(O)--, in another embodiment from the series consisting
of R5-N(R6)-, R7-C(O)--N(R8)- and R7-S(O).sub.2--N(R8)-, in another
embodiment from the series consisting of R5-N(R6)-, R7-C(O)--N(R8)-
and R5-N(R6)-C(O)--, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl and R5-N(R6)-, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl
and R5-N(R6)-C(O)--, in another embodiment from the series
consisting of R5-N(R6)- and R5-N(R6)-C(O)--, wherein in all these
embodiments (C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted
by one or more identical or different substituents R20.
[0070] In one embodiment, R2 is (C.sub.1-C.sub.6)-alkyl which is
unsubstituted or substituted by one or more identical or different
substituents R20. In another embodiment, R(2) is R5-N(R6)- and the
compounds of the formula I thus are compounds of the formula
Ia.
##STR00005##
[0071] In another embodiment, R(2) is R7-C(O)--N(R8)- and the
compounds of the formula I thus are compounds of the formula
Ib.
##STR00006##
[0072] In another embodiment, R(2) is R7-S(O).sub.2--N(R8)- and the
compounds of the formula I thus are compounds of the formula
Ic.
##STR00007##
[0073] In another embodiment, R(2) is R5-N(R6)-C(O)-- and the
compounds of the formula I thus are compounds of the formula
Id.
##STR00008##
[0074] The groups Ar, R1, R3 to R8 and the numbers p and q in the
compounds of the formulae Ia, Ib, Ic and Id are defined as in the
compounds of the formula I.
[0075] In one embodiment, the number of substituents R20 in a
substituted (C.sub.1-C.sub.6)-alkyl group which represents R2 or is
present in the groups (C.sub.1-C.sub.6)-alkyl-O-- or
(C.sub.1-C.sub.6)-alkyl-C(O)--O-- representing R2, is 1, 2, 3 or 4,
in another embodiment 1, 2 or 3, in another embodiment 1 or 2, in
another embodiment 1. In one embodiment, a (C.sub.1-C.sub.6)-alkyl
group which represents R2, is substituted by one or more identical
or different substituents R20, i.e. it is not unsubstituted. In one
embodiment, a (C.sub.1-C.sub.6)-alkyl group which represents R2 is
substituted by one or more identical or different substituents R20,
one of which is bonded to the carbon atom of the alkyl group which
is bonded to the cycloalkane ring depicted in formula I, i.e. in
position 1 of the alkyl group. In one embodiment, a
(C.sub.1-C.sub.6)-alkyl group which represents R2 or is present in
the groups (C.sub.1-C.sub.6)-alkyl-O-- or
(C.sub.1-C.sub.6)-alkyl-C(O)--O-- representing R2, is a
(C.sub.1-C.sub.4)-alkyl group, in another embodiment a
(C.sub.1-C.sub.3)-alkyl group, in another embodiment a
(C.sub.1-C.sub.2)-alkyl group, in another embodiment a methyl
group, which are all unsubstituted or substituted by one or more
identical or different substituents R20, and in one embodiment are
substituted by one or more identical or different substituents R20,
wherein in one embodiment the number of substituents R20 is 1, 2 or
3, in another embodiment 1 or 2, and in another embodiment 1. In
one embodiment, a (C.sub.1-C.sub.6)-alkyl group which represents R2
is a methyl group which is substituted by one substituent R20, and
in this embodiment the group R2 thus is the group
R20-CH.sub.2--.
[0076] In one embodiment of the invention, the group R3 is
hydrogen, in another embodiment it is (C.sub.1-C.sub.6)-alkyl,
which is unsubstituted or substituted by one or two identical or
different substituents selected from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl, phenyl, HO-- and
(C.sub.1-C.sub.4)-alkyl-O--, wherein alkyl groups representing R3,
like alkyl groups in general, can independently of these specified
substituents be substituted by one or more fluorine substituents.
In one embodiment, the number of substituents selected from the
series consisting of (C.sub.3-C.sub.7)-cycloalkyl, phenyl, HO-- and
(C.sub.1-C.sub.4)-alkyl-O-- in a substituted alkyl group
representing R3 is one. In one embodiment, an alkyl group
representing R3 is not substituted by substituents selected from
the series consisting of (C.sub.3-C.sub.7)-cycloalkyl, phenyl, HO--
and (C.sub.1-C.sub.4)-alkyl-O--. In one embodiment, the
substituents in an alkyl group representing R3 are selected from
the series consisting of (C.sub.3-C.sub.7)-cycloalkyl, phenyl and
(C.sub.1-C.sub.4)-alkyl-O--, in another embodiment from the series
consisting of (C.sub.3-C.sub.7)-cycloalkyl and phenyl, and in
another embodiment they are phenyl groups. In one embodiment, a
(C.sub.1-C.sub.6)-alkyl group representing R3 is a
(C.sub.1-C.sub.4)-alkyl group, in another embodiment a
(C.sub.1-C.sub.3)-alkyl group, in another embodiment a
(C.sub.1-C.sub.2)-alkyl group, in another embodiment a methyl
group. In one embodiment, R2 and R3 have their individual meanings,
but together are not oxo. In another embodiment, R2 and R3 together
are oxo.
[0077] As indicated above, in the free binding sites of the chroman
ring, i.e. binding sites in positions 2, 3, 4, 5, 7 and 8 of the
chroman ring which are not occupied by bonds within the ring or the
bond to the group Ar, hydrogen atoms or substituents selected from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O-- can be present which represent groups
R4. In one embodiment of the invention, in the free binding site in
position 2 of the chroman ring, i.e. the free binding site of the
ring carbon atom which carries the group Ar, a hydrogen atom is
present, and in the free binding sites in positions 3, 4, 5, 7 and
8 of the chroman ring hydrogen atoms or substituents selected from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O-- are present. In another embodiment of
the invention, in the free binding sites in positions 2, 3 and 4 of
the chroman ring hydrogen atoms are present, and in the free
binding sites in positions 5, 7 and 8 of the chroman ring hydrogen
atoms or substituents selected from the series consisting of
halogen, (C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--
are present. In another embodiment of the invention, in the free
binding sites in positions 2 and 5 of the chroman ring hydrogen
atoms are present, and in the free binding sites in positions 3, 4,
7 and 8 of the chroman ring hydrogen atoms or substituents selected
from the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O-- are present. In another embodiment of
the invention, in the free binding sites in positions 2, 5, 7 and 8
of the chroman ring hydrogen atoms are present, and in the free
binding sites in positions 3 and 4 of the chroman ring hydrogen
atoms or substituents selected from the series consisting of
halogen, (C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--
are present. In one embodiment, the number of groups R4 which are
different from hydrogen, i.e. the number of substituents R4 which
are selected from halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, is 1, 2 or 3, in another embodiment it
is 1 or 2, in another embodiment it is 1, and in another embodiment
it is 0, and in the latter embodiment thus no groups R4 which are
different from hydrogen are present in the chroman ring, and
hydrogen atoms are present in all its free binding sites. In one
embodiment, R4 is hydrogen or one or more identical or different
substituents selected from the series consisting of halogen and
(C.sub.1-C.sub.4)-alkyl, in another embodiment R4 is hydrogen or
one or more identical or different substituents selected from the
series consisting of fluorine, chlorine and
(C.sub.1-C.sub.4)-alkyl. In one embodiment, R4 in the free binding
sites in positions 2, 3 and 4 of the chroman ring is hydrogen or
one or more identical or different substituents selected from the
series consisting of fluorine and (C.sub.1-C.sub.4)-alkyl, in
another embodiment R4 in the free binding sites in positions 2, 3
and 4 of the chroman ring is hydrogen or one or more identical or
different substituents selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl, and R4 in the free binding sites in
positions 5, 7 and 8 of the chroman ring is hydrogen or one or more
identical or different substituents selected from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, in another embodiment R4 in the free
binding sites in positions 5, 7 and 8 of the chroman ring is
hydrogen or one or more identical or different substituents
selected from the series consisting of halogen and
(C.sub.1-C.sub.4)-alkyl, in another embodiment R4 in the free
binding sites in positions 5, 7 and 8 of the chroman ring is
hydrogen or one or more identical or different substituents
selected from the series consisting of halogen. In one embodiment
of the invention, a (C.sub.1-C.sub.4)-alkyl group representing R4
or present in R4 is (C.sub.1-C.sub.2)-alkyl, in another embodiment
it is methyl.
[0078] In one embodiment of the invention, R5 and R6 are
independently of one another selected from the series consisting of
hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl, Het1
and Het2, in another embodiment from the series consisting of
hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and (C.sub.6-C.sub.10)-bicycloalkyl,
in another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2, in
another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein in all these embodiments
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
more identical or different substituents R20, and
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl and
Het2 all are unsubstituted or substituted by one or more identical
or different substituents R21, and Het1 is unsubstituted or
substituted by one or more identical or different substituents R22,
or the groups R5 and R6, together with the nitrogen atom carrying
them, form a 4-membered to 7-membered, monocyclic, saturated or
partially unsaturated heterocycle which, in addition to the
nitrogen atom carrying R5 and R6, comprises 0 or 1 further ring
heteroatom selected from the series consisting of nitrogen, oxygen
and sulfur, and which is unsubstituted or substituted by one or
more identical or different substituents R21.
[0079] In one embodiment, R5 and R6 are independently of one
another selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl, Het1
and Het2, in another embodiment from the series consisting of
hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.3-C.sub.7)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and (C.sub.6-C.sub.10)-bicycloalkyl,
in another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2, in
another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein in all these embodiments
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
more identical or different substituents R20, and
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl and
Het2 all are unsubstituted or substituted by one or more identical
or different substituents R21, and Het1 is unsubstituted or
substituted by one or more identical or different substituents
R22.
[0080] In one embodiment of the invention, one of the groups R5 and
R6 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.2)-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment is
hydrogen, and the other of the groups R5 and R6 is selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, phenyl, Het1 and Het2, in another
embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl, Het1
and Het2, in another embodiment from the series consisting of
hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and (C.sub.6-C.sub.10)-bicycloalkyl,
in another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2, in
another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein in all these embodiments
(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.2)-alkyl and methyl representing R5 or R6 is
unsubstituted or substituted by one or more identical or different
substituents R20, and (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and Het1 is unsubstituted or substituted by one or more identical
or different substituents R22, or the groups R5 and R6, together
with the nitrogen atom carrying them, form a 4-membered to
7-membered, monocyclic, saturated or partially unsaturated
heterocycle which, in addition to the nitrogen atom carrying R5 and
R6, comprises 0 or 1 further ring heteroatom selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents R21.
[0081] In one embodiment of the invention, one of the groups R5 and
R6 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.2)-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment is
hydrogen, and the other of the groups R5 and R6 is selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, phenyl, Het1 and Het2, in another
embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl, Het1
and Het2, in another embodiment from the series consisting of
hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and (C.sub.6-C.sub.10)-bicycloalkyl,
in another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2, in
another embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein in all these embodiments
(C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.2)-alkyl and methyl representing R5 or R6 is
unsubstituted or substituted by one or more identical or different
substituents R20, and (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and Het1 is unsubstituted or substituted by one or more identical
or different substituents R22. In one embodiment, R5 and R6 both
are hydrogen.
[0082] In one embodiment of the invention, one of the groups R5 and
R6 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.2)-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment is
hydrogen, and the other of the groups R5 and R6 is selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, phenyl, Het1 and Het2, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, Het1 and Het2, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl, Het1 and
Het2, in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, Het1 and
Het2, in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.6-C.sub.10)-bicycloalkyl, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and Het2, in another embodiment from
the series consisting of (C.sub.1-C.sub.6)-alkyl and
(C.sub.3-C.sub.7)-cycloalkyl, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl, wherein in all these
embodiments (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.2)-alkyl and methyl representing R5 or R6 is
unsubstituted or substituted by one or more identical or different
substituents R20, and (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and Het1 is unsubstituted or substituted by one or more identical
or different substituents R22, or the groups R5 and R6, together
with the nitrogen atom carrying them, form a 4-membered to
7-membered, monocyclic, saturated or partially unsaturated
heterocycle which, in addition to the nitrogen atom carrying R5 and
R6, comprises 0 or 1 further ring heteroatom selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents R21.
[0083] In one embodiment of the invention, one of the groups R5 and
R6 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.2)-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment is
hydrogen, and the other of the groups R5 and R6 is selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, phenyl, Het1 and Het2, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl, Het1 and Het2, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl, Het1 and
Het2, in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, Het1 and
Het2, in another embodiment from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.6-C.sub.10)-bicycloalkyl, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and Het2, in another embodiment from
the series consisting of (C.sub.1-C.sub.6)-alkyl and
(C.sub.3-C.sub.7)-cycloalkyl, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl, wherein in all these
embodiments (C.sub.1-C.sub.6)-alkyl, (C.sub.1-C.sub.6)-alkyl,
(C.sub.1-C.sub.2)-alkyl and methyl representing R5 or R6 is
unsubstituted or substituted by one or more identical or different
substituents R20, and (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and Het1 is unsubstituted or substituted by one or more identical
or different substituents R22.
[0084] In one embodiment of the invention, a
(C.sub.1-C.sub.6)-alkyl group representing R5 or R6 is a
(C.sub.1-C.sub.4)-alkyl group, in another embodiment a
(C.sub.1-C.sub.3)-alkyl group, in another embodiment a
(C.sub.1-C.sub.2)-alkyl group, in another embodiment any one or
more groups selected from the series consisting of butyl, propyl,
isopropyl, ethyl and methyl, for example selected from the series
consisting of methyl, ethyl and propyl, which are all unsubstituted
or substituted by one or more, for example 1, 2 or 3, or 1 or 2, or
1, identical or different substituents R20, which substituents can
be present in any positions, for example in position 1 and/or in
position 2 of an ethyl group representing R5 or R6, or in position
1 and/or in position 2 and/or in position 3 of a propyl group
representing R5 or R6.
[0085] In one embodiment of the invention, the number of identical
or different substituents R20 which are optionally present in a
(C.sub.1-C.sub.6)-alkyl group representing R5 or R6, is 1, 2, 3 or
4, in another embodiment it is 1, 2 or 3, in another embodiment it
is 1 or 2, in another embodiment it is 1, in another embodiment it
is 0. In one embodiment, the number of groups R24 representing
substituents R20, which are optionally present in a
(C.sub.1-C.sub.6)-alkyl group representing R5 or R6 besides any
other substituents R20, is 1 or 2, in another embodiment it is 1,
in another embodiment it is 0 (zero), i.e., in the latter
embodiment R20 is as defined, but is not R24. In one embodiment,
the number of oxo groups representing substituents R20, which are
optionally present in a (C.sub.1-C.sub.6)-alkyl group representing
R5 or R6 besides any other substituents R20, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of groups selected from the series
consisting of R31-N(R32)-C(O)--, R34-O--C(O)-- and
R31-N(R32)-S(O).sub.2-- representing substituents R20, which are
optionally present in a (C.sub.1-C.sub.6)-alkyl group representing
R5 or R6 besides any other substituents R20, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0.
[0086] In one embodiment of the invention, the number of identical
or different substituents R21 which are optionally present in
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl and
Het2 groups representing R5 or R6, is independently of each other
1, 2, 3 or 4, in another embodiment it is 1, 2 or 3, in another
embodiment it is 1 or 2, in another embodiment it is 1. In one
embodiment, the number of groups R24 representing substituents R21,
which are optionally present in (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl and Het2 groups representing R5 or
R6 besides any other substituents R21, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of oxo groups representing substituents R21,
which are optionally present in (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.6-C.sub.10)-bicycloalkyl and Het2 groups representing R5 or
R6 besides any other substituents R21, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of groups selected from the series
consisting of R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--
representing substituents R21, which are optionally present in
(C.sub.3-C.sub.7)-cycloalkyl, (C.sub.6-C.sub.10)-bicycloalkyl and
Het2 groups representing R5 or R6 besides any other substituents
R21, is 1 or 2, in another embodiment it is 1, in another
embodiment it is 0.
[0087] In one embodiment of the invention, the number of identical
or different substituents R22 which are optionally present in
phenyl and Het1 groups representing R5 or R6, is independently of
each other 1, 2, 3 or 4, in another embodiment it is 1, 2 or 3, in
another embodiment it is 1 or 2, in another embodiment it is 1, in
another embodiment it is 0. In one embodiment, the number of groups
selected from the series consisting of R31-N(R32)-C(O)--,
R34-O--C(O)-- and R31-N(R32)-S(O).sub.2-representing substituents
R22, which are optionally present in phenyl and Het1 groups
representing R5 or R6 besides any other substituents R22, is 1 or
2, in another embodiment it is 1, in another embodiment it is
0.
[0088] The monocyclic heterocycle which can be formed by the groups
R5 and R6 together with the nitrogen atom carrying them, which
heterocycle is thus bonded via a ring nitrogen atom, can be
4-membered, 5-membered, 6-membered or 7-membered. In one embodiment
of the invention, this heterocycle is 4-membered to 6-membered, in
another embodiment it is 5-membered to 6-membered, in another
embodiment it is 5-membered, in another embodiment it is
6-membered. In one embodiment, a heterocycle formed by the groups
R5 and R6 together with the nitrogen atom carrying them, is
saturated or contains one double bond within the ring, in another
embodiment it is saturated. In one embodiment, the further ring
heteroatom which is optionally present in a heterocycle formed by
the groups R5 and R6 together with the nitrogen atom carrying them,
is selected from the series consisting of nitrogen and oxygen, in
another embodiment it is a nitrogen atom, and in another embodiment
it is an oxygen atom. Examples of heterocyclic groups, from any one
or more of which the heterocyclic groups formed by the groups R5
and R6 together with the nitrogen atom carrying them is selected in
one embodiment of the invention, are azetidin-1-yl,
pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, imidazolidin-1-yl,
oxazolidin-3-yl, thiazolidin-3-yl, piperazin-1-yl, morpholin-4-yl
and thiomorpholin-4-yl, which can all be unsubstituted or
substituted by one or more identical or different substituents
R21.
[0089] In one embodiment of the invention, the number of identical
or different substituents R21 which are optionally present in a
heterocycle formed by R5 and R6 together with the nitrogen atom
carrying them, is 1, 2, 3 or 4, in another embodiment it is 1, 2 or
3, in another embodiment it is 1 or 2, in another embodiment it is
1, in another embodiment it is 0. In one embodiment, the number of
groups R24 representing substituents R21, which are optionally
present in a heterocycle formed by R5 and R6 together with the
nitrogen atom carrying them besides any other substituents R21, is
1 or 2, in another embodiment it is 1, in another embodiment it is
0. In one embodiment, the number of oxo groups representing
substituents R21, which are optionally present in a heterocycle
formed by R5 and R6 together with the nitrogen atom carrying them
besides any other substituents R21, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of groups selected from the series
consisting of R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--
representing substituents R21, which are optionally present in a
heterocycle formed by R5 and R6 together with the nitrogen atom
carrying them besides any other substituents R21, is 1 or 2, in
another embodiment it is 1, in another embodiment it is 0.
[0090] In one embodiment of the invention, R7 is in any of its
occurrences, independently of other occurrences, selected from the
series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and Het2, in another embodiment from
the series consisting of (C.sub.1-C.sub.6)-alkyl, Het1 and Het2, in
another embodiment from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl, Het1 and Het2, in another embodiment
from the series consisting of (C.sub.1-C.sub.6)-alkyl and Het2, in
another embodiment from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl and Het2, in another embodiment from
the series consisting of phenyl and Het1, in another embodiment it
is (C.sub.1-C.sub.6)-alkyl, in another embodiment it is
(C.sub.3-C.sub.7)-cycloalkyl, in another embodiment is phenyl, in
another embodiment is Het1, and in another embodiment is Het2,
wherein all groups (C.sub.1-C.sub.6)-alkyl are unsubstituted or
substituted by one or more identical or different substituents R20,
all groups (C.sub.3-C.sub.7)-cycloalkyl and Het2 are unsubstituted
or substituted by one or more identical or different substituents
R2, and all groups phenyl and Het1 are unsubstituted or substituted
by one or more identical or different substituents R22.
[0091] In one embodiment of the invention, the number of identical
or different substituents R20 which are optionally present in a
(C.sub.1-C.sub.6)-alkyl group representing R7, is 1, 2, 3 or 4, in
another embodiment it is 1, 2 or 3, in another embodiment it is 1
or 2, in another embodiment it is 1, in another embodiment it is 0.
In one embodiment, the number of groups R24 representing
substituents R20, which are optionally present in a
(C.sub.1-C.sub.6)-alkyl group representing R7 besides any other
substituents R20, is 1 or 2, in another embodiment it is 1, in
another embodiment it is 0 (zero), i.e., in the latter embodiment
R20 is as defined, but is not R24. In one embodiment, the number of
oxo groups representing substituents R20, which are optionally
present in a (C.sub.1-C.sub.6)-alkyl group representing R7 besides
any other substituents R20, is 1 or 2, in another embodiment it is
1, in another embodiment it is 0. In one embodiment, the number of
groups selected from the series consisting of R31-N(R32)-C(O)--,
R34-O--C(O)-- and R31-N(R32)-S(O).sub.2-- representing substituents
R20, which are optionally present in a (C.sub.1-C.sub.6)-alkyl
group representing R7 besides any other substituents R20, is 1 or
2, in another embodiment it is 1, in another embodiment it is
0.
[0092] In one embodiment of the invention, the number of identical
or different substituents R21 which are optionally present in
(C.sub.3-C.sub.7)-cycloalkyl and Het2 groups representing R7, is
independently of each other 1, 2, 3 or 4, in another embodiment it
is 1, 2 or 3, in another embodiment it is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of groups R24 representing substituents R21,
which are optionally present in (C.sub.3-C.sub.7)-cycloalkyl and
Het2 groups representing R7 besides any other substituents R21, is
1 or 2, in another embodiment it is 1, in another embodiment it is
0. In one embodiment, the number of oxo groups representing
substituents R21, which are optionally present in
(C.sub.3-C.sub.7)-cycloalkyl and Het2 groups representing R7
besides any other substituents R21, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of groups selected from the series
consisting of R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--
representing substituents R21, which are optionally present in
(C.sub.3-C.sub.7)-cycloalkyl and Het2 groups representing R7
besides any other substituents R21, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0.
[0093] In one embodiment of the invention, the number of identical
or different substituents R22 which are optionally present in
phenyl and Het1 groups representing R7, is independently of each
other 1, 2, 3 or 4, in another embodiment it is 1, 2 or 3, in
another embodiment it is 1 or 2, in another embodiment it is 1, in
another embodiment it is 0. In one embodiment, the number of groups
selected from the series consisting of R31-N(R32)-C(O)--,
R34-O--C(O)-- and R31-N(R32)-S(O).sub.2-representing substituents
R22, which are optionally present in phenyl and Het1 groups
representing R7 besides any other substituents R22, is 1 or 2, in
another embodiment it is 1, in another embodiment it is 0.
[0094] In one embodiment of the invention, R8 is in any of its
occurrences, independently of its other occurrences, selected from
the series consisting of hydrogen and (C.sub.1-C.sub.3)-alkyl, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.2)-alkyl, in another embodiment from the series
consisting of hydrogen and methyl, and in another embodiment R8 is
hydrogen.
[0095] In one embodiment of the invention, R9 is selected from the
series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl
and (C.sub.3-C.sub.7)-cycloalkyl, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl, and in another
embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl.
[0096] In one embodiment of the invention, R10 is selected from the
series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-, in another embodiment from the
series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in another
embodiment from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl, and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl
and (C.sub.3-C.sub.7)-cycloalkyl, in another embodiment from the
series consisting of (C.sub.1-C.sub.6)-alkyl, and in another
embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl.
[0097] In one embodiment of the invention, R20 is selected from the
series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)alkyl-S(O).sub.2--,
(C.sub.3-C.sub.7)-cycloalkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in
another embodiment from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, R30-C(O)--O--, R30-NH--C(O)--O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(HO).sub.2P(O)--O--CH--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in
another embodiment from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O)--, R31-N(R32)-, R33-C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, R31-N(R32)-C(O)--,
R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in another embodiment
from the series consisting of R24, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--. HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, R31-N(R32)-C(O)--,
R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in another embodiment
from the series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O)O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in
another embodiment from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O)--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O)--N(R32)-,
R31-N(R32)-C(O)-- and R31-N(R32)-S(O).sub.2--, in another
embodiment from the series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)- and
R31-N(R32)-C(O)--, in another embodiment from the series consisting
of R24, fluorine, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, R31-N(R32)-C(O)--,
R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in another embodiment
from the series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2N(R32)-,
R31-N(R32)-C(O)-- and R34-O--C(O)--, in another embodiment from the
series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32), R33-C(O)--N(R32)-
and (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, in another
embodiment from the series consisting of R31-N(R32)-,
R33-C(O)--N(R32)- and (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
in another embodiment from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n-- and R31-N(R32)-, in another
embodiment from the series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O-- and (HO).sub.2P(O)--O--, in another
embodiment from the series consisting of R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O-- and (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
in another embodiment from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O-- and
(HO).sub.2P(O)--O--, in another embodiment from the series
consisting of HO--, (C.sub.1-C.sub.6)-alkyl-O--, R30-C(O)--O--,
R30-NH--C(O)--O--, HO--S(O)--O-- and (HO).sub.2P(O) O--, in another
embodiment from the series consisting of HO--, R30-C(O)--O--,
R30-NH--C(O)--O--, HO--S(O).sub.2--O-- and (HO).sub.2P(O)--O--, in
another embodiment from the series consisting of HO--,
HO--S(O).sub.2--O-- and (HO).sub.2P(O)--O--, in another embodiment
from the series consisting of HO-- and (HO).sub.2P(O)--O--, in
another embodiment from the series consisting of R24, HO-- and
(HO).sub.2P(O)--O--, in another embodiment from the series
consisting of R24 and HO--, and in another embodiment R20 is HO--,
and in another embodiment R20 is R24, wherein in case that more
than one substituent R20 is present, the substituents R20 are
independently of one another defined as in any of these
embodiments.
[0098] In one embodiment of the invention, R21 is selected from the
series consisting of (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-, R24, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--, HO--S(O).sub.2O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O)--,
(C.sub.3-C.sub.7)-cycloalkyl-S(O)--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--, in
another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-, R24, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, R30-C(O)--O--, R30-NH--C(O)--O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.4)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)-- and R34-O--C(O)--, in another embodiment from the
series consisting of (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R24, fluorine, HO--, oxo, (C.sub.1-C.sub.6)-alkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
R31-N(R32)-, R33-C(O)--N(R32)- and
(C.sub.1-C.sub.6)-alkyl-S(O)--N(R32)-, in another embodiment from
the series consisting of (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R24, fluorine, HO--, oxo, (C.sub.1-C.sub.6)-alkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O-- and R31-N(R32)-, in
another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-.
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O-- and
R31-N(R32)-, in another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-, fluorine,
HO--, oxo, (C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O-- and (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
in another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-, R24, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)- and R31-N(R32)-C(O)--,
in another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-, R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O)--O--, (HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O)--,
R31-N(R32)-, R33-C(O)--N(R32)- and R31-N(R32)-C(O)--, in another
embodiment from the series consisting of (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
fluorine, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2O--,
(HO).sub.2P(O)--O--, R31-N(R32)-, R33-C(O)--N(R32)- and
R31-N(R32)-C(O)--, in another embodiment from the series consisting
of (C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2O--, (HO).sub.2P(O)--O--. R31-N(R32)-,
R33-C(O)--N(R32)- and R31-N(R32)-C(O)--, in another embodiment from
the series consisting of (C.sub.1-C.sub.4)-alkyl, fluorine, HO--,
oxo, HO--S(O).sub.2--O--, (HO).sub.2P(O)--O-- and
(HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--, in another embodiment
from the series consisting of (C.sub.1-C.sub.4)-alkyl, fluorine,
HO--, oxo, HO--S(O).sub.2--O-- and (HO).sub.2P(O)--O--, in another
embodiment from the series consisting of (C.sub.1-C.sub.4)-alkyl,
fluorine, HO--, oxo and (HO).sub.2P(O)--O--, in another embodiment
from the series consisting of (C.sub.1-C.sub.4)-alkyl, fluorine,
HO-- and oxo, in another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O-- and
(HO).sub.2P(O)--O--, in another embodiment from the series
consisting of (C.sub.1-C.sub.4)-alkyl, fluorine, HO--,
HO--S(O).sub.2--O-- and (HO).sub.2P(O)--O--, in another embodiment
from the series consisting of (C.sub.1-C.sub.4)-alkyl, fluorine,
HO--, HO--S(O).sub.2--O-- and (HO).sub.2P(O)--O--, in another
embodiment from the series consisting of (C.sub.1-C.sub.4)-alkyl,
fluorine, HO-- and (HO).sub.2P(O)--O--, in another embodiment from
the series consisting of (C.sub.1-C.sub.4)-alkyl, fluorine and
HO--, wherein in case that more than one substituent R21 is
present, the substituents R21 are independently of one another
defined as in any of these embodiments. In one embodiment,
substituents R21 which are bonded to a ring nitrogen atom, as can
occur in the case of the group Het2 or the ring which can be formed
by R5 and R6 together with the nitrogen atom carrying them, are
selected from the series consisting of (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-
and R24, wherein R24 is bonded via a ring carbon atom, in another
embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl.
[0099] In one embodiment of the invention, R22 is selected from the
series consisting of halogen, (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, (C.sub.3-C.sub.7)-cycloalkyl, HO--,
oxo, (C.sub.1-C.sub.6)-alkyl-O--, HO--S(O)--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, R33-O--C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, NC--,
R31-N(R32)-C(O)-- and R31-N(R32)-S(O).sub.2--, in another
embodiment from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.3-C.sub.7)-alkyl-S(O).sub.n--, R31-N(R32)-, NC-- and
R31-N(R32)-C(O)--, in another embodiment from the series consisting
of halogen, (C.sub.1-C.sub.4)-alkyl, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-, NC-- and
R31-N(R32)-C(O)--, in another embodiment from the series consisting
of halogen, (C.sub.1-C.sub.4)-alkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (HO).sub.2P(O)--O--CH.sub.2--O--C(O)--O--,
R31-N(R32)-, NC-- and R31-N(R32)-C(O)--, in another embodiment from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, (C.sub.3-C.sub.7)-cycloalkyl, HO--,
oxo, (C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O)--, R31-N(R32)-, R33-C(O)--N(R32)-,
R33-O--C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
NC--, R33-C(O)-- and R31-N(R32)-C(O)--, in another embodiment from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl,
HO--(C.sub.1-C.sub.4)-alkyl-, (C.sub.3-C.sub.7)-cycloalkyl, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, NC--, R33-C(O)-- and R31-N(R32)-C(O)--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)- and R31-N(R32)-C(O)--, in another
embodiment from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--, R31-N(R32)- and NC--, in
another embodiment from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O-- and NC--, in another
embodiment from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(HO).sub.2P(O)--O-- and NC--, in another embodiment from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.6)-alkyl-O-- and NC--, in another embodiment from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.6)-alkyl-O--, in another embodiment from the series
consisting of halogen and (C.sub.1-C.sub.4)-alkyl, wherein in case
that more than one substituent R22 is present, the substituents R22
are independently of one another defined as in any of these
embodiments. In one embodiment, substituents R22 which are bonded
to a ring nitrogen atom, as can occur in the case of the group Het1
and R24, are selected from the series consisting
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl- and
(C.sub.3-C.sub.7)-cycloalkyl, in another embodiment from the series
consisting of (C.sub.1-C.sub.4)-alkyl.
[0100] The monocyclic or bicyclic group R24 can be 3-membered,
4-membered, 5-membered, 6-membered, 7-membered, 8-membered,
9-membered or 10-membered. In one embodiment of the invention, a
monocyclic group R24 is 3-membered, 4-membered, 5-membered,
6-membered or 7-membered, and a bicyclic group R24 is 6-membered,
7-membered, 8-membered, 9-membered or 10-membered. In one
embodiment of the invention, R24 is a monocyclic ring, in another
embodiment a 3-membered to 7-membered monocyclic ring, in another
embodiment a 3-membered to 6-membered monocyclic ring, in another
embodiment a 4-membered to 6-membered monocyclic ring, in another
embodiment a 5-membered or 6-membered monocyclic ring, in another
embodiment a bicyclic ring, in another embodiment a 6-membered to
10-membered bicyclic ring, in another embodiment a 7-membered to
10-membered bicyclic ring, in another embodiment a 7-membered to
9-membered bicyclic ring. The two cycles in a bicyclic group R24
can be fused or form a bridged bicycle or a spirocycle. The
monocyclic or bicyclic ring R24 can be saturated, i.e. not contain
any double bonds within the ring system, or be partially
unsaturated, i.e. contain one or more double bonds within the ring
system, for example, one two, three or four double bonds, or one,
two or three double bonds, or one or two double bonds, or one
double bond, but is not fully aromatic, i.e. it does not contain a
cyclic system of six delocalized pi electrons in the case of a
monocycle or of ten delocalized pi electrons in the case of a
bicycle, or it can be aromatic. The number of double bonds which
can be present in a ring, depends on the type of the ring system
and the ring size. Partially unsaturated rings R24 include also
bicyclic ring systems in which one of the two cycles is aromatic
and the other is not aromatic. In one embodiment, R24 is a
saturated or aromatic ring, in another embodiment a saturated ring,
in another embodiment an aromatic ring.
[0101] The ring R24 can be carbocyclic, i.e. contain 0 (zero) ring
heteroatoms, or heterocyclic, i.e. contain 1, 2, 3 or 4 identical
or different ring heteroatoms. In one embodiment, the number of
ring heteroatoms which are present in R24 is 0, 1, 2 or 3, in
another embodiment 0, 1 or 2, in another embodiment 0 or 1. In one
embodiment of the invention, R24 is in any of its occurrences,
independently of its other occurrences, a carbocyclic ring, and in
another embodiment it is a heterocyclic ring. In a bicyclic ring
R24, ring heteroatoms can be present in one of the two rings or in
both rings in any suitable positions, in bridged and fused bicyclic
rings, ring nitrogen atoms can also be present in bridgehead
positions and fusion positions. In one embodiment of the invention,
a 3-membered ring R24 is carbocyclic ring, specifically a
cyclopropane ring, i.e., in this case the group R24 is a
cyclopropyl group. In one embodiment, ring heteroatoms which are
present in R24, are selected from the series consisting of nitrogen
and oxygen, in another embodiment from the series consisting of
nitrogen and sulfur, and in another embodiment they are nitrogen
atoms. R24 can be bonded via any ring carbon atom and any ring
nitrogen atom which has a free binding position. In a bicyclic
group R24, the ring atom via which R24 is bonded, can be present in
a saturated ring, a partially unsaturated ring or in an aromatic
ring. In one embodiment of the invention, R24 is bonded in any of
its occurrences, independently of its other occurrences, via a ring
carbon atom, in another embodiment via a ring nitrogen atom.
[0102] Types of cyclic groups which are comprised by the definition
of R24, are cycloalkyl groups, bicycloalkyl groups, phenyl groups,
naphthyl groups including naphthalen-1-yl groups and
naphthalen-2-yl groups, partially hydrogenated naphthyl groups such
as 1,2,3,4-tetrahydronaphthalenyl groups, monocyclic and bicyclic
aromatic heterocyclic groups such as the group Het1, for example,
and saturated and partially unsaturated monocyclic and bicyclic
heterocyclic groups such as the group Het2. The explanations given
above and below with respect to such groups apply correspondingly
to such groups representing R24, as do the explanations given above
with respect to heterocyclic groups in general. Examples of groups,
from any one or more of which the group R24 is selected in one
embodiment of the invention, are the groups of the following
formulae,
##STR00009## ##STR00010## ##STR00011##
in which the line crossed with the symbol represents the free bond
via which the group is bonded. The bond originating at the
substituent R22 which is depicted in these formulae, which is not
directed to a specific atom, indicates that these groups are
optionally substituted by one or more identical or different
substituents R22, i.e. they are unsubstituted or substituted by one
or more identical or different substituents R22, and that the
substituents R22 can be present in any positions.
[0103] In one embodiment of the invention, the number of identical
or different substituents R22 which are optionally present in the
group R24, is 1, 2, 3 or 4, in another embodiment it is 1, 2 or 3,
in another embodiment it is 1 or 2, in another embodiment it is 1,
in another embodiment it is 0. In one embodiment, the number of oxo
groups representing substituents R22, which are optionally present
in R24 besides any other substituents R22, is 1 or 2, in another
embodiment it is 1, in another embodiment it is 0. In one
embodiment, the number of groups selected from the series
consisting of R31-N(R32)-C(O)--, R34-O--C(O)-- and
R31-N(R32)-S(O).sub.2-- representing substituents R22, which are
optionally present in R24 besides any other substituents R22, is 1
or 2, in another embodiment it is 1, in another embodiment it is
0.
[0104] In one embodiment of the invention, R30 is in any of its
occurrences, independently of its other occurrences, selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
in another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, in another embodiment from the series
consisting of (C.sub.1-C.sub.6)-alkyl, in another embodiment from
the series consisting of (C.sub.1-C.sub.2)-alkyl, and in another
embodiment R30 is methyl.
[0105] In one embodiment of the invention, R31 and R32 are in any
of their occurrences, independently of other occurrences, and
independently of one another, selected from the series consisting
of hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl
and (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and methyl, or
the groups R31 and R32, together with the nitrogen atom carrying
them, form a 4-membered to 7-membered, monocyclic saturated
heterocycle which, in addition to the nitrogen atom carrying R31
and R32, comprises 0 or 1 further ring heteroatom selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl. In another embodiment, R31 and R32 are in
any of their occurrences, independently of other occurrences, and
independently of one another, selected from the series consisting
of hydrogen, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl
and (C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in
another embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and methyl.
[0106] The monocyclic heterocycle which can be formed by the groups
R31 and R32 together with the nitrogen atom carrying them, which
heterocycle is thus bonded via a ring nitrogen atom, can be
4-membered, 5-membered, 6-membered or 7-membered. In one embodiment
of the invention, the heterocycle formed by the groups R31 and R32
together with the nitrogen atom carrying them, is 5-membered or
6-membered, in another embodiment it is 6-membered. In one
embodiment, the further ring heteroatom which is optionally present
in a heterocycle formed by the groups R31 and R32 together with the
nitrogen atom carrying them, is selected from the series consisting
of nitrogen and oxygen, in another embodiment it is a nitrogen
atom, and in another embodiment it is an oxygen atom. In one
embodiment of the invention, the number of substituents selected
from the series consisting of fluorine and (C.sub.1-C.sub.4)-alkyl,
which can be present in a ring formed by the groups R31 and R32
together with the nitrogen atom carrying them, is 1, 2 or 3, in
another embodiment 1 or 2, in another embodiment 1, in another
embodiment it is 0. In one embodiment of the invention,
substituents which can be present in a ring formed by the groups
R31 and R32 together with the nitrogen atom carrying them, are
fluorine substituents, and in another embodiment they are
(C.sub.1-C.sub.4)-alkyl substituents, for example methyl
substituents, and in another embodiment are substituents in such a
ring bonded to a ring nitrogen atom selected from the series
consisting of (C.sub.1-C.sub.4)-alkyl. Examples of heterocyclic
groups, from any one or more of which the heterocyclic groups
formed by the groups R31 and R32 together with the nitrogen atom
carrying them is selected in one embodiment of the invention, are
azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl,
thiomorpholin-4-yl, and 4-methylpiperazin-1-yl.
[0107] In one embodiment of the invention, R33 is in any of its
occurrences, independently of its other occurrences, selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, in another
embodiment from the series consisting of (C.sub.1-C.sub.6)-alkyl,
in another embodiment from the series consisting of
(C.sub.1-C.sub.4)-alkyl, in another embodiment from the series
consisting of (C.sub.1-C.sub.3)-alkyl, in another embodiment from
the series consisting of (C.sub.1-C.sub.2)-alkyl, and in another
embodiment R33 is methyl.
[0108] In one embodiment of the invention, R34 is in any of its
occurrences, independently of its other occurrences, selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4-alkyl-, in another
embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, in another embodiment from the series
consisting of hydrogen and (C.sub.1-C.sub.4)-alkyl, in another
embodiment from the series consisting of hydrogen and
(C.sub.1-C.sub.3)-alkyl, in another embodiment from the series
consisting of (C.sub.1-C.sub.4)-alkyl, in another embodiment from
the series consisting of (C.sub.1-C.sub.3)-alkyl, and in another
embodiment R34 is hydrogen.
[0109] In one embodiment of the invention, the aromatic group Het1
is in any of its occurrences, independently of other occurrences, a
5-membered heterocycle which comprises one ring heteroatom which is
selected from the series consisting of nitrogen, oxygen and sulfur,
and a further ring heteroatom which is a ring nitrogen atom, or it
is 6-membered heterocycle which comprises one or two ring nitrogen
atoms, in another embodiment Het1 is selected from the series
consisting of the aromatic heterocycles pyrazole, imidazole,
isoxazole, oxazole, thiazole, pyridine, pyrimidine and pyrazine, in
another embodiment from the series consisting of pyrazole,
isoxazole, oxazole, thiazole, pyridine and pyrimidine, in another
embodiment from the series consisting of pyrazole, isoxazole,
oxazole, thiazole and pyridine, in another embodiment from the
series consisting of pyrazole, isoxazole, thiazole and pyridine, in
another embodiment from the series consisting of pyrazole,
isoxazole and pyridine, in another embodiment from the series
consisting of pyrazole, isoxazole and thiazole, which are all
unsubstituted or substituted as indicated. In one embodiment, the
group Het1 is bonded via a ring carbon atom. In one embodiment, the
number of substituents which are optionally present in a group
Het1, is 1, 2 or 3, in another embodiment 1 or 2, in another
embodiment 1, in another embodiment it is 0. In case a certain
group Het1 is optionally substituted by substituents selected from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O-- and no other substitution is specified
for this group Het1, in one embodiment such a group Het1 is
optionally substituted by substituents selected from the series
consisting of halogen and (C.sub.1-C.sub.4)-alkyl, and, in another
embodiment, a substituent in such a group Het1 which is bonded to a
ring nitrogen atom, such as in a pyrrole, pyrazole or imidazole
ring, is selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl.
[0110] The heterocyclic group Het2 can be 4-membered, 5-membered,
6-membered, 7-membered, 8-membered, 9-membered or 10-membered. In
one embodiment of the invention, a monocyclic group Het2 is
4-membered, 5-membered, 6-membered or 7-membered, and a bicyclic
group Het2 is 6-membered, 7-membered, 8-membered, 9-membered or
10-membered. In one embodiment of the invention, Het2 is in any of
its occurrences, independently of other occurrences, a monocyclic
ring, in another embodiment a 4-membered to 7-membered monocyclic
ring, in another embodiment a 4-membered to 6-membered monocyclic
ring, in another embodiment a 5-membered or 6-membered monocyclic
ring, in another embodiment a bicyclic ring, in another embodiment
a 6-membered to 10-membered bicyclic ring, in another embodiment a
7-membered to 10-membered bicyclic ring, in another embodiment a
7-membered to 9-membered bicyclic ring. The two cycles in a
bicyclic group Het2, can be fused or form a bridged bicycle or a
spirocycle. In one embodiment, the group Het2 is saturated or
contains one double bond within the ring, in another embodiment it
is saturated. In one embodiment, the further ring heteroatom which
is optionally present in a group Het2, is selected from the series
consisting of nitrogen and oxygen, in another embodiment it is a
nitrogen atom, and in another embodiment it is an oxygen atom. Het2
can be bonded via any ring carbon atom and any ring nitrogen atom
which has a free binding position. In one embodiment of the
invention, Het2 is bonded in any of its occurrences, independently
of its other occurrences, via a ring carbon atom, in another
embodiment via a ring nitrogen atom. Examples of heterocyclic
groups, from any one or more of which Het2 is selected in one
embodiment of the invention, are oxetanyl, azetidinyl,
tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl,
tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, azepanyl,
morpholinyl, thiomorpholinyl, piperazinyl and
3-azabicyclo[3.1.0]hexyl, which in one embodiment are bonded via a
ring carbon atom and, for example, are the residues oxetan-3-yl,
azetidin-2-yl, azetidin-3-yl, tetrahydrofuran-2-yl,
tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl,
tetrahydrothiophen-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl,
tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl,
tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl,
tetrahydrothiopyran-4-yl, piperidin-2-yl, piperidin-3-yl,
piperidin-4-yl and 3-azabicyclo[3.1.0]hex-6-yl.
[0111] If one or both of the numbers p and q is 0 (zero), one or
both of the parenthesized corners of the cycloalkane ring depicted
in formula I are not present, and the ring carbon atom carrying the
groups R2 and R3 is bonded via a single bond to one or both of the
ring carbons which are adjacent to the atom carrying the oxygen
atom which links the cycloalkane ring to the chroman ring. In one
embodiment of the invention, one of the numbers p and q, for
example p, is selected from the series consisting of 0 and 1, and
the other of the numbers p and q, for example q, is 0. In another
embodiment, both of the numbers p and q are 0, and the respective
compounds are compounds of the formula Ie. In another embodiment of
the invention, one of the numbers p and q is 0 and the other is 1,
and the respective compounds are compounds of the formula If. In
another embodiment of the invention, both of the numbers p and q
are 1, and the respective compounds are compounds of the formula
Ig. The groups Ar and R1 to R4 in the compounds of the formulae Ie,
If and Ig are defined as in the compounds of the formula I.
##STR00012##
[0112] In one embodiment of the invention, the substituents in a
phenyl group in any occurrence in a compound of the formula I,
independently of any other occurrences, are selected from the
series consisting of halogen and (C.sub.1-C.sub.4)-alkyl, unless
specified otherwise. In one embodiment, the number of substituents
in a phenyl group is 1, 2 or 3, in another embodiment 1 or 2, in
another embodiment 1, in another embodiment it is 0, unless
specified otherwise.
[0113] In one embodiment of the invention, the chiral carbon atom
in position 2 of the chroman ring in a compound of the formula I is
present, or is essentially present, for example with a molar ratio
of the two stereoisomers of 98:2, or 99:1, or greater, in uniform
configuration, either in R configuration or in S configuration, as
is indicated by the wavy wedge in the compound of the formula Ih.
In another embodiment of the invention, the chiral carbon atom in
position 2 of the chroman ring in a compound of the formula I is
present, or is essentially present, for example with a molar ratio
of the two stereoisomers of 98:2, or 99:1, or greater, in the
configuration depicted in formula Ik, i.e. in the respective
compound of the formula I the group Ar is located above the plane
which may be assumed to be formed by the chroman ring arranged as
depicted in formula Ik, which configuration is R configuration in
case all groups R4 are hydrogen. In another embodiment of the
invention, the chiral carbon atom in position 2 of the chroman ring
in a compound of the formula I is present, or is essentially
present, for example with a molar ratio of the two stereoisomers of
98:2, or 99:1, or greater, in the configuration depicted in formula
Im, i.e. in the respective compound of the formula I the group Ar
is located below the plane which may be assumed to be formed by the
chroman ring arranged as depicted in formula Im, which
configuration is S configuration in case all groups R4 are
hydrogen.
##STR00013##
[0114] The groups Ar, R1 to R4 and the numbers p and q in the
compounds of the formulae Ih, Ik and Im are defined as in the
compounds of the formula I.
[0115] In one embodiment of the invention, the group R2 and the
oxygen atom, which links the cycloalkane ring depicted in formula I
to the chroman ring, are in cis position with respect to one
another, i.e. they are located on the same side of the plane, for
example above the plane, which may be assumed to be formed by the
cycloalkane ring arranged as depicted in formula In, and the
respective compounds are compounds of the formula In. In another
embodiment of the invention, the group R2 and the oxygen atom,
which links the cycloalkane ring depicted in formula I to the
chroman ring, are in trans position with respect to one another,
i.e. they are located on opposite sides of the plane which may be
assumed to be formed by the cycloalkane ring arranged as depicted
in formula Io, and the respective compounds are compounds of the
formula Io.
##STR00014##
[0116] A subject of the invention are all compounds of the formula
I wherein any one or more structural elements such as groups,
residues, substituents, numbers and stereochemical configurations
are defined as in any of the specified embodiments or definitions
of the elements, or have one or more of the specific meanings which
are mentioned herein as examples of elements, wherein all
combinations of one or more definitions of compounds or elements
and/or specified embodiments and/or specific meanings of elements
are a subject of the present invention. Also with respect to all
such compounds of the formula I, all their stereoisomeric forms and
mixtures of stereoisomeric forms in any ratio, and their
pharmaceutically acceptable salts are a subject of the present
invention.
[0117] As an example of compounds of the invention which with
respect to any structural elements are defined as in specified
embodiments of the invention or definitions of such elements,
compounds of the formula I may be mentioned, wherein
[0118] Ar is phenyl which is unsubstituted or substituted by one or
more identical or different substituents R0;
[0119] R0 is selected from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O;
[0120] R1 is hydrogen or one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0121] R2 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.1-C.sub.6)-alkyl-C(O)--O--, Het1-C(O)--O--, R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O).sub.2--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted
or substituted by one or more identical or different substituents
R20;
[0122] R3 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein (C.sub.1-C.sub.6)-alkyl is
unsubstituted or substituted by one or two identical or different
substituents selected from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl and phenyl;
[0123] or the groups R2 and R3 together are oxo;
[0124] R4 is hydrogen or one or more identical or different
substituents selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--;
[0125] R5 and R6 are independently of one another selected from the
series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl, Het1 and
Het2, wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted or
substituted by one or more identical or different substituents R20,
and (C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and Het1 is unsubstituted or substituted by one or more identical
or different substituents R22,
[0126] or the groups R5 and R6, together with the nitrogen atom
carrying them, form a 4-membered to 7-membered, monocyclic,
saturated or partially unsaturated heterocycle which, in addition
to the nitrogen atom carrying R5 and R6, comprises 0 or 1 further
ring heteroatom selected from the series consisting of nitrogen,
oxygen and sulfur, and which is unsubstituted or substituted by one
or more identical or different substituents R21;
[0127] R7 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl, phenyl, Het1
and Het2, wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted or
substituted by one or more identical or different substituents R20,
and (C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents R21,
and phenyl and Het1 all are unsubstituted or substituted by one or
more identical or different substituents R22;
[0128] R8 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.4)-alkyl;
[0129] R9 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl;
[0130] R10 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl;
[0131] R20 is selected from the series consisting of R24, fluorine,
HO--, oxo, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, R30-C(O)--O--, R30-NH--C(O)--O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(HO).sub.2P(O)--O--CH--O--C(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O)--,
(C.sub.3-C.sub.7)-cycloalkyl-S(O)--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--;
[0132] R21 is selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R34-O--C(O)--(C.sub.1-C.sub.6)-alkyl-, R24, fluorine, HO--, oxo,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
R30-C(O)--O--, R30-NH--C(O)--O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)- and
R31-N(R32)-C(O)--;
[0133] R22 is selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, oxo,
(C.sub.3-C.sub.7)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, R33-O--C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, NC--, R33-C(O)-- and
R31-N(R32)-C(O)--;
[0134] R24 is a 3-membered to 7-membered, monocyclic ring which is
saturated, partially unsaturated or aromatic and comprises 0, 1, 2
or 3 identical or different ring heteroatoms selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents R22;
[0135] R30 and R33 are independently of one another selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-;
[0136] R31 and R32 are independently of one another selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-,
phenyl-(C.sub.1-C.sub.4)-alkyl- and
Het1-(C.sub.1-C.sub.4)-alkyl-;
[0137] R34 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-;
[0138] Het1 is a 5-membered or 6-membered, monocyclic, aromatic
heterocycle which comprises 1, 2 or 3 identical or different ring
heteroatoms selected from the series consisting of nitrogen, oxygen
and sulfur, and which is unsubstituted or substituted by one or
more identical or different substituents selected from the series
consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise;
[0139] Het2 is a 4-membered to 7-membered, monocyclic, saturated or
partially unsaturated heterocycle which comprises 1 or 2 identical
or different ring heteroatoms selected from the series consisting
of nitrogen, oxygen and sulfur;
[0140] n is selected from the series consisting of 0, 1 and 2,
wherein all numbers n are independent of one another;
[0141] p and q are independently of one another selected from the
series consisting of 0 and 1;
[0142] wherein all phenyl groups are unsubstituted or substituted
by one or more identical or different substituents selected from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise;
[0143] wherein all cycloalkyl groups, independently of any other
substituents which can be present on a cycloalkyl group, can be
substituted by one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0144] wherein all alkyl groups, independently of any other
substituents which can be present on an alkyl group, can be
substituted by one or more fluorine substituents;
[0145] in any of their stereoisomeric forms or a mixture of
stereoisomeric forms in any ratio, and the pharmaceutically
acceptable salt thereof.
[0146] As another such example, compounds of the formula I may be
mentioned, wherein
[0147] Ar is phenyl which is unsubstituted or substituted by one or
more identical or different substituents R0;
[0148] R0 is selected from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-O--;
[0149] R1 is hydrogen or one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0150] R2 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
R5-N(R6)-, R7-C(O)--N(R8)-, R9-N(R10)-C(O)--N(R8)- and
R5-N(R6)-C(O)--, wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted
or substituted by one or more identical or different substituents
R20;
[0151] R3 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.6)-alkyl, wherein (C.sub.1-C.sub.65)-alkyl is
unsubstituted or substituted by one or two identical or different
substituents selected from the series consisting of
(C.sub.3-C.sub.7)-cycloalkyl and phenyl;
[0152] or the groups R2 and R3 together are oxo;
[0153] R4 is hydrogen or one or more identical or different
substituents selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl and (C.sub.1-C.sub.4)-alkyl-O--;
[0154] R5 and R6 are independently of one another selected from the
series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and Het2, wherein
(C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by one or
more identical or different substituents R20, and
(C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents
R21,
[0155] or the groups R5 and R6, together with the nitrogen atom
carrying them, form a 4-membered to 7-membered, monocyclic,
saturated or partially unsaturated heterocycle which, in addition
to the nitrogen atom carrying R5 and R6, comprises 0 or 1 further
ring heteroatom selected from the series consisting of nitrogen,
oxygen and sulfur, and which is unsubstituted or substituted by one
or more identical or different substituents R21;
[0156] R7 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2,
wherein (C.sub.1-C.sub.8)-alkyl is unsubstituted or substituted by
one or more identical or different substituents R20, and
(C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents
R21;
[0157] R8 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.4)-alkyl;
[0158] R9 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl;
[0159] R10 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.3-C.sub.7)-cycloalkyl-;
[0160] R20 is selected from the series consisting of R24, fluorine,
HO--, oxo, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, R30-C(O)--O--, R30-NH--C(O)--O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-,
R31-N(R32)-C(O)--, R34-O--C(O)-- and R31-N(R32)-S(O).sub.2--;
[0161] R21 is selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-,
R34-O--C(O)--(C.sub.1-C.sub.4)-alkyl-, R24, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O)--O--, (HO).sub.2P(O)--O--,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.n--, R31-N(R32)-,
R33-C(O)--N(R32)- and R31-N(R32)-C(O)--;
[0162] R22 is selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)-, NC--, R33-C(O)-- and
R31-N(R32)-C(O)--;
[0163] R24 is a 3-membered to 7-membered, monocyclic ring which is
saturated, partially unsaturated or aromatic and comprises 0, 1, 2
or 3 identical or different ring heteroatoms selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents R22;
[0164] R30 and R33 are independently of one another selected from
the series consisting of (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-;
[0165] R31 and R32 are independently of one another selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-;
[0166] R34 is selected from the series consisting of hydrogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-;
[0167] Het2 is a 4-membered to 7-membered, monocyclic, saturated or
partially unsaturated heterocycle which comprises 1 or 2 identical
or different ring heteroatoms selected from the series consisting
of nitrogen, oxygen and sulfur;
[0168] n is selected from the series consisting of 0, 1 and 2,
wherein all numbers n are independent of one another;
[0169] p and q are independently of one another selected from the
series consisting of 0 and 1;
[0170] wherein all phenyl groups are unsubstituted or substituted
by one or more identical or different substituents selected from
the series consisting of halogen, (C.sub.1-C.sub.4)-alkyl and
(C.sub.1-C.sub.4)-alkyl-O--, unless specified otherwise;
[0171] wherein all cycloalkyl groups, independently of any other
substituents which can be present on a cycloalkyl group, can be
substituted by one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0172] wherein all alkyl groups, independently of any other
substituents which can be present on an alkyl group, can be
substituted by one or more fluorine substituents;
[0173] in any of their stereoisomeric forms or a mixture of
stereoisomeric forms in any ratio, and the pharmaceutically
acceptable salt thereof.
[0174] As another such example, compounds of the formula I may be
mentioned, wherein
[0175] Ar is phenyl which is unsubstituted or substituted by one or
more identical or different substituents R0;
[0176] R0 is selected from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl,
(C.sub.1-C.sub.6)-alkyl-O-- and
(C.sub.3-C.sub.7)-cycloalkyl-O--;
[0177] R1 is hydrogen or one or more identical or different
substituents selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0178] R2 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, HO--, R5-N(R6)-, R7-C(O)--N(R8)- and
R5-N(R6)-C(O)--, wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted
or substituted by one or more identical or different substituents
R20;
[0179] R3 is hydrogen;
[0180] R4 is hydrogen or one or more identical or different
substituents selected from the series consisting of halogen and
(C.sub.1-C.sub.4)-alkyl;
[0181] one of the groups R5 and R6 is selected from the series
consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl, and the other
of the groups R5 and R6 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2,
wherein (C.sub.1-C.sub.6)-alkyl all are unsubstituted or
substituted by one or more identical or different substituents R20,
and (C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents
R21;
[0182] R7 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2,
wherein (C.sub.1-C.sub.6)-alkyl is unsubstituted or substituted by
one or more identical or different substituents R20, and
(C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents
R21;
[0183] R8 is selected from the series consisting of hydrogen and
(C.sub.1-C.sub.4)-alkyl;
[0184] R20 is selected from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)-,
(C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)-, R31-N(R32)-C(O)-- and
R31-N(R32)-S(O).sub.2--;
[0185] R21 is selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--, R31-N(R32)-,
R33-C(O)--N(R32)- and R31-N(R32)-C(O)--;
[0186] R22 is selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O)--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O)--, R31-N(R32)-,
R33-C(O)--N(R32)- and R31-N(R32)-C(O)--;
[0187] R24 is a 3-membered to 7-membered, monocyclic ring which is
saturated, partially unsaturated or aromatic and comprises 0, 1, 2
or 3 identical or different ring heteroatoms selected from the
series consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents R22;
[0188] R33 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl;
[0189] R31 and R32 are independently of one another selected from
the series consisting of hydrogen, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.7)-cycloalkyl and
(C.sub.3-C.sub.7)-cycloalkyl-(C.sub.1-C.sub.4)-alkyl-;
[0190] Het2 is a 4-membered to 7-membered, monocyclic, saturated or
partially unsaturated heterocycle which comprises 1 or 2 identical
or different ring heteroatoms selected from the series consisting
of nitrogen, oxygen and sulfur;
[0191] n is selected from the series consisting of 0, 1 and 2,
wherein all numbers n are independent of one another;
[0192] p and q are 1;
[0193] wherein all cycloalkyl groups, independently of any other
substituents which can be present on a cycloalkyl group, can be
substituted by one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0194] wherein all alkyl groups, independently of any other
substituents which can be present on an alkyl group, can be
substituted by one or more fluorine substituents;
[0195] in any of their stereoisomeric forms or a mixture of
stereoisomeric forms in any ratio, and the pharmaceutically
acceptable salt thereof.
[0196] As another such example, compounds of the formula I may be
mentioned, wherein
[0197] Ar is phenyl which is unsubstituted or substituted by one or
two identical or different substituents R0;
[0198] R0 is selected from the series consisting of halogen,
(C.sub.1-C.sub.6)-alkyl and (C.sub.1-C.sub.6)-alkyl-O--;
[0199] R1 is hydrogen;
[0200] R2 is R5-N(R6)-C(O)--;
[0201] R3 is hydrogen;
[0202] R4 is hydrogen;
[0203] one of the groups R5 and R6 is selected from the series
consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl, and the other
of the groups R5 and R6 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.7)-cycloalkyl and Het2,
wherein (C.sub.1-C.sub.6)-alkyl all are unsubstituted or
substituted by one or more identical or different substituents R20,
and (C.sub.3-C.sub.7)-cycloalkyl and Het2 all are unsubstituted or
substituted by one or more identical or different substituents
R21;
[0204] R20 is selected from the series consisting of R24, fluorine,
HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)--O--, (C.sub.1-C.sub.6)-alkyl-S(O)--, R31-N(R32)-,
R33-C(O)--N(R32)-, (C.sub.1-C.sub.6)-alkyl-S(O).sub.2--N(R32)- and
R31-N(R32)-C(O)--;
[0205] R21 is selected from the series consisting of
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
R31-N(R32)-(C.sub.1-C.sub.4)-alkyl-, fluorine, HO--,
(C.sub.1-C.sub.6)-alkyl-O--, (C.sub.3-C.sub.7)-cycloalkyl-O--,
HO--S(O).sub.2--O--, (HO).sub.2P(O)--O--, R31-N(R32)-,
R33-C(O)--N(R32)- and R31-N(R32)-C(O)--;
[0206] R22 is selected from the series consisting of halogen,
(C.sub.1-C.sub.4)-alkyl, HO--(C.sub.1-C.sub.4)-alkyl-,
(C.sub.3-C.sub.7)-cycloalkyl, HO--, (C.sub.1-C.sub.6)-alkyl-O--,
(C.sub.3-C.sub.7)-cycloalkyl-O--, HO--S(O).sub.2--O--,
(HO).sub.2P(O)O--, (C.sub.1-C.sub.6)-alkyl-S(O).sub.n--,
R31-N(R32)-, R33-C(O)--N(R32)- and R31-N(R32)-C(O)--;
[0207] R24 is a 3-membered to 7-membered, monocyclic ring which is
saturated, partially unsaturated or aromatic and comprises 0, 1 or
2 identical or different ring heteroatoms selected from the series
consisting of nitrogen, oxygen and sulfur, and which is
unsubstituted or substituted by one or more identical or different
substituents R22;
[0208] R33 is selected from the series consisting of
(C.sub.1-C.sub.6)-alkyl;
[0209] R31 and R32 are independently of one another selected from
the series consisting of hydrogen and (C.sub.1-C.sub.6)-alkyl;
[0210] Het2 is a 4-membered to 7-membered, monocyclic, saturated or
partially unsaturated heterocycle which comprises 1 or 2 identical
or different ring heteroatoms selected from the series consisting
of nitrogen, oxygen and sulfur;
[0211] n is selected from the series consisting of 0, 1 and 2,
wherein all numbers n are independent of one another;
[0212] p and q are 1;
[0213] wherein all cycloalkyl groups independently of any other
substituents which can be present on a cycloalkyl, can be
substituted by one or more identical or different substituents
selected from the series consisting of fluorine and
(C.sub.1-C.sub.4)-alkyl;
[0214] wherein all alkyl groups, independently of any other
substituents which can be present on an alkyl group, can be
substituted by one or more fluorine substituents;
[0215] in any of their stereoisomeric forms or a mixture of
stereoisomeric forms in any ratio, and the pharmaceutically
acceptable salt thereof.
[0216] A subject of the invention also is a compound of the formula
I which is selected from any of the specific compounds of the
formula I which are disclosed herein, or is any one of the specific
compounds of the formula I which are disclosed herein, irrespective
thereof whether they are disclosed as a free compound and/or as a
specific salt, or a pharmaceutically acceptable salt thereof,
wherein the compound of the formula I is a subject of the invention
in any of its stereoisomeric forms or a mixture of stereoisomeric
forms in any ratio as well as any specific salts and stereoisomeric
forms disclosed herein. For example, a subject of the invention is
a compound of the formula I which is selected from the series
consisting of: [0217]
trans-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexylamine, [0218]
N-(Isoxazol-5-ylmethyl)-4-(2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxam-
ide, [0219]
2-Amino-N-[trans-4-((S)-2-phenyl-chroman-6-yloxy)-cyclohexyl]-acetamide,
[0220]
4-(2-o-Tolyl-chroman-6-yloxy)-N-(1,3,5-trimethylpyrazol-4-ylmethyl-
)-cyclohexylamine, [0221]
(S)--N-[trans-4-(2-Phenyl-chroman-6-yloxy)-cyclohexyl]-pyrrolidine-2-carb-
oxamide, [0222]
trans-4-((R)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide, [0223]
trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide, [0224]
cis-4-((R)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide, [0225]
cis-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide, and [0226] Phosphoric acid
mono-(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-am-
ino}-ethyl) ester disodium salt, or which is any one of these
compounds, and its pharmaceutically acceptable salts, wherein the
compound of the formula I is a subject of the invention in any of
its stereoisomeric forms or a mixture of stereoisomeric forms in
any ratio, unless a specific stereoisomeric form is specified with
respect to any carbon atoms in the respective compound.
[0227] Another subject of the present invention are processes for
the preparation of the compounds of the formula I which are
outlined below and by which the compounds of the formula I and
intermediates occurring in the course of their synthesis are
obtainable. For example, one such process relates to the synthesis
of compounds of the formula I from chroman-6-ols of the formula II
and cycloalkanols of the formula III, and includes the formation of
the ether linkage between the cycloalkane ring and the chroman ring
to give compounds of the formula IV and, depending on the meaning
of the groups X and Y in the compound of the formula III and the
groups R2 and R3 in the final compound of the formula I, the
subsequent conversion of the groups X and Y into the groups R2 and
R3 and/or other conversions of groups.
##STR00015##
[0228] The groups Ar, R1 and R4 and the numbers p and q in the
compounds of the formulae II, III and IV are defined as in the
compounds of the formula I, and additionally can functional groups
be present in protected form or in the form of a precursor group
which is subsequently converted into the final group. One or both
of the groups X and Y in the compounds of the formulae III and IV
can be the groups R2 and R3 which are present in the final compound
of the formula I, and thus in certain cases the compound of the
formula IV already be the compound of the formula I, or one or both
of the groups X and Y can be protected forms or precursor groups of
the groups R2 and R3 or starting groups for the formation of the
groups R2 and R3. For example, in case the groups R2 and R3 in the
compound of the formula I do not interfere with the formation of
the ether linkage, such as in case R2 is hydrogen, or alkyl which
may be unsubstituted or substituted by indifferent substituents, or
alkyl-O--, for example, and/or R3 is hydrogen, or alkyl which may
be unsubstituted or substituted by indifferent substituents, the
groups X and Y in the compound of the formula III may already have
the meaning of the respective groups R2 and R3. For the synthesis
of compounds of the formula I in which R2 is HO--, alkyl-O--,
alkyl-C(O)--O--, phenyl-C(O)--O-- or Het1-C(O)--O--, and R3 is
hydrogen or alkyl, or R2 and R3 together are oxo, compounds of the
formula III may be employed in which X is a protected hydroxy group
and Y is hydrogen or alkyl, or X and Y together are a protected oxo
group, and the obtained compounds of the formula IV deprotected and
subjected to a variety of further reactions. Likewise, for the
synthesis of compounds of the formula I in which R2 is R5-N(R6)-,
R7-C(O)--N(R8)-, R7-S(O)--N(R8)- or R9-N(R10)-C(O)--N(R8)-,
compounds of the formula III may be employed in which X is a
protected amino group and Y is hydrogen or alkyl, and the obtained
compounds of the formula IV deprotected and subjected to a variety
of further reactions. For the synthesis of compounds of the formula
I in which R2 is an amide group R5-N(R6)-C(O)--, compounds of the
formula III may be employed in which X is an ester group such as
alkyl-O--C(O)-- and Y is hydrogen or alkyl, and the obtained
compounds of the formula IV either directly or via the respective
carboxylic acids converted in the amide compounds of the formula I.
More details on such synthesis strategies are given below and in
the examples. A wide range of suitable starting cycloalkanols of
the formula III are commercially available or can be prepared
according to, or analogously to, procedures described in the
literature, as applies likewise to the other starting compounds
employed in the syntheses of the compounds of the formula I.
[0229] The reaction of the compounds of the formulae II and III,
i.e. the formation of the ether linkage, is conveniently performed
by means of the well-known Mitsunobu reaction in the presence of a
tertiary phosphine, such as a triarylphosphine like
triphenylphosphine or a trialkylphosphine like tributylphosphine,
and an azodicarboxylic acid derivative, such an azodicarboxylic
acid diester like diethyl azodicarboxylate (DEAD) and diisopropyl
azodicarboxylate (DIAD) or an azodicarboxylic acid diamide like
azodicarboxylic acid dipiperidide (ADDP). The Mitsunobu reaction,
which proceeds with inversion of the configuration at the carbon
atom in the compound of the formula III which carries the hydroxy
group depicted in formula III, is performed under anhydrous
conditions in an inert solvent such as a hydrocarbon like benzene
and toluene, a chlorinated hydrocarbon like dichloromethane or
chloroform, an ether like diethyl ether, tetrahydrofuran (THF) or
dioxane, a nitrile like acetonitrile, or an amide like
dimethylformamide (DMF), generally at temperatures from about
-50.degree. C. to about 100.degree. C., in particular from about
0.degree. C. to about 30.degree. C. More details are found in the
various literature articles about the Mitsunobu reaction, such as
the review articles by O. Mitsunobu, Synthesis (1981): 1-28; D. L.
Hughes, Organic Reactions 42 (1992): 335-656; K. C. Kumara Swamy et
al., Chemical Reviews 109 (2009): 2551-2651.
[0230] As an example of the syntheses of types of compounds of the
formula I from compounds of the formulae II and III via the
compounds of the formula IV mentioned above, in the following
scheme the synthesis of the compounds of the formula Id is
illustrated, i.e. compounds of the formula I in which R2 is
R5-N(R6)-C(O)--.
##STR00016##
[0231] As mentioned above, compounds of the formula III in which X
is an ester group, can be reacted with compounds of the formula II
to give compounds of the formula IV, such as the compounds of the
formula IVa in which R50 is (C.sub.1-C.sub.4)-alkyl, for example.
The compounds of the formula IVa, in particular compounds of the
formula IVa in which R50 is (C.sub.1-C.sub.2)-alkyl, can be reacted
with amines of the formula V under standard conditions for the
aminolysis of esters, for example in a solvent such as a
hydrocarbon like toluene, a chlorinated hydrocarbon like
dichloromethane, 1,2-dichloroethane or chlorobenzene or an ether
like THF, dioxane or 1,2-dimethoxyethane (DME) at temperatures from
about 20.degree. C. to about 120.degree. C., to give compounds of
the formula Id. Compounds of the formula IVa can also be
transformed into compounds of the formula Id in a convenient manner
by first converting the compound of the formula IVa into the
respective carboxylic acid of the formula IVb, or a salt thereof,
and reacting the compound of the formula IVb or its salt with an
amine of the formula V under standard conditions for the formation
of amides from carboxylic acids. The groups Ar, R1, R3, R4, R5 and
R6 and the numbers p and q in the compounds of the formulae IVa,
IVb and V are defined as in the compounds of the formula I, and
additionally can functional groups be present in protected form or
in the form of a precursor group which is subsequently converted
into the final group.
[0232] Compounds of the formula IVa can be converted into compounds
of the formula IVb by treatment with an acid or base, for example
by treatment with an alkali metal hydroxide such as lithium
hydroxide, sodium hydroxide or potassium hydroxide in a solvent
such as an ether like THF, dioxane or DME or an alcohol such as
methanol or ethanol, or a mixture of solvents, in particular an
aqueous solvent or mixture of solvents, or by treatment with
hydrochloric acid or trifluoroacetic acid in a solvent such as a
chlorinated hydrocarbon like dichloromethane, an ether or an
alcohol, in particular in the case of a tert-butyl ester, at
temperatures from about 20.degree. C. to about 100.degree. C.,
followed by standard work-up procedures such as an acidification in
case the ester of the formula IVa is hydrolyzed in the presence of
a base and a free carboxylic acid of the formula IVb is to be
prepared, wherein the detailed conditions depend on the particulars
of the specific case, as usual, and are readily chosen by a person
skilled in the art. For the reaction with the compound of the
formula V, the carboxylic acid group HO--C(O)-- in the compound of
the formula IVb is generally activated in situ by means of a
customary amide coupling reagent or converted into a reactive
carboxylic acid derivative which can be prepared in situ or
isolated. For example, the compound of the formula IVb can be
converted into an acid halide, e.g. by treatment with thionyl
chloride, phosphorus pentachloride or oxalyl chloride, or treated
with an alkyl chloroformate like ethyl chloroformate or isobutyl
chloroformate to give a mixed anhydride. Customary coupling
reagents which can be employed, are propanephosphonic anhydride,
N,N'-carbonyldiazoles like N,N'-carbonyldiimidazole (CDI),
carbodiimides like 1,3-diisopropylcarbodiimide (DIC),
1,3-dicyclohexylcarbodiimide (DCC) or
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC),
carbodiimides together with additives like 1-hydroxybenzotriazole
(HOBT) or 1-hydroxy-7-azabenzotriazole (HOAT), uronium-based
coupling reagents like
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HATU),
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HBTU) or
O-(cyano(ethoxycarbonyl)methyleneamino)-N,N,N',N'-tetramethylur-
onium tetrafluoroborate (TOTU), and phosphonium-based coupling
reagents like (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate (BOP),
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyBOP) or bromotripyrrolidinophosphonium hexafluorophosphate
(PyBroP). The reaction of the activated compound of the formula IVb
or a reactive derivative of the compound of the formula IVb is
generally carried out in an inert solvent, for example a
hydrocarbon like toluene, a chlorinated hydrocarbon like
dichloromethane, an ether like THF, dioxane or DME, an ester like
ethyl acetate or butyl acetate, a nitrile like acetonitrile, an
amide like DMF or N-methylpyrrolidin-2-one (NMP), or water, or a
mixture of solvents, at temperatures from about -10.degree. C. to
about 100.degree. C., in particular at temperatures from about
0.degree. C. to about 60.degree. C. Favorably, the reaction is
carried out in the presence of a base such as a tertiary amine,
like triethylamine, ethyldiisopropylamine, N-methylmorpholine or
pyridine, or an inorganic base such as an alkali metal hydroxide,
carbonate or hydrogencarbonate, like sodium hydroxide, potassium
hydroxide, sodium carbonate or sodium hydrogencarbonate.
[0233] As another example, in the following scheme the synthesis of
compounds of the formula I in which R2 and R3 together are oxo,
i.e. compounds of the formula Ip, and their use in the synthesis of
further compounds of the formula I is illustrated.
##STR00017##
[0234] Compounds of the formula II can be reacted with compounds of
the formula III in which the groups X and Y together are a divalent
1,2-ethylenedioxy group (--O--CH.sub.2--CH.sub.2--O--), i.e.
1,4-dioxaspirocycloalkanols of the formula IIIa, which are a
protected form of the respective hydroxycycloalkanones in which the
oxo group is ketalized with ethylene glycol. The obtained compounds
of the formula IVc can be deprotected under standard conditions,
for example by treatment with hydrochloric acid at temperatures
from about 20.degree. C. from about 30.degree. C., to give the
respective ketones, i.e. the compounds of the formula Ip, which
already are final compounds of the formula I. The compounds of the
formula Ip can readily be transformed into further compounds of the
formula I under standard conditions. For example, they can be
converted into compounds of the formula I in which R2 is HO--, i.e.
compounds of the formula Iq, by reduction with a complex hydride
reducing agent such as sodium borohydride to give compounds of the
formula Iq in which R3 is hydrogen, or by treatment with a Grignard
reagent to give compounds of the formula Iq in which R3 is an
optionally substituted alkyl group. The compounds of the formula Ip
can also be reacted with amines of the formula V, in particular
amines in which at least one of the groups R5 and R6 is different
from hydrogen, in a reductive amination reaction, for example with
a complex borohydride as reducing agent such as sodium
cyanoborohydride or sodium triacetoxyborohydride, to give compounds
of the formula I in which R2 is the group R5-N(R6)-, i.e. compounds
of the formula Ia, and R3 is hydrogen. By reaction with
tert-butylsulfinamide of the formula VI and subsequently with a
Grignard reagent the compounds of the formula Ip can be converted
into compounds of the formula Ia in which R3 is an optionally
substituted alkyl group and R5 and R6 are hydrogen, which compounds
can be further modified at the nitrogen atom, for example alkylated
in a reductive amination reaction, or acylated or sulfonylated,
under standard conditions. The groups Ar, R1 and R4 and the numbers
p and q in the compounds of the formulae IIIa and IVc are defined
as in the compounds of the formula I, and additionally can
functional groups be present in protected form or in the form of a
precursor group which is subsequently converted into the final
group.
[0235] As another example, in the following scheme the conversion
of compounds of the formula IV in which the group X is a protected
amino group and the group Y is the group R3, for example hydrogen,
into compounds of the formula I is illustrated.
##STR00018##
[0236] Compounds of the formula IVd, which can be obtained from
compounds of the formula II and readily available
aminocycloalkanols of the formula III which are protected at the
nitrogen atom by a tert-butyloxy (Boc) group, can be deprotected by
treatment with an acid, for example trifluoroacetic acid, at
temperatures from about 20.degree. C. to about 30.degree. C. to
give compounds of the formula Ir, which already are final compounds
of the formula I. The compounds of the formula Ir can readily be
transformed into further compounds of the formula I, for example
acylated with compounds of the formula VII and sulfonylated with
compounds of the formula VIII to give compounds of the formula I in
which R2 is the group R7-C(O)--NH-- and the group
R7-S(O).sub.2--NH--, respectively, and R8 is hydrogen, i.e.
compounds of the formulae Is and It. The compounds of the formula
Ir can also alkylated at the amino group, for example in a
reductive amination reaction, to give corresponding compounds of
the formula Ir in which the nitrogen atom carries one or two alkyl
groups, and the latter compounds carrying one alkyl group acylated
with compounds of the formula VII and sulfonylated with compounds
of the formula VIII to give corresponding compounds of the formulae
Is and It in which R8 is alkyl. The groups Ar, R1, R3, R4 and R7
and the numbers p and q in the compounds of the formulae IVd, VII
and VIII are defined as in the compounds of the formula I, and
additionally can functional groups be present in protected form or
in the form of a precursor group which is subsequently converted
into the final group. The groups Z1 and Z2 in the compounds of the
formulae VII and VIII are nucleophilically substitutable leaving
groups, in particular chlorine, in which latter case the compounds
of the formulae VII and VIII are carboxylic acid chlorides and
sulfonic acid chlorides. The groups Z1 and Z2 can also be a hydroxy
group, in which case the compounds of the formulae VII and VIII are
carboxylic acids and sulfonic acids which are generally activated
in situ by means of a customary amide coupling reagent or converted
into a reactive carboxylic acid derivative, such as the compound in
which Z1 or Z2 is chlorine, for the reaction with the compound of
the formula Ir. The explanations on activating agents and reaction
conditions given above with respect to the reaction of the
compounds of the formula IVb with the compounds of the formula V to
give carboxamides apply correspondingly to the reaction of the
compounds of the formulae VII and VIII with the compounds of the
formula Ir to give carboxamides and sulfonamides.
[0237] For obtaining further compounds of the formula I, various
transformations of functional groups can be carried out under
standard conditions in compounds of the formula I obtained as
described above, or in intermediates or starting compounds in the
synthesis of the compounds of the formula I. For example, a hydroxy
group can be reacted with a carboxylic acid or a reactive
derivative thereof in a similar manner as described above for the
reaction of a carboxylic acid with an amine, to give a carboxylic
acid ester. Etherifications of hydroxy groups can be performed by
alkylation with the respective halogen compound, for example a
bromide or iodide, in the presence of a base such an alkali metal
hydride like sodium hydride or an alkali metal carbonate like
potassium carbonate or cesium carbonate in an inert solvent such as
an amide like DMF or NMP or a ketone like acetone or butan-2-one,
or with the respective alcohol under the conditions of the
Mitsunobu reaction in the presence of a phosphine like
triphenylphosphine or tributylphosphine and an azodicarboxylic acid
derivative like diethyl azodicarboxylate or diisopropyl
azodicarboxylate. By reaction with an isocyanate, a hydroxy group
can be converted into an N-substituted carbamic acid ester. By
treatment with a suitable halogenating agent, a hydroxy group can
be converted into a halide. By treatment with sulfur trioxide in
the presence of pyridine, a hydroxy group can be converted into the
sulfuric acid mono ester. By treatment with a suitable
phosphoramidite, such as dibenzyl N,N-diisopropyl-phosphoramidite,
diallyl N,N-diisopropylphosphoramidite or di-tert-butyl
N,N-diisopropyl-phosphoramidite of the formula
(isopropyl).sub.2N--P(O--R55).sub.2, in which R55 is benzyl, allyl
or tert-butyl, for example, in the presence of tetrazole and
subsequent oxidation, for example with a peracid like
3-chloro-perbenzoic acid, a hydroxy group can be converted into its
phosphoric acid ester dibenzyl ester, phosphoric acid ester diallyl
ester and phosphoric acid ester di-tert-butyl ester, respectively,
which can be cleaved to the phosphoric acid mono ester of the
hydroxy group, i.e. the compound which contains the group
(HO).sub.2P(O)-- attached to the oxygen atom of the hydroxy group,
by catalytic hydrogenation in the presence of a palladium catalyst
in the case of the dibenzyl ester, by a palladium-catalyzed
nucleophilic substitution in the case of the diallyl ester, and by
treatment with an acid such as trifluoroacetic acid in the case of
the di-tert-butyl ester. By treatment with chloromethyl
chloroformate and subsequently with silver dibenzylphosphate, a
hydroxy group can be converted into the carbonic acid ester
dibenzyloxyphosphoryloxymethyl ester, which can be cleaved to the
carbonic acid ester phosphonooxymethyl ester of the hydroxy group.
i.e. the compound which contains the group
(HO).sub.2P(O)--O--CH.sub.2--O--C(O)-- attached to the oxygen atom
of the hydroxy group, by catalytic hydrogenation in the presence of
a palladium catalyst (cf. WO 2010/039474). A halogen atom can be
replaced with a variety of groups in a substitution reaction which
may also be a transition-metal catalyzed reaction. An amino group
can be modified under standard conditions for alkylation, for
example by reaction with a halogen compound or by reductive
amination of a carbonyl compound, or for acylation or
sulfonylation, for example by reaction with an activated carboxylic
acid or a carboxylic acid derivative like an acid chloride or
anhydride. A carboxylic acid ester group can be hydrolyzed under
acidic or basic conditions to give a carboxylic acid. A carboxylic
acid group can be activated or converted into a reactive derivative
as outlined above and reacted with an alcohol or an amine or
ammonia to give an ester or amide. A primary amide can be
dehydrated to give a nitrile. A sulfur atom in an alkyl-S-- group
or in a heterocyclic ring can be oxidized with a peroxide like
hydrogen peroxide or a peracid to give a sulfoxide moiety (S(O)) or
a sulfone moiety (S(O).sub.2). A carboxylic acid group, carboxylic
acid ester group and a ketone group can be reduced to an alcohol,
for example with a complex hydride such al lithium aluminium
hydride, lithium borohydride or sodium borohydride. A hydroxy group
can be oxidized to an oxo group by means of pyridinium
chlorochromate or the Dess-Martin periodinane reagent, for example.
All such reactions in the preparation of the compounds of the
formula I are known per se and can be carried out in a manner
familiar to a person skilled in the art according to, or
analogously, to procedures which are described in the standard
literature, for example in Houben-Weyl, Methods of Organic
Chemistry, Thieme; or Organic Reactions, John Wiley & Sons; or
R. C. Larock, Comprehensive Organic Transformations: A Guide to
Functional Group Preparations, 2. ed. (1999), John Wiley &
Sons, and the references quoted therein.
[0238] The chroman-6-ols of the formula II which are employed in
the synthesis of the compounds of the formula IV described above,
can be obtained by various processes. In one of them, an
acetophenone of the formula IX, which is substituted in the benzene
ring by a hydroxy group and a group G1 and can additionally be
substituted in the benzene ring and the acetyl group by
substituents R4, is condensed with an aldehyde of the formula X in
the presence of a base to give a chroman-4-one of the formula XII
and/or a chalcone of the formula XI, and an obtained chalcone of
the formula XI subsequently cyclized to the chroman-4-one of the
formula XII.
##STR00019##
[0239] The groups Ar and R4 in the compounds of the formulae IX, X,
XI and XII are defined as in the compounds of the formula I, and
additionally can functional groups be present in protected form or
in the form of a precursor group which is subsequently converted
into the final group. The group G1 in the compounds of the formulae
IX, XI and XII is a hydroxy group or bromine. When performing the
reaction of the compounds of the formulae IX and X in the presence
of an alkali metal hydroxide such as potassium hydroxide as the
base in a solvent such as an alcohol like methanol or ethanol at
temperatures from about 30.degree. C. to about 70.degree. C., the
obtained product is the chalcone of the formula XI. When performing
the reaction of the compounds of the formulae IX and X in the
presence of a salt of a weak acid such as ammonium acetate, for
example, in a solvent such as acetic acid at temperatures from
about 100.degree. C. to about 120.degree. C. the obtained product
is a mixture of the chalcone of the formula XI and chroman-4-one of
the formula XII. The compound of the formula XI, as well as a
mixture of the compounds of the formulae XI and XII, can be
employed in the cyclization reaction to give the compound of the
formula XII, which can be carried out by treating the starting
material with an acid like hydrochloric acid or with an amine like
ethyldiisopropylamine and potassium fluoride, in a solvent such as
an alcohol like methanol or ethanol at temperatures from about
60.degree. C. to about 100.degree. C.
[0240] The oxo group in the ring position 4 of the compounds of the
formula XII is then reduced to a CH.sub.2 group to give the
compounds of the formula XIV, favorably stepwise via the
4-hydroxy-chroman derivatives of the formula XIII.
##STR00020##
[0241] The groups Ar and R4 in the compounds of the formulae XIII
and XIV are defined as in the compounds of the formula I, and
additionally can functional groups be present in protected form or
in the form of a precursor group which is subsequently converted
into the final group. The group G1 in the compounds of the formulae
XIII and XIV is a hydroxy group or bromine. The reduction of the
compounds of the formula XII to the compounds of the formula XIII
can be carried out under standard conditions for the reduction of a
ketone to an alcohol, for example by means of a complex hydride as
reducing agent, or a borane derivative, such as the
borane-tetrahydrofuran complex in a solvent such as an ether like
THF or dioxane, at temperatures from about 30.degree. C. to about
80.degree. C. The reduction of the compounds of the formula XIII to
the compounds of the formula XIV can be performed, for example, by
treatment with a silane reducing agent such as a trialkylsilane
like triethylsilane and an acid such as trifluoroacetic acid in a
solvent such as a chlorinated hydrocarbon like dichloromethane at
temperatures from about 0.degree. C. to about 40.degree. C. In case
the group G1 in the compound of the formula XIII and its precursor
compounds is a hydroxy group, the obtained compound of the formula
XIV already is a compound of the formula II. In case the group G1
in the obtained compound of the formula XIV is bromine, it can be
converted into a hydroxy group by metalation of the compound of the
formula XIV with a organolithium compound such as butyllithium and
treatment with a trialkyl borate such as triisopropyl borate in a
solvent such as a hydrocarbon like heptane or cyclohexane or an
ether like THF or dioxane at temperatures from about -80.degree. C.
to about 0.degree. C., followed by oxidative cleavage, for example
by means of hydrogen peroxide in the presence of a base such as
sodium hydroxide.
[0242] Further processes for the preparation of chroman-6-ols of
the formula II involve a cyclization of a
3-hydroxypropyl-substituted benzene derivative of the formula XV,
which is substituted in the benzene ring by two suitable groups G2
and G3 and can additionally be substituted in the benzene ring and
the propyl group by substituents R4, to give a chroman derivative
of the formula XVI, in which the group G3 is then converted into
the hydroxy group present in the compounds of the formula II.
##STR00021##
[0243] The groups Ar and R4 in the compounds of the formulae XV and
XVI are defined as in the compounds of the formula I, and
additionally can functional groups be present in protected form or
in the form of a precursor group which is subsequently converted
into the final group. The group G2 in the compounds of the formula
XV can be a hydroxy group or a nucleophilically substitutable
leaving group, for example fluorine. The group G3 in the compounds
of the formulae XV and XVI can be bromine or
(C.sub.1-C.sub.4)-alkyl-O-- such as methoxy, for example. In case
G3 is bromine, the conversion of the group G3 in the compound of
the formula XVI into the hydroxy group in the compound of the
formula II can be performed as described above for the conversion
of the compounds of the formula XIV into the compounds of the
formula II. In case G3 is (C.sub.1-C.sub.4)-alkyl-O--, the
conversion into the hydroxy group can be performed according to
standard procedures for ether cleavage, for example by treatment
with boron tribromide in a chlorinated hydrocarbon such as
dichloromethane at temperatures from about -20.degree. C. to about
10.degree. C. in the case of a methoxy group. In case the group G2
is a hydroxy group, the cyclization of the compound of the formula
XV to the compound of the formula XVI can conveniently be performed
under the conditions of the Mitsunobu reaction by treatment with a
phosphine such as triphenylphosphine or tributylphosphine and an
azodicarboxylic acid derivative such as diethyl azodicarboxylate or
diisopropyl azodicarboxylate in a solvent such as an ether like THF
or dioxane at temperatures from about 0.degree. to about 30.degree.
C. In case the benzene ring carrying G2 in the compound of the
formula XV is susceptible to a nucleophilic aromatic substitution
and G2 is a leaving group such as fluorine, the cyclization can be
performed by treatment of the compound of the formula XV with a
base which enhances the nucleophilicity of the hydroxy group in
position 3 of the propyl group, for example an alkali metal amide
or an alkali metal hydride like sodium hydride, in an inert solvent
such as an ether like THF or dioxane or an amide like DMF or NMP at
temperatures from about -20.degree. C. to about 100.degree. C.
[0244] By cyclization of compounds of the formula XV also
individual stereoisomeric forms of the compounds of the formula XVI
and II, and finally of compounds of the formula I, can conveniently
be prepared in which the chiral carbon atom in position 2 of the
chroman ring is present either in R configuration or in S
configuration. For the synthesis of such individual stereoisomers,
which can otherwise be obtained, for example, by chromatographic
resolution on a chiral phase of a mixture of the stereoisomers of
the final compounds of the formula I or at any stage of the
synthesis, the individual stereoisomeric forms of the
3-hydroxypropyl-substituted benzene of the formula XV are employed,
i.e. the compounds of the formula XVa. Depending on the cyclization
reaction and the conditions chosen, the cyclization can proceed
with retention or inversion of the configuration of the chiral
carbon atom to give the individual stereoisomeric forms of the
compounds of the formula XVI, i.e. the compounds of the formula
XVIa, which can be reacted further to the individual stereoisomeric
forms compounds of the formulae II and I. In the compounds of the
formulae XVa and XVIa are the groups Ar, R4, G2 and G3 defined as
in the compounds of the formula XV and XVI, respectively, and the
depicted chiral carbon atom is present, or is essentially present,
either in R configuration or in S configuration, as is indicated by
the wavy wedge.
##STR00022##
[0245] One embodiment of the present invention thus relates to a
process for the preparation of a compound of the formula I,
##STR00023##
which comprises cyclizing a compound of the formula XV to a
compound of the formula XVI, converting the compound of the formula
XVI into a compound of the formula II, reacting the compound of the
formula II with a compound of the formula III to give a compound of
the formula IV, and converting the compound of the formula IV into
a compound of the formula I.
[0246] Another embodiment of the present invention relates to the
process described afore, in which the chiral carbon atom carrying
the group Ar in the compounds of the formulae II, IV, XV and XVI is
present, or is essentially present, in uniform configuration,
either in R configuration or in S configuration, i.e. to a process
for the preparation of a compound of the formula Ih,
##STR00024##
which comprises cyclizing a compound of the formula XVa to a
compound of the formula XVIa, converting the compound of the
formula XVIa into a compound of the formula IIa, reacting the
compound of the formula IIa with a compound of the formula III to
give a compound of the formula IVe, and converting the compound of
the formula IVe into a compound of the formula Ih. In the compounds
of the formulae IIa and IVe are the groups Ar, R1, R4, X and Y and
the numbers p and q defined as in the compounds of the formula II
and IV, respectively.
[0247] The compounds of the formula XV, including the
stereoisomeric forms of the formula XVa, which are employed in the
cyclization reaction to the compounds of the formulae XVI and XVIa
described above, can be obtained according to, or analogously to,
various processes which are described in the literature. For
example, a 3-oxo-propionic acid ester of the formula XVII can be
alkylated with a benzyl halide of the formula XVIII to give a
3-oxo-propyl-substituted benzene derivative of the formula XIX, in
which the ketone group is then reduced to the alcohol group to give
a compound of the formula XV.
##STR00025##
[0248] The groups Ar and R4 in the compounds of the formulae XVII,
XVIII and XIX are defined as in the compounds of the formula I, and
additionally can functional groups be present in protected form or
in the form of a precursor group which is subsequently converted
into the final group. In the preparation of compounds of the
formula XV according to this process, the group G2 in the compounds
of the formulae XVIII and XIX is in particular a nucleophilically
substitutable leaving group, for example fluorine, and the group G3
in the compounds of the formulae XVIII and XIX in particular is
bromine. The group R51 in the compounds of the formula XVII is
(C.sub.1-C.sub.4)-alkyl, for example methyl or ethyl. The group Z3
in the compounds of the formula XVIII is a nucleophilically
substitutable leaving group, for example chlorine or bromine. The
reaction of the compounds of the formulae XVII and XVIII to give
the compounds of the formula XIX is performed in an inert solvent
such as an ether like THF, dioxane or DME in the presence of base
such as an alkali metal alkoxide or an alkali metal hydride, for
example sodium hydride, at temperatures from about 0.degree. C. to
about 50.degree. C. By treatment of the obtained benzylated
3-oxo-propionic acid ester with an acid, for example hydrochloric
acid in an aqueous solvent such as an ether like dioxane or an acid
like acetic acid or a mixture of solvents at temperatures from
about 60.degree. C. to about 120.degree. C. the ester moiety is
then saponified and decarboxylated to give the ketone of the
formula XIX. For the reduction of the ketone moiety in the
compounds of the formula XIX to the compounds of the formula XV,
various reducing agents can be employed, for example complex metal
hydride such as sodium borohydride or lithium borohydride in a
solvent such as an ether or an alcohol. In an asymmetric reduction
reaction, by employing a chiral reducing agent, for example an
enantiomeric form of a chiral complex metal hydride or a chiral
borane, such as an alpha-pinene-based organoborane like
B-chloro-diisopinocampheylborane, which is commonly abbreviated as
(-)-Ipc.sub.2BCl or (-)-DipCl, and (+)-Ipc.sub.2BCl or (+)-DipCl,
respectively, in an inert solvent such as an ether like THF or
dioxane at temperatures from about -40.degree. C. to about
30.degree. C., conveniently the individual stereoisomeric forms of
the compounds of the formula XV can be obtained, i.e. compounds of
the formula XVa, which can be cyclized to the enantiomeric forms of
the compounds of the formula XVI, i.e. the compounds of the formula
XVIa, as described above.
[0249] In another process for the preparation of compounds of the
formula XV, an indan-1-one of the formula XX is subjected to a ring
enlargement to give a chroman-2-one of the formula XXI, in which
the lactone moiety can be reduced to an aldehyde moiety which is
present in the form of the cyclic hemiacetal of the formula XXII
and which can be reacted with a suitable organometal compound of
the formula XXIII.
##STR00026##
[0250] The groups Ar and R4 in the compounds of the formulae XX,
XXI, XXII and XXIII are defined as in the compounds of the formula
I, and additionally can functional groups be present in protected
form or in the form of a precursor group which is subsequently
converted into the final group. In the preparation of compounds of
the formula XV according to this process, the group G3 in the
compounds of the formulae XX, XXI and XXII is in particular a
(C.sub.1-C.sub.4)-alkyl-O-- group. The group M in the compounds of
the formula XXIII is a metal or a metal equivalent, for example
lithium. The conversion of the compound of the formula XX into the
compound of the formula XXI can be performed by treatment with a
peracid such as 3-chloro-perbenzoic acid in a solvent such as a
chlorinated hydrocarbon like dichloromethane at temperatures from
about -10.degree. C. to about 30.degree. C. For the reduction of
the lactone moiety in the compound of the formula XXI to the masked
aldehyde moiety in the compound of the formula XXII, a complex
metal reducing agent can be used, such as diisobutylaluminum
hydride, in a solvent such as a hydrocarbon like cyclohexane or
toluene or a chlorinated hydrocarbon like dichloromethane or an
ether like THF or dioxane, or a mixture of solvents, at
temperatures from about -80.degree. C. to about 30.degree. C. For
the subsequent step, the compound of the formula XXIII is generally
prepared in situ from a suitable respective benzene or
halogen-substituted benzene by metalation, for example with an
organolithium compound like butyllithium or a lithium amide like
lithium diisopropylamide or lithium 2,2,6,6-tetramethylpiperidide,
and reacted with the compound of the formula XXII in an inert
solvent such as a hydrocarbon like heptane or cyclohexane or an
ether like THF or a mixture of solvents at temperatures from about
-80.degree. C. to about 30.degree. C.
[0251] As already indicated, it can be advantageous or necessary in
all reactions which are carried out in the course of the
preparation of the compounds of the formula I to temporarily
protect functional groups or have them initially present in the
form of precursor groups, and later deprotect them or convert them
into the desired groups. Appropriate synthesis strategies and
protective groups and precursor groups which are suitable for the
respective case, are known to the person skilled in the art and can
be found in P. G. M. Wuts and T. W. Greene, Greene's Protective
Groups in Organic Synthesis, 4. ed. (2007), John Wiley & Sons,
for example. Examples of protective groups which may be mentioned,
are benzyl protective groups, for example benzyl ethers of hydroxy
compounds and benzyl esters of carboxylic acids, from which the
benzyl group can be removed by catalytic hydrogenation in the
presence of a palladium catalyst, tert-butyl protective groups, for
example tert-butyl esters of carboxylic acids, from which the
tert-butyl group can be removed by treatment with trifluoroacetic
acid, acyl protective groups, for example ester and amides of
hydroxy compounds and amino compounds, which can be cleaved again
by acidic or basic hydrolysis, or alkoxycarbonyl protective groups,
for example tert-butoxycarbonyl derivatives of amino compounds,
which can be cleaved again by treatment with trifluoroacetic acid.
Examples of precursors which may be mentioned are halogen atoms
which can be replaced by many other groups, or nitro groups which
can be converted, for example by catalytic hydrogenation, into
amino groups which can be diazotized and converted into a large
number of groups.
[0252] As is usual and applies to all reactions performed in the
course of the synthesis of a compound of the formula I, appropriate
details of the conditions applied in a specific preparation
process, including the solvent, a base or acid, the temperature,
the order of addition, the molar ratios and other parameters, are
routinely chosen by the skilled person in view of the
characteristics of the starting compounds and the final compound
and the other particularities of the specific case. As is also
known by the skilled person, not all processes described herein
will in the same way be suitable for the preparation of all
compounds of the formula I and their intermediates, and adaptations
have to be made. In all processes for the preparation of the
compounds of the formula I, workup of the reaction mixture and the
purification of the product is performed according to customary
methods known to the skilled person which include, for example,
quenching of a reaction mixture with water, adjustment of a certain
pH, precipitation, extraction, drying, concentration,
crystallization, distillation and chromatography. Also for the
characterization of the product, customary methods are used such as
NMR, IR and mass spectroscopy.
[0253] Another subject of the present invention are the novel
starting compounds and intermediates occurring in the synthesis of
the compounds of the formula I, including the compounds of the
formulae II, IIa, III, IIIa, IV, IVa, IVb, IVc, IVd, IVe, V, VI,
VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVa, XVI, XVIa, XVII,
XVIII, XIX, XX, XXI, XXII and XXIII, wherein the groups Ar, R1 to
R7, R50, R51, G1, G2, G3, M, X, Y and Z1 to Z3 and the numbers p
and q are defined as above, in any of their stereoisomeric forms or
a mixture of stereoisomeric forms in any ratio, and their salts,
and their use as synthetic intermediates or starting compounds. All
general explanations, specifications of embodiments and definitions
of numbers and groups given above with respect to the compounds of
the formula I apply correspondingly to the said intermediates and
starting compounds. A subject of the invention are in particular
the novel specific starting compounds and intermediates described
herein. Independently thereof whether they are described as a free
compound and/or as a specific salt, they are a subject of the
invention both in the form of the free compounds and in the form of
their salts, and if a specific salt is described, additionally in
the form of this specific salt.
[0254] The compounds of the formula I inhibit the sodium-calcium
exchanger (NCX), especially the sodium-calcium exchanger of subtype
1 (NCX1), as can be demonstrated in the pharmacological tests
described below and in other pharmacological tests which are known
to a person skilled in the art, for example in animal models in
which the effect on heart function can be determined ex vivo or in
vivo. The compounds of the formula I and their pharmaceutically
acceptable salts therefore are valuable pharmaceutical active
compounds. The compounds of the formula I and their
pharmaceutically acceptable salts can be used for the treatment of
heart failure, including acute and chronic congestive heart failure
(CHF), systolic heart failure, diastolic heart failure, heart
failure with preserved ejection fraction, diabetic heart failure
and decompensated heart failure and the management of heart failure
in combination with a device, cardiac arrhythmias including atrial
arrhythmias, atrial fibrillation, atrial fibrillation in CHF
patients, ventricular arrhythmias, ventricular tachycardia,
monomorphic ventricular tachycardia, polymorphic ventricular
tachycardia, Torsade-de-pointes tachycardia and ventricular
arrhythmias in CHF patients, stroke, dementia including Alzheimer's
Disease, hypertension, cardiac ischemia, renal failure, shock
including hemodynamic shock, cardiogenic shock and septic shock,
age-related disorders, and diseases which are caused secondarily by
an NCX-related damage, for example. The treatment of diseases is to
be understood as meaning both the therapy of existing pathological
changes or malfunctions of the organism or of existing symptoms
with the aim of relief, alleviation or cure, and the prophylaxis or
prevention of pathological changes or malfunctions of the organism
or of symptoms in humans or animals which are susceptible thereto
and are in need of such a prophylaxis or prevention, with the aim
of a prevention or suppression of their occurrence or of an
attenuation in the case of their occurrence. For example, in
patients who on account of their disease history are susceptible to
cardiac arrhythmias or cardiac decompensation, by means of the
prophylactic or preventive medicinal treatment the occurrence or
re-occurrence of arrhythmias or decompensation can be prevented or
their extent and sequelae decreased. The treatment of diseases can
occur both in acute cases and in chronic cases. The compounds of
the formula I and their pharmaceutically acceptable salts can
further be used in various disorders in order to achieve an
improvement of the perfusion of heart, brain and kidney, and in
general in disorders in which intracellular calcium homeostasis is
disturbed, or the NCX is activated in an undesired manner, or an
inhibition of the NCX is intended by the physician for improving
the patient's condition, wherein the compounds of the formula I and
their pharmaceutically acceptable salts can also be employed in
cases where only a certain partial inhibition of the NCX is
intended, for example by use of a low dosage.
[0255] The compounds of the formula I and their pharmaceutically
acceptable salts can therefore be used in animals, in particular in
mammals and specifically in humans, as a pharmaceutical or
medicament on their own, in mixtures with one another, or in the
form of pharmaceutical compositions. A subject of the present
invention also are the compounds of the formula I and their
pharmaceutically acceptable salts for use as a pharmaceutical. A
subject of the present invention also are pharmaceutical
compositions and medicaments which comprise at least one compound
of the formula I and/or a pharmaceutically acceptable salt thereof
as an active ingredient, in an effective dose for the desired use,
and a pharmaceutically acceptable carrier, i.e. one or more
pharmaceutically innocuous, or nonhazardous, vehicles and/or
excipients, and optionally one or more other pharmaceutical active
compounds. A subject of the present invention also are the
compounds of the formula I and their pharmaceutically acceptable
salts for use as an anti-arrhythmic. A subject of the present
invention also are the compounds of the formula I and their
pharmaceutically acceptable salts for use in the treatment of the
diseases mentioned above or below, including the treatment of any
one of the mentioned diseases, for example heart failure, cardiac
arrhythmias, stroke, dementia, hypertension, cardiac ischemia,
renal failure, shock, age-related disorders or diseases which are
caused secondarily by an NCX-related damage, wherein treatment of
diseases comprises their therapy and prophylaxis as mentioned
above, or for use as an inhibitor of the NCX. A subject of the
present invention also are the use of the compounds of the formula
I and their pharmaceutically acceptable salts for the manufacture
of a medicament for the treatment of the diseases mentioned above
or below, including the treatment of any one of the mentioned
diseases, for example heart failure, cardiac arrhythmias, stroke,
dementia, hypertension, cardiac ischemia, renal failure, shock,
age-related disorders or diseases which are caused secondarily by
an NCX-related damages, wherein treatment of diseases comprises
their therapy and prophylaxis as mentioned above, or a medicament
for inhibition of the NCX. A subject of the present invention also
are methods for the treatment of the diseases mentioned above or
below, including the treatment of any one of the mentioned
diseases, for example heart failure, cardiac arrhythmias, stroke,
dementia, hypertension, cardiac ischemia, renal failure, shock,
age-related disorders or diseases which are caused secondarily by
an NCX-related damage, wherein treatment of diseases comprises
their therapy and prophylaxis as mentioned above, and a method for
inhibiting the NCX, which comprise administering an efficacious
amount of at least one compound of the formula I and/or a
pharmaceutically acceptable salt thereof to a human or an animal
which is in need thereof. The compounds of the formula I and their
pharmaceutically acceptable salts, and pharmaceutical compositions
and medicaments comprising them, can be administered enterally, for
example by oral or rectal administration, parenterally, for example
by intravenous, intramuscular or subcutaneous injection or
infusion, or by another type of administration such as topical,
percutaneous, transcutaneous, nasal, pharyngeal or inhalative
administration, the preferred form of administration depending on
the particulars of the specific case. The compounds of the formula
I and their pharmaceutically acceptable salts can also be used in
combination with other pharmaceutical active compounds.
[0256] The pharmaceutical compositions and medicaments according to
the invention normally contain from about 0.5 to about 90 percent
by weight of a compound or compounds of the formula I or
pharmaceutically acceptable salts thereof, and an amount of active
ingredient of the formula I and/or its pharmaceutically acceptable
salt which in general is from about 0.1 mg to about 1 g, in
particular from about 0.2 mg to about 500 mg, for example from
about 1 mg to about 300 mg, per dose unit. Depending on the kind of
the pharmaceutical composition and other particulars of the
specific case, the amount may deviate from the indicated ones. The
production of the pharmaceutical compositions and medicaments can
be carried out in a manner known per se and familiar to the person
skilled in the art. For this, the compounds of the formula I and/or
their pharmaceutically acceptable salts are mixed together with one
or more solid or liquid vehicles and/or excipients, if desired also
in combination with one or more other pharmaceutical active
compounds, and brought into a suitable form for dosage and
administration, which can then be used in human medicine or
veterinary medicine.
[0257] As vehicles, which may also be looked upon as diluents or
solvents or bulking agents, and excipients suitable organic and
inorganic substances can be used which do not react in an undesired
manner with the compounds of the formula I. As examples of types of
excipients, or additives, which can be contained in the
pharmaceutical compositions and medicaments, lubricants,
preservatives, gel formers, thickeners, stabilizers, disintegrants,
wetting agents, emulsifiers, dispersants, antifoaming agents,
salts, buffer substances, colorants, flavorings and antioxidants
may be mentioned. Examples of vehicles and excipients are water,
physiological saline, vegetable oils such as sunflower oil, animal
oils such as fish liver oil, waxes, alcohols such as ethanol,
isopropanol, 1,2-propanediol, glycerol, polyols, polyethylene
glycols, polyvinylpyrrolidone, gelatin, gum arabic, cellulose,
carbohydrates such as glucose, lactose or starch like corn starch,
magnesium carbonate, potassium phosphate, sodium chloride, stearic
acid and its salts such as magnesium stearate, talc, lanolin,
petroleum jelly, or mixtures thereof, for example mixtures of water
or saline with one or more organic solvents such as mixtures of
water with alcohols.
[0258] For oral and rectal use, pharmaceutical forms such as, for
example, tablets, coated tablets, sugar-coated tablets, granules,
hard and soft gelatin capsules, suppositories, solutions, including
oily, alcoholic or aqueous solutions, or drops, furthermore
suspensions or emulsions, can be used. For parenteral use, for
example by injection or infusion, pharmaceutical forms such as
solutions, for example aqueous solutions, can be used. For topical
use, pharmaceutical forms such as ointments, creams, pastes,
lotions, gels, sprays, foams, aerosols, solutions or powders can be
used. Pharmaceutical formulations such as, for example, aerosols
and sprays may comprise solutions, suspensions or emulsions of the
active ingredient in a pharmaceutically acceptable solvent, such as
ethanol or water, or a mixture of such solvents. The formulation
may also comprise other pharmaceutical excipients such as
surfactants, emulsifiers and stabilizers, and a propellant gas.
Such a pharmaceutical form normally comprises the active ingredient
in a concentration from about 0.1 to about 10%, in particular from
about 0.3 to about 3% by weight.
[0259] As usual, the dosage of the compounds of the formula I and
the frequency of administration depend on the circumstances of the
specific case and is adjusted by the physician according to the
customary rules and procedures. It depends, for example, on the
compound of the formula I administered and its potency and duration
of action, on the nature and severity of the individual syndrome,
on the gender, age, weight and the individual responsiveness of the
human or animal to be treated, on whether the treatment is acute or
chronic or prophylactic, or on whether further pharmaceutical
active compounds are administered in addition to a compound of the
formula I. Normally, in the case of administration to an adult
weighing about 75 kg, a dose from about 0.1 mg to about 100 mg per
kg per day, in particular from about 1 mg to about 10 mg per kg per
day (in each case in mg per kg of body weight), is sufficient. The
daily dose can be administered in the form of a single dose or
divided into a number of individual doses, for example two, three
or four individual doses. The administration can also be carried
out continuously, for example by continuous injection or infusion.
Depending on the individual behavior in a specific case, it may be
necessary to deviate upward or downward from the indicated
dosages.
[0260] Besides as a pharmaceutical active compound in human
medicine and veterinary medicine, the compounds of the formula I
can also be employed as an aid in biochemical investigations or as
a scientific tool or for diagnostic purposes, for example in in
vitro diagnoses of biological samples, if an inhibition of the NCX
is intended. The compounds of the formula I and their salts can
also be used as intermediates for the preparation of further
pharmaceutical active substances.
[0261] The following examples illustrate the invention.
[0262] When example compounds containing a basic group were
purified by preparative high pressure liquid chromatography (HPLC)
on reversed phase (RP) column material and, as customary, the
eluent was a gradient mixture of water and acetonitrile containing
trifluoroacetic acid, they were in part obtained in the form of
their acid addition salts with trifluoroacetic acid, depending on
the details of the workup such as evaporation or lyophilization
conditions. In the names of the example compounds and the
structural formulae such contained trifluoroacetic acid is not
specified.
[0263] The prepared compounds were in general characterized by
spectroscopic data and chromatographic data, in particular mass
spectra (MS) and HPLC retention times (Rt; in min) which were
obtained by combined analytical HPLC/MS characterization (LC/MS),
and/or nuclear magnetic resonance (NMR) spectra. .sup.1H-NMR
spectra were recorded at 500 MHz in D.sub.6-DMSO as solvent at 298
K, unless specified otherwise. In the NMR characterization, the
chemical shift .delta. (in ppm), the number of hydrogen atoms (H)
and the multiplicity (s: singlet, d: doublet, dd: double doublet,
t: triplet, m: multiplet; br: broad) of the peaks as determined on
printouts are given. In the MS characterization, in general the
mass number (m/z) of the peak of the molecular ion [M], e.g.
[M.sup.+], or of a related ion such as the ion [M+1], e.g.
[(M+1).sup.+], i.e. the protonated molecular ion [(M+H).sup.+]
([MH.sup.+]), or the ion [M-1], e.g. [(M-1).sup.-], i.e. the
deprotonated molecular ion [(M-H).sup.-], which was formed
depending on the ionization method used, is given. Generally, the
ionization method was electrospray ionization (ESI.sup.+). The UV
wavelength for HPLC detection generally was 220 nm. The particulars
of the LC/MS methods used are as follows. "ACN" means acetonitrile,
"TFA" means trifluoroacetic acid, and "FA" means "formic acid.
Method A
[0264] Column: Waters UPLC BEH C18, 1.7 .mu.m, 2.1.times.50 mm;
temperature: 55.degree. C.; flow rate: 0.9 ml/min; eluent A:
water+0.1% FA; eluent B: ACN+0.08% FA; gradient: 95% A+5% B (0 min)
to 5% A+95% B (1.1 min) to 5% A+95% B (1.7 min) to 95% A+5% B (1.8
min) to 95% A+5% B (2.0 min)
Method B
[0265] Column: Waters XBridge C18, 2.5 .mu.m, 4.6.times.50 mm;
temperature: 30.degree. C.; flow rate: 1.3 ml/min; eluent A:
water+0.1% FA; eluent B: ACN+0.1% FA; gradient: 97% A+3% B (0 min)
to 40% A+60% B (3.5 min) to 2% A+98% B (4.0 min) to 2% A+98% B (5.0
min) to 97% A+3% B (6.5 min)
Method C
[0266] Column: Waters Atlantis T3 C18, 3 .mu.m, 3.times.100 mm;
temperature: 55.degree. C.; flow rate: 1.0 ml/min; eluent A:
water+0.05% TFA; eluent B: ACN+0.05% TFA; gradient: 95% A+5% B (0
min) to 5% A+95% B (5.0 min) to 95% A+5% B (7.0 min)
Method D
[0267] Column: Waters Atlantis T3 C18, 3 .mu.m, 3.times.50 mm;
temperature: 55.degree. C.; flow rate: 0.6 ml/min; eluent A:
water+0.05% TFA; eluent B: ACN+0.05% TFA; gradient: 95% A+5% B (0
min) to 5% A+95% B (4.0 min) to 2% A+98% B (6.5 min) to 95% A+5% B
(9.0 min)
Method E
[0268] Waters UPLC BEH C18, 1.7 .mu.m, 2.1.times.50 mm;
temperature: 55'C; flow rate: 0.9 ml/min; eluent A: water+0.05% FA;
eluent B: ACN+0.035% FA; gradient: 95% A+5% B (0 min) to 5% A+95% B
(1.1 min) to 5% A+95% B (1.7 min) to 95% A+5% B (1.8 min) to 95%
A+5% B (2.0 min)
Method F
[0269] Waters UPLC BEH C18, 1.7 .mu.m, 2.1.times.50 mm;
temperature: 55.degree. C.; flow rate: 0.9 ml/min; eluent A:
water+0.05% FA; eluent B: ACN+0.035% FA; gradient: 95% A+5% B (0
min) to 5% A+95% B (1.1 min) to 5% A+95% B (1.7 min) to 95% A+5% B
(1.9 min) to 95% A+5% B (2.0 min)
EXEMPLARY SYNTHESIS EXAMPLES
Example A
(E)-1-(5-Bromo-2-hydroxy-phenyl)-3-o-tolyl-propenone and
6-bromo-2-o-tolyl-chroman-4-one
##STR00027##
[0271] To a solution of o-tolylaldehyde (4.1 g, 33.7 mmol, 1.1 eq)
and 5-bromo-2-hydroxy-acetophenone (6.9 g, 32.1 mmol) at room
temperature in ethanol (100 ml) powdered potassium hydroxide (5.2
g, 93 mmol, 5 eq) was added and the suspension was stirred at
50.degree. C. for 3 h while a red solution formed. The solution was
allowed to reach room temperature and poured on ice. The aqueous
mixture was adjusted to pH<7 using aqueous hydrochloric acid.
The resulting yellow suspension was stirred till a yellow solid
formed, and the precipitate filtered, washed with water and dried.
The yellow (E)-1-(5-bromo-2-hydroxy-phenyl)-3-o-tolyl-propenone
(9.6 g, 94%) was used in the cyclization reaction without further
purification.
[0272] To a solution of
(E)-1-(5-bromo-2-hydroxy-phenyl)-3-o-tolyl-propenone (9.6 g, 30.3
mmol) in ethanol (130 ml) concentrated aqueous hydrochloric acid
was added (1.5 ml). The solution was heated to reflux for 5 h.
Afterwards the solution was cooled to room temperature and the
solvents was removed under reduced pressure. The resulting red
6-bromo-2-o-tolyl-chroman-4-one (9.5 g, 100%) was used in the next
step without further purification.
[0273] According to the described procedure, also the following
chromanones were synthesized: [0274]
6-Bromo-2-(5-fluoro-2-methyl-phenyl)-chroman-4-one [0275]
6-Bromo-2-(2,6-dimethyl-phenyl)-chroman-4-one [0276]
2-(3-Fluoro-2-methoxy-phenyl)-6-hydroxy-chroman-4-one [0277]
6-Hydroxy-7-methyl-2-o-toyl-chroman-4-one [0278]
2-(2-Fluoro-3-methoxy-phenyl)-6-hydroxy-chroman-4-one [0279]
6-Hydroxy-3-methyl-2-phenyl-chroman-4-one [0280]
2-(2-Fluoro-phenyl)-6-hydroxy-chroman-4-one [0281]
2-(3-Fluoro-2-methyl-phenyl)-6-hydroxy-chroman-4-one
Example B
6-Bromo-2-o-tolyl-chroman-4-ol and 6-bromo-2-o-tolyl-chroman
##STR00028##
[0283] To a solution of 6-bromo-2-o-tolyl-chroman-4-one (11.0 g,
34.7 mmol) in tetrahydrofuran (100 ml) at room temperature a
solution of borane tetrahydrofuran adduct (1M in tetrahydrofuran,
86.7 ml, 2.5 eq) was added dropwise. The solution was heated to
reflux for 1 h, cooled to room temperature and added with caution
to a mixture of ice water and 1N aqueous hydrochloric acid. The
aqueous layer was extracted with dichloromethane, and the combined
organic layers washed with water, dried with sodium sulfate and
filtered and the solvent removed under reduced pressure.
6-Bromo-2-o-tolyl-chroman-4-ol was obtained as a yellow oil (11.1
g, 100%) and used in the reduction to the chroman without further
purification.
[0284] To a solution of 6-bromo-2-o-tolyl-chroman-4-ol (11.9 g,
37.3 mmol) in dichloromethane (130 ml) at 0.degree. C.
triethylsilane (29.6 g, 255 mmol, 6.8 eq) and trifluoroacetic acid
(75 ml, 27 eq) were added. The solution was stirred at room
temperature for 2.5 h. The solvent was removed under reduced
pressure and the residue separated between water and ethyl acetate.
The aqueous layer was extracted with ethyl acetate and the combined
organic layers washed with water and saturated aqueous solution of
sodium hydrogencarbonate, dried with sodium sulfate and filtered,
and the solvent removed under reduced pressure. The crude product
was purified by column chromatography (silica gel; ethyl
acetate/heptane gradient). 6-Bromo-2-o-tolyl-chroman was obtained
as a pale yellow oil (7.10 g, 63%).
[0285] According to the described procedure, also the following
chroman derivatives were synthesized: [0286]
7-Methyl-2-o-tolyl-chroman-6-ol [0287]
6-Bromo-2-(2,6-dimethyl-phenyl)-chroman [0288]
2-(2-Fluoro-3-methoxy-phenyl)-chroman-6-ol [0289]
6-Bromo-2-(5-fluoro-2-methyl-phenyl)-chroman [0290]
2-(3-Fluoro-2-methoxy-phenyl)-chroman-6-ol [0291]
2-(2-Fluoro-phenyl)-chroman-6-ol [0292]
2-(3-Fluoro-2-methyl-phenyl)-chroman-6-ol [0293]
3-Methyl-2-phenyl-chroman-6-ol
Example C
(S)-6-Bromo-2-o-tolyl-chroman
##STR00029##
[0294] a) 3-(5-Bromo-2-fluoro-phenyl)-1-o-tolyl-propan-1-one
[0295] Sodium hydride (60% in oil, 2.1 g, 52 mmol) and methyl
3-oxo-3-o-tolylpropanoate (10 g, 52 mmol) were suspended in
tetrahydrofuran and 4-bromo-2-(bromomethyl)-1-fluoro-benzene (15.3
g, 57 mmol) was added. After complete conversion, the mixture was
quenched with ice and a saturated solution of ammonium chloride and
extracted with n-heptane. The combined organic layers were washed
once with a saturated solution of ammonium chloride, water and
brine. The organic layer was dried over magnesium sulfate and
evaporated to dryness. The obtained yellow oil was dissolved in 25
ml of acetic acid, 25 ml of concentrated hydrochloric acid and 20
ml of 1,4-dioxane and heated under reflux for 4 h until LC/MS
showed consumption of the starting material. 50 ml of water and 100
ml of tert-butyl methyl ether were added and the product was
extracted. The combined organic layers were washed once with
saturated solution of ammonium chloride, water and brine. The
organic layer was dried over magnesium sulfate and evaporated to
dryness. The residue was purified by column chromatography (silica
gel, heptane/ethyl acetate gradient) to give 11.2 g of
3-(5-bromo-2-fluoro-phenyl)-1-o-tolyl-propan-1-one as a colorless
oil.
b) (S)-3-(5-Bromo-2-fluoro-phenyl)-1-o-tolyl-propan-1-ol
[0296] 1 3-(5-Bromo-2-fluoro-phenyl)-1-o-tolyl-propan-1-one (14 g,
43.6 mmol) was diluted with 20 ml of dry tetrahydrofuran and added
dropwise to a solution of (-)-B-chloro-diisopinocampheyl-borane
((-)-DipCl, 27.96 g, 87.2 mmol) in 100 ml of dry tetrahydrofuran
while maintaining the temperature between -30.degree. C. and
-25.degree. C. After 6 h, LC/MS showed complete conversion of the
starting material. The cold mixture was quenched with 10 ml of
methanol and 10 g of sodium hydrogencarbonate and allowed to come
to room temperature. The solvents were removed in vacuum and the
obtained yellow oil was dissolved in 200 ml of ethyl acetate and a
saturated solution of ammonium chloride. The phases were separated
and the organic layer was washed once with 50 ml of brine, dried
over magnesium sulfate and evaporates to give 45 g of a yellow oil.
This oil was purified by column chromatography (silica gel,
heptane/ethyl acetate gradient) to give 11.2 g of
(S)-3-(5-bromo-2-fluoro-phenyl)-1-o-tolyl-propan-1-ol as a
colorless oil.
[0297] Ratio of enantiomers (HPLC; column: Chiralcel OJ-H,
250.times.4.6 mm; eluent heptane/ethyl acetate/methanol 20:1:1):
(S):(R)=99.4:0.6
c) (S)-6-Bromo-2-o-tolyl-chroman
[0298] 3-(5-Bromo-2-fluoro-phenyl)-1-o-tolyl-propan-1-ol (10.5 g)
was dissolved in 10 ml of dry N-methylpyrrolidin-2-one, and the
solution was added dropwise to a suspension of sodium hydride (60%
in oil, 1.56 g, 39 mmol) in 20 ml of dry N-methylpyrrolidin-2-one
at 60.degree. C. After complete addition the mixture was stirred at
60.degree. C. to reach complete consumption of the starting
material after 12 h. Then the mixture was quenched on ice and a
saturated solution of ammonium chloride and extracted with
n-heptane. The combined organic layers were washed once with a
saturated solution of ammonium chloride, water and brine. The
organic layer was dried over magnesium sulfate and evaporated to
give 12 g of a clear oil. This oil was purified by column
chromatography (silica gel, heptane/ethyl acetate gradient) to give
7.7 g of (S)-6-bromo-2-o-tolyl-chroman as a colorless oil.
Example D
2-o-Tolyl-chroman-6-ol
##STR00030##
[0300] To a solution of 6-bromo-2-o-tolyl-chroman (1 g, 3.3 mmol)
in tetrahydrofuran (3 ml) at -78.degree. C. n-butyllithium (2.2 M
in cyclohexane, 1.8 ml, 1.2 eq) was slowly added and the mixture
kept at -78.degree. C. for 30 min. Triisopropyl borate (1.9 g, 2.3
ml, 9.9 mmol, 3 eq) was added and stirring was continued at the
same temperature for 1 h. The cold solution was poured in a
solution of ethanol (1.1 ml), water (3.0 ml) and aqueous sodium
hydroxide (8 M, 1.6 ml). To this solution hydrogen peroxide
(aqueous 35%, 0.9 ml, 3.1 eq) was slowly added while the
temperature was kept <30.degree. C. Stirring at room temperature
was continued for 15 min, the suspension was cooled to 0.degree. C.
and adjusted to pH<7 using aqueous hydrochloric acid. To the
resulting solution a saturated aqueous solution of sodium sulfite
(4 ml) was added and the aqueous layer extracted with ethyl
acetate. The combined organic layers were dried with sodium sulfate
and filtered, and the solvent removed under reduced pressure. The
crude product was purified by column chromatography (silica get;
ethyl acetate/heptane gradient). 2-o-Tolyl-chroman-6-ol was
obtained as a pale yellow solid (480 mg, 60%).
[0301] According to the described procedure, also the following
chromanols were synthesized: [0302]
2-(5-Fluoro-2-methyl-phenyl)-chroman-6-ol [0303]
2-(2,6-Dimethyl-phenyl)-chroman-6-ol [0304]
(S)-2-o-Tolyl-chroman-6-ol
Example E
5-Chloro-2-phenyl-chroman-6-ol
##STR00031##
[0306] To a suspension of 200 mg of 2-phenyl-chroman-6-ol (0.88
mmol) and 142 mg of iron(III) chloride (0.88 mmol) in 15 ml of
acetonitrile at room temperature 118 mg of N-chlorosuccinimide
(0.88 mmol) were added in one portion and stirring was continued
for 16 h. The volatile components were removed under reduced
pressure. The resulting residue was purified by reversed phase
HPLC. 127 mg of the title compound were obtained as a pale yellow
solid (55%).
Example F
[4-trans-(2-o-Tolyl-chroman-6-yloxy)-cyclohexyl]-carbamic acid
tert-butyl ester
##STR00032##
[0308] 6.5 g (27 mmol) 2-o-tolyl-chroman-6-ol, 8.16 g (31.1 mmol)
triphenylphosphine and 6.7 g (31.1 mmol) tert-butyl
cis-4-hydroxycyclohexylcarbamate were dissolved in 50 ml dry
tetrahydrofuran. 6.5 ml (31.1 mmol) diisopropyl azodicarboxylate
were added to the solution and the reaction mixture was stirred at
room temperature for 48 h. The solvent was removed by evaporation
and the resulting oil was purified by chromatography over silica
gel using heptane/ethyl acetate 4:1 as the eluent. The product
fractions were collected and evaporated to yield 6 g of the title
compound. .sup.1H-NMR (400 MHz): .delta. (ppm)=1.29-1.33 (4H, m),
1.38 (9H, s), 1.79 (2H, m), 1.82 (1H, m), 2.12 (1H, m), 2.35 (3H,
s), 2.73 (1H, dd), 3.02 (1H, m), 3.28 (1H, m), 4.13 (1H, m), 5.17
(1H, dd), 6.69 (1H), 6.74 (1H), 6.79 (1H), 7.21 (3H), 7.43
(1H).
[0309] According to the described procedure, also the following
compounds were synthesized: [0310]
6-(1,4-Dioxa-spiro[4.5]dec-8-yloxy)-2-o-tolyl-chroman [0311]
[cis-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexylmethyl]-carbamic acid
tert-butyl ester [0312]
4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid ethyl
ester [0313]
cis-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid ethyl
ester [0314]
trans-4-((S)-2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
ethyl ester [0315]
trans-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
ethyl ester [0316]
[cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexyl]-carbamic acid
tert-butyl ester [0317]
[trans-4-(2-Phenyl-chroman-6-yloxy)-cyclohexyl]-carbamic acid
tert-butyl ester [0318]
[cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexylmethyl]-carbamic acid
tert-butyl ester [0319]
{1-[1-Ethyl-4-(2-phenyl-chroman-6-yloxy)-cyclohexyl]-propyl}-carbamic
acid tert-butyl ester [0320]
6-(1,4-Dioxa-spiro[4.5]dec-8-yloxy)-2-phenyl-chroman [0321]
cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexanecarboxylic acid ethyl
ester [0322] 4-(2-Phenyl-chroman-6-yloxy)-cyclohexanecarboxylic
acid ethyl ester [0323]
[4-(2-Phenyl-chroman-6-yloxy)-1-propyl-cyclohexyl]-carbamic acid
tert-butyl ester [0324]
4-[2-(2,6-Dimethyl-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid ethyl ester [0325]
{trans-4[(2-(2,6-Dimethyl-phenyl)-chroman-6-yloxy]-cyclohexyl}-carbamic
acid tert-butyl ester [0326]
2-(2,6-Dimethyl-phenyl)-6-(1,4-dioxa-spiro[4.5]dec-8-yloxy)-chroman
[0327]
4-[2-(3-Fluoro-2-methyl-phenyl)-chroman-6-yloxy]-cyclohexanecarbox-
ylic acid ethyl ester [0328]
6-(1,4-Dioxa-spiro[4.5]dec-8-yloxy)-2-(3-fluoro-2-methyl-phenyl)-chroman
[0329]
6-(1,4-Dioxa-spiro[4.5]dec-8-yloxy)-2-(2-fluoro-phenyl)-chroman
[0330]
4-[2-(2-Fluoro-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic acid
ethyl ester [0331]
{trans-4-[2-(5-Fluoro-2-methyl-phenyl)-chroman-6-yloxy]-cyclohexyl}-carba-
mic acid tert-butyl ester [0332]
{trans-4-[2-(2-Fluoro-phenyl)-chroman-6-yloxy]-cyclohexyl}-carbamic
acid tert-butyl ester [0333]
4-(7-Methyl-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
ethyl ester [0334]
4-(5-Chloro-2-phenyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
ethyl ester [0335]
4-[2-(2-Fluoro-3-methoxy-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid ethyl ester [0336]
4-(3-Methyl-2-phenyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
ethyl ester [0337]
4-[2-(3-Fluoro-2-methoxy-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid ethyl ester
Example G
trans-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexylamine
hydrochloride
##STR00033##
[0339] 6 g (13.7 mmol) of
[trans-4-(2-o-tolyl-chroman-6-yloxy)-cyclohexyl]-carbamic acid
tert-butyl ester were dissolved in 50 ml of 1,4-dioxane and 25 ml
of 2N hydrogen chloride in diethyl ether. The diethyl ether was
removed by evaporation and the remaining solution was refluxed
until no starting material could be detected by RP-HPLC. The
resulting suspension was cooled to 0.degree. C. and the crystals
were collected by filtration, washed once with cold methyl
tert-butyl ether and dried in vacuum at 25.degree. C. to yield 3.6
g of the title compound.
[0340] .sup.1H-NMR (400 MHz): .delta. (ppm)=1.42 (4H, m), 1.88 (1H,
m), 1.95 (2H, m), 2.08 (3H, m), 2.35 (3H, s), 2.73 (1H, dd), 3.02
(2H, m), 4.13 (1H, m), 5.17 (1H, dd), 6.74 (2H), 6.79 (1H), 7.21
(3H), 7.43 (1H), 8.08 (3H, s).
[0341] According to the described procedure, also the following
compounds were synthesized: [0342]
cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexylamine [0343]
trans-4-(2-Phenyl-chroman-6-yloxy)-cyclohexylamine [0344]
[cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexylmethyl]amine [0345]
4-(2-Phenyl-chroman-6-yloxy)-1-propyl-cyclohexylamine [0346]
1-[1-Ethyl-4-(2-phenyl-chroman-6-yloxy)-cyclohexyl]-propylamine
[0347] [cis-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexylmethyl]amine
[0348]
trans-4-[2-(2,6-Dimethyl-phenyl)-chroman-6-yloxy]-cyclohexylamine
[0349]
trans-4-[2-(2-Fluoro-phenyl)-chroman-6-yloxy]-cyclohexylamine
[0350]
trans-4-[2-(5-Fluoro-2-methyl-phenyl)-chroman-6-yloxy]-cyclohexylamine
Example H
trans-4-((S)-2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic
acid
##STR00034##
[0352] 0.75 g (1.9 mmol) of
trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
ethyl ester was dissolved in 10 ml of tetrahydrofuran. 94 mg (3.9
mmol) lithium hydroxide (dissolved in 2 ml of water) were added.
The solution was stirred at room temperature overnight until no
starting material could be detected by RP-HPLC. The solution was
diluted with methyl tert-butyl ether, and 2N hydrochloric acid was
added until a pH of 2. After phase separation, the organic layer
was dried over magnesium sulfate and the solvent was evaporated.
The resulting product crystallized on standing to yield 0.65 g of
the title compound.
[0353] .sup.1H-NMR (400 MHz): .delta. (ppm)=1.36 (2H, m), 1.48 (2H,
m), 1.85-2.11 (6H, m), 2.35 (3H, s), 2.38 (1H, m), 2.73 (1H, dd),
3.02 (1H, m), 4.18 (1H, m), 5.17 (1H, dd), 6.72 (3H), 7.21 (3H),
7.43 (1H), 12.10 (1H, s).
[0354] According to the described procedure, also the following
compounds were synthesized: [0355]
cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexanecarboxylic acid [0356]
4-(2-Phenyl-chroman-6-yloxy)-cyclohexanecarboxylic acid [0357]
4-(7-Methyl-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
[0358] 4-(5-Chloro-2-phenyl-chroman-6-yloxy)-cyclohexanecarboxylic
acid [0359]
4-[2-(2-Fluoro-3-methoxy-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid [0360]
4-(3-Methyl-2-phenyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
[0361]
4-[2-(3-Fluoro-2-methoxy-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid [0362] 4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic
acid [0363]
trans-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
[0364] cis-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
[0365]
4-[2-(2,6-Dimethyl-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid [0366]
4-[2-(3-Fluoro-2-methyl-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid [0367]
4-[2-(2-Fluoro-phenyl)-chroman-6-yloxy]-cyclohexanecarboxylic
acid
Example J
4-(2-Phenyl-chroman-6-yloxy)-cyclohexanone
##STR00035##
[0369] 430 mg of
6-(1,4-dioxa-spiro[4.5]dec-8-yloxy)-2-phenyl-chroman were dissolved
at room temperature in 5 ml of tetrahydrofuran. 5 ml of 10% aqueous
hydrochloric acid were added and stirring at room temperature was
continued for 16 h. The reaction mixture was diluted with ethyl
acetate and the organic layer washed with saturated aqueous
solution of sodium hydrogencarbonate. The organic layer was dried
with sodium sulfate and filtered, and the volatile components
removed under reduced pressure. 357 mg of the title compound were
obtained as a pale yellow solid.
[0370] According to the described procedure, also the following
compounds were synthesized: [0371]
4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanone [0372]
4-[2-(2,6-Dimethyl-phenyl)-chroman-6-yloxy]-cyclohexanone [0373]
4-[2-(3-Fluoro-2-methyl-phenyl)-chroman-6-yloxy]-cyclohexanone
[0374] 4-[2-(2-Fluoro-phenyl)-chroman-6-yloxy]-cyclohexanone
Example K
[4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexyl]-(1,3,5-trimethyl-1H-pyrazol-4-y-
lmethyl)-amine
##STR00036##
[0376] To a solution of 100 mg
4-(2-o-tolyl-chroman-6-yloxy)-cyclohexanone (0.30 mmol) in 2 ml of
methanol and 0.15 ml of acetic acid at room temperature 124 mg
(1,3,5-trimethyl-1H-pyrazol-4-yl-methyl)amine (0.89 mmol) and 56 mg
of sodium cyanoborohydride (0.89 mmol) were added in one portion
and stirring at room temperature was continued for 2 h. Volatile
components were removed under reduced pressure and the resulting
residue dissolved in dichloromethane. The organic layer was washed
with aqueous 2N sodium hydroxide solution and saturated aqueous
sodium chloride solution. The organic layer was dried with sodium
sulfate and filtered, and the solvent removed under reduced
pressure. The crude product was purified by reversed phase HPLC.
132 mg of the title compound were isolated.
Example L
(Tetrahydrofuran-3-ylmethyl)-[trans-4-(2-o-tolyl-chroman-6-yloxy)-cyclohex-
yl]-amine and
bis-(tetrahydrofuran-3-ylmethyl)-[trans-4-(2-o-tolyl-chroman-6-yloxy)-cyc-
lohexyl]-amine
##STR00037##
[0378] To a solution of 61 mg
trans-4-(2-tolyl-chroman-6-yloxy)-cyclohexylamine (0.18 mmol) in 3
ml methanol and 0.2 ml of acetic acid at room temperature 39 mg
tetrahydrofuran-3-carboxaldehyde (0.20 mmol) in 3 ml of methanol
were added, and 12 mg of sodium cyanoborohydride (0.89 mmol(0.20
mmol) were then added in one portion. Stirring at room temperature
was continued for 16 h. The solution was diluted with aqueous
saturated sodium hydrogencarbonate solution and the aqueous layer
extracted with dichloromethane. The combined organic layers were
dried with sodium sulfate and filtered, and the solvent removed
under reduced pressure. The crude product was purified by RP-HPLC.
23 mg of
(tetrahydrofuran-3-ylmethyl)-[trans-4-(2-o-tolyl-chroman-6-yloxy)-cyclohe-
xyl]-amine and 19 mg of
bis-(tetrahydrofuran-3-ylmethyl)-[trans-4-(2-o-tolyl-chroman-6-yloxy)-cyc-
lohexyl]-amine were isolated.
Example M
({[cis-4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexylmethyl]-carbamoyl}-methyl)--
carbamic acid tert-butyl ester
##STR00038##
[0380] To a suspension of 110 mg of
[cis-4-(2-o-tolyl-chroman-6-yloxy)-cyclohexylmethyl]amine
hydrochloride (0.28 mmol), 75 mg of N-tert-butoxycarbonylglycine
(0.43 mmol), 76 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (0.40 mmol) and 54 mg of hydroxybenzotriazole (0.40
mmol) at room temperature in 2 ml of dimethylformamide 0.16 ml of
N-methylmorpholine (1.42 mmol) were added and stirring at room
temperature was continued for 16 h. The reaction mixture was
diluted with water and extracted with ethyl acetate. The combined
organic layers were washed with diluted aqueous sodium carbonate
solution, dried with sodium sulfate and filtered, and the solvent
removed under reduced pressure. The crude product was purified by
column chromatography using ethyl acetate/heptane/methanol 5:10:1
as eluent. 95 mg of the title compound were isolated.
Example N
N-[cis-4-(2-Phenyl-chroman-6-yloxy)-cyclohexylmethyl]-methanesulfonamide
##STR00039##
[0382] To a solution of 150 mg
[cis-4-(2-phenyl-chroman-6-yloxy)-cyclohexylmethyl]amine
hydrochloride (0.40 mmol) at room temperature in 4 ml of pyridine
47 .mu.l of methanesulfonyl chloride (0.60 mmol) were added and
stirring at room temperature was continued for 16 h. The reaction
mixture was diluted with water and extracted with dichloromethane
The combined organic layers were washed with diluted aqueous
hydrochloric acid, dried with sodium sulfate and filtered, and the
solvent removed under reduced pressure. The crude product was
purified by reversed phase HPLC. 97 mg of the title compound were
isolated as a white solid.
Example O
4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide
##STR00040##
[0384] To a solution of 100 mg of
4-(2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid (0.40
mmol) at room temperature in 25 ml of dichloromethane 103 mg of
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.54
mmol), 73 mg of hydroxybenzotriazole (0.54 mmol), 0.12 ml of
triethylamine (0.88 mmol) and 11 .mu.l of 2-aminoethanol (0.19
mmol) were added, and stirring at room temperature was continued
for 16 h. The reaction mixture was diluted with water and extracted
with dichloromethane. The combined organic layers were dried with
sodium sulfate and filtered, and the solvent removed under reduced
pressure. The crude product was purified by reversed phase HPLC. 42
mg of a white solid were isolated which was a mixture of four
stereoisomers of the title compound.
[0385] The stereoisomers were separated by preparative HPLC on a
chiral phase (column: Chiralpak AS-H, 250.times.30 mm; temperature:
30.degree. C.; flow rate: 40 mid/min; eluent:
heptane/ethanol/methanol 20:1:1) to give
trans-4-((R)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide,
trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide, stereoisomer 1 of
cis-4-(2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide, and stereoisomer 2 of
cis-4-(2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide. The configuration at the chiral carbon
atom in position 2 of the chroman ring of stereoisomers 1 and 2 of
cis-4-(2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide is not known; one of them is
cis-4-((R)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide and the other is
cis-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide.
Example P
4-(2-Phenyl-chroman-6-yloxy)-1-propyl-cyclohexanol
##STR00041##
[0387] 100 mg of 4-(2-phenyl-chroman-6-yloxy)-cyclohexanone were
dissolved at room temperature in 5 ml of tetrahydrofuran. A 2M
solution of propylmagnesium chloride in diethyl ether (0.31 ml, 2
eq) was added, and stirring at room temperature was continued for 4
h. The reaction was stopped by careful addition of saturated
aqueous ammonium chloride solution. The aqueous layer was extracted
with methyl tert-butyl ether. The organic layer was dried over
sodium sulfate and filtered, and the solvent removed by
evaporation. The resulting oil was chromatographed over silica gel
using heptane/ethyl acetate 20:1 as the eluent. 54 mg of the title
compound were isolated as a pale yellow oil (48%).
Example Q
4-(2-Phenyl-chroman-6-yloxy)-cyclohexanol
##STR00042##
[0389] 500 mg of 4-(2-phenyl-chroman-6-yloxy)-cyclohexanone (1.6
mmol) were dissolved at 0.degree. C. in 2.5 ml of ethanol. 30 mg of
sodium borohydride (0.78 mmol) were added in portions, and stirring
at room temperature was continued for 2 h. The solvent was removed
under reduced pressure and the residue separated between saturated
aqueous sodium hydrogencarbonate solution and dichloromethane. The
aqueous layer was extracted with dichloromethane. The combined
organic layers were dried with sodium sulfate and filtered, and
volatile components removed under reduced pressure. 500 mg of the
title compound were obtained as a pale yellow solid.
Example R
3-Fluoro-isonicotinic acid 4-(2-phenyl-chroman-6-yloxy)-cyclohexyl
ester
##STR00043##
[0391] To a solution of 158 mg of 3-fluoroisonicotinic acid (1.12
mmol) and 156 .mu.l of triethylamine (1.12 mmol) in 16 ml of
dichloromethane at 15.degree. C. 138 .mu.l of pivaloyl chloride
(1.12 mmol) were added dropwise. The solution was stirred for 30
min. A solution of 110 mg of
4-(2-phenyl-chroman-6-yloxy)-cyclohexanol (0.34 mmol) in 4 ml of
dichloromethane was added and 82 mg of 4-dimethylamino-pyridine
(0.68 mmol) were added in one portion. Stirring at room temperature
was continued for 16 h. The organic layer was washed with saturated
aqueous sodium hydrogencarbonate solution, and the aqueous layer
extracted with dichloromethane. The combined organic layers were
dried over sodium sulfate and filtered, and the solvent removed by
evaporation. The resulting oil was purified by reversed phase HPLC.
104 mg of the title compound were isolated as solid (69%).
Example S
1-Benzyl-4-(2-phenyl-chroman-6-yloxy)-cyclohexylamine
##STR00044##
[0393] a) To a solution of 352 mg of
4-(2-phenyl-chroman-6-yloxy)-cyclohexanone (1.1 mmol) in 10 ml of
tetrahydrofuran at room temperature 0.46 ml of titanium(IV)
ethoxide (2.18 mmol) and 139 mg of tert-butylsulfinamide (1.15
mmol) were added and the resulting solution heated to reflux for 16
h. The solution was cooled to 0.degree. C. and 1.09 ml of
benzylmagnesium chloride (2M in tetrahydrofuran, 2.18 mmol) were
added. The mixture was stirred at room temperature for 16 h and
additional 1.09 ml of benzylmagnesium chloride solution were added.
After additional 16 h of stirring the reaction was stopped by
careful addition of water. The suspension was filtered and the
filter cake washed with dichloromethane. The aqueous layer was
extracted with dichloromethane. The combined organic layers were
dried over sodium sulfate and filtered, and the solvent removed by
evaporation. The resulting oil was purified by chromatography over
silica gel using a heptane/ethyl acetate gradient (0% ethyl acetate
to 25% ethyl acetate). 248 mg of 2-methyl-propane-2-sulfinic acid
[1-benzyl-4-(2-phenyl-chroman-6-yloxy)-cyclohexyl]-amide were
isolated as a mixture of diastereomers (44%).
[0394] b) 120 mg of 2-methyl-propane-2-sulfinic acid
[1-benzyl-4-(2-phenyl-chroman-6-yloxy)-cyclohexyl]-amide (0.23
mmol) were dissolved in 2 ml of trifluoroacetic acid in a sealed
microwave tube and heated in a microwave reactor for 1 h at
130.degree. C. The solvent was removed under reduced pressure and
the resulting residue purified by reversed phase HPLC
chromatography. 21 mg of
1-benzyl-4-(2-phenyl-chroman-6-yloxy)-cyclohexylamine were obtained
as a solid (17%).
Example T
Phosphoric acid
mono-(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-am-
ino}-ethyl) ester disodium salt
##STR00045##
[0395] a) Phosphoric acid dibenzyl ester
(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-amino}--
ethyl) ester
[0396] To a suspension of
trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarboxylic acid
(2-hydroxy-ethyl)-amide (0.5 g, 1.22 mmol) and tetrazole (102 mg,
1.47 mmol, 1.2 eq) in dichloromethane (7 ml) and acetonitrile (7
ml) at 0.degree. C., dibenzyl-N,N-diisopropylphosphoramidite (0.46
g, 1.34 mmol, 1.1 eq) was added and the mixture stirred at
0.degree. C. for 60 min (TLC control). To the resulting solution
3-chloro-perbenzoic acid (65%, 390 mg, 1.47 mmol, 1.2 eq) was added
in one portion, and vigorous stirring at 0.degree. C. was continued
for 30 min (TLC control). The mixture was diluted with
dichloromethane and the organic layer washed with a saturated
aqueous solution of sodium hydrogencarbonate and subsequently with
a saturated aqueous solution of ammonium chloride. The combined
organic layers were dried over sodium sulfate and filtered, and the
solvent removed under reduced pressure. The crude product was
purified by column chromatography (silica gel, ethyl
acetate/methanol gradient). Phosphoric acid dibenzyl ester
(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-amino}--
ethyl) ester was obtained as a colorless oil (0.66 g, 81%).
b) Phosphoric acid
mono-(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-am-
ino}-ethyl) ester disodium salt
[0397] Phosphoric acid dibenzyl ester
(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-amino}--
ethyl) ester (0.33 g, 0.49 mmol) was dissolved in methanol (10 ml)
and palladium on charcoal was added (10% Pd, 54% water, 0.3 g). The
suspension was vigorously stirred for 1.5 h under a hydrogen
atmosphere. The mixture was filtered and the filter cake rinsed
with methanol. The filtrate was evaporated under reduced pressure
and the resulting crude product submitted to preparative reversed
phase HPLC purification (water/acetonitrile gradient (+0.1%
trifluoroacetic acid)). The obtained phosphoric acid
mono-(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-am-
ino}-ethyl) ester was suspended in water and converted into the
disodium salt by addition of 2 equivalents of an aqueous 0.5 N
sodium hydroxide solution. The obtained aqueous solution was
lyophilized to yield phosphoric acid
mono-(2-{[trans-4-((S)-2-o-tolyl-chroman-6-yloxy)-cyclohexanecarbonyl]-am-
ino}-ethyl) ester disodium salt as a white solid (113 mg, 43%).
[0398] In analogy to the procedures described above in the
synthesis examples, the example compounds of the formula I listed
in Table 1 were prepared. In Table 1, "Ex. no." means the number of
the example compound; "LC/MS" means the LC/MS method described
above which was used in the HPLC and MS characterization of the
example compound; "MS" means the mass number (in amu) of the peak
of the molecular ion or a related ion such as M+1 in the mass
spectrum, in the case of a salt the mass number of the parent
compound, i.e. of the free acid or base, unless another ion is
specified; "Rt" means the HPLC retention time (in minutes); and
"NCX1rv IC.sub.50" means the IC.sub.50 value (in .mu.M
(micromol/liter) for inhibition of NCX1 in reverse mode determined
in the assay for inhibition of Ca.sup.2+ influx into cells (reverse
mode) described below).
TABLE-US-00001 TABLE 1 Example compounds of the formula I Ex. LC/
MS NCX1rv no. Compound name MS (1) Rt IC.sub.50 1
[cis-4-(2-Phenylchroman-6- A 338.41 1.03 0.5
yloxy)cyclohexylmethyl]amine hydrochloride 2
cis-4-(2-Phenylchroman-6-yloxy)cyclohexylamine B 324.27 3.56 1.3
hydrochloride 3 N-[cis-4-(2-Phenylchroman-6- A 416.32 1.36 0.7
yloxy)cyclohexylmethyl]methanesulfonamide 4
N-[cis-4-(2-Phenylchroman-6- A 380.33 1.32 0.4
yloxy)cyclohexylmethyl]acetamide 5 trans-4-(2-Phenylchroman-6- C
365.34 3.81 0.3 yloxy)cyclohexylamine [M + H + CH.sub.3CN].sup.+ 6
N-[cis-4-(2-Phenylchroman-6- A 366.31 1.31 0.5
yloxy)cyclohexyl]acetamide 7 N-[trans-4-(2-Phenylchroman-6- A
366.17 1.18 0.3 yloxy)cyclohexyl]acetamide 8
N-[trans-4-(2-Phenylchroman-6- B 400.42 4.76 30
yloxy)cyclohexyl]methanesulfonamide [M - H].sup.- 9
trans-4-((R)-2-Phenylchroman-6- A 324.24 0.99 0.3
yloxy)cyclohexylamine hydrochloride 10
trans-4-((S)-2-Phenylchroman-6- A 324.25 0.99 0.3
yloxy)cyclohexylamine hydrochloride 11
1-[1-Ethyl-4-(2-phenylchroman-6-yloxy)- A 394.39 1.20 2.8
cyclohexyl]propylamine hydrochloride 12
2-Amino-N-[4-(2-phenylchroman-6- B 381.33 3.62 0.2
yloxy)cyclohexyl]acetamide hydrochloride 13
N-(Isoxazol-5-ylmethyl)-4-(2-phenylchroman-6- A 433.27 1.33 0.3
yloxy)-cyclohexanecarboxamide 14
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-(2- A 460.34 1.34 0.4
phenylchroman-6-yloxy)-cyclohexanecarboxamide 15
2-[4-(2-Phenylchroman-6- A 368.26 1.11 0.2
yloxy)cyclohexylamino]ethanol 16
1,1-Dimethyl-3-[4-(2-phenylchroman-6- A 395.25 1.33 1.3
yloxy)cyclohexyl]urea 17 4-(2-Phenylchroman-6-yloxy)-1-propyl- A
366.25 1.16 1.0 cyclohexylamine hydrochloride 18
trans-4-((S)-2-Phenylchroman-6-yloxy)-N-propyl- B 366.31 3.75 0.5
cyclohexylamine 19 2-Methylsulfanyl-N-[trans-4-(2-phenylchroman-6-
A 412.2 1.35 0.1 yloxy)cyclohexyl]acetamide 20
N-[trans-4-(2-Phenylchroman-6- B 406.28 4.85 0.2
yloxy)cyclohexyl]cyclobutanecarboxamide 21
3-Methylsulfonyl-N-[trans-4-(2-phenylchroman-6- A 458.22 1.29 0.2
yloxy)cyclohexyl]propanamide 22
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 466.23 1.40 30
2-(trifluoromethylsulfanyl)acetamide 23
(R)-2-Methoxy-N-[trans-4-(2-phenylchroman-6- A 410.24 1.35 0.3
yloxy)cyclohexyl]propanamide 24
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 432.26 1.32 0.3
2-pyrazol-1-yl-acetamide 25
2-(3-Methylisoxazol-5-yl)-N-[trans-4-(2- A 447.23 1.33 0.2
phenylchroman-6-yloxy)cyclohexyl]acetamide 26
N-[trans-4-(2-Phenylchroman-6- A 392.22 1.34 0.1
yloxy)cyclohexyl]cyclopropanecarboxamide 27
2-Cyclopropyl-N-[trans-4-(2-phenylchroman-6- B 406.28 4.81 0.2
yloxy)cyclohexyl]acetamide 28
2-(3-Methylpyrazol-1-yl)-N-[trans-4-(2- A 446.26 1.34 0.2
phenylchroman-6-yloxy)cyclohexyl]acetamide 29
2-Methyl-N-[trans-4-(2-phenylchroman-6- A 449.21 1.40 0.3
yloxy)cyclohexyl]thiazole-4-carboxamide 30
3-Methoxy-N-[trans-4-(2-phenylchroman-6- B 410.31 4.66 0.3
yloxy)cyclohexyl]propanamide 31
3-Fluoro-N-[trans-4-(2-phenylchroman-6- A 447.22 1.36 0.1
yloxy)cyclohexyl]isonicotinamide 32
2,2-Difluoro-N-[trans-4-(2-phenylchroman-6- A 428.21 1.37 0.1
yloxy)cyclohexyl]cyclopropanecarboxamide 33
3,5-Dimethyl-N-[trans-4-(2-phenylchroman-6- B 447.29 4.84 30
yloxy)cyclohexyl]isoxazole-4-carboxamide 34
trans-4-((S)-2-Phenylchroman-6-yloxy)-N,N- B 408.34 4.06 1.3
dipropyl-cyclohexylamine 35
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 433.23 1.27 0.1
2-([1,2,4]triazol-1-yl)acetamide 36
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 488.59 1.29 0.3
3-(1,3,5-trimethylpyrazol-4-yl)propanamide 37
3-(3,5-Dimethyl-1H-pyrazol-4-yl)-N-[trans-4-(2- A 474.3 1.23 0.3
phenylchroman-6-yloxy)cyclohexyl]propanamide 38
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 447.27 1.26 0.4
3-([1,2,4]triazol-1-yl)propanamide 39
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 446.26 1.32 0.3
3-pyrazol-1-yl-propanamide 40
2-(2,5-Dimethylthiazol-4-yl)-N-[trans-4-(2- A 477.25 1.36 0.3
phenylchroman-6-yloxy)cyclohexyl]acetamide 41
2-(3,5-Dimethylpyrazol-1-yl)-N-[trans-4-(2- A 460.48 1.35 0.3
phenylchroman-6-yloxy)cyclohexyl]acetamide 42
3-(5-Methylpyrazol-1-yl)-N-[trans-4-(2- A 460.03 1.33 0.2
phenylchroman-6-yloxy)cyclohexyl]propanamide 43
2-(3,5-Dimethyl-1H-pyrazol-4-yl)-N-[trans-4-(2- A 460.29 1.26 0.1
phenylchroman-6-yloxy)cyclohexyl]acetamide 44
2-Hydroxy-2-methyl-N-[trans-4-(2-phenylchroman- A 424.24 1.34 0.3
6-yloxy)cyclohexyl]butanamide 45
1-Benzyl-4-(2-phenylchroman-6-yloxy)- B 414.28 3.47 22
cyclohexylamine, stereoisomeric mixture 1 46
1-Benzyl-4-(2-phenylchroman-6-yloxy)- A 414.24 1.13 11
cyclohexylamine, stereoisomeric mixture 2 47
trans-4-(2-Phenylchroman-6-yloxy)-N-(thiazol-5- A 421.2 1.13 0.4
ylmethyl)cyclohexylamine 48 N-(3-Methylsulfanylpropyl)-[trans-4-(2-
A 412.24 1.17 0.5 phenylchroman-6-yloxy)]-cyclohexylamine 49
N-(5-Methylisoxazol-3-ylmethyl)-[trans-4-(2- B 419.29 3.78 0.6
phenylchroman-6-yloxy)]-cyclohexylamine 50
trans-4-(2-Phenylchroman-6-yloxy)-N-(thiophen-3- A 420.25 1.04 0.6
ylmethyl)cyclohexylamine 51
trans-4-(2-Phenylchroman-6-yloxy)-N-(thiophen-2- A 420.18 1.17 0.6
ylmethyl)cyclohexylamine 52
N-[(4-Methylthiazol-2-yl)methyl]-[trans-4-(2- A 435.23 1.16 0.5
phenylchroman-6-yloxy)]-cyclohexylamine 53
N-(Furan-3-ylmethyl)-[trans-4-(2-phenylchroman-6- A 404.24 1.03 0.5
yloxy)]-cyclohexylamine 54
trans-4-(2-Phenylchroman-6-yloxy)-N-(3,3,3- A 420.26 1.03 0.6
trifluoropropyl)cyclohexylamine 55
trans-4-(2-Phenylchroman-6-yloxy)-N-(thiazol-2- A 421.21 1.14 0.4
ylmethyl)cyclohexylamine 56
N-(1,5-Dimethylpyrazol-3-ylmethyl)-[trans-4-(2- A 432.28 1.15 0.5
phenylchroman-6-yloxy)]-cyclohexylamine 57
N-(3-Methylimidazol-4-ylmethyl)-[trans-4-(2- A 418.24 1.02 0.5
phenylchroman-6-yloxy)]-cyclohexylamine 58
N-(2,2-Dimethylpropyl)-[trans-4-(2-phenylchroman- A 394.31 1.05 0.6
6-yloxy)]-cyclohexylamine 59
N-(2-Methylthiazol-4-ylmethyl)-[trans-4-(2- B 435.26 3.79 0.5
phenylchroman-6-yloxy)]-cyclohexylamine 60
trans-4-(2-Phenylchroman-6-yloxy)-N-(1,3,5- A 446.25 1.15 0.4
trimethylpyrazol-4-ylmethyl)cyclohexylamine 61
trans-4-(2-Phenylchroman-6-yloxy)-N- A 408.29 1.00 0.3
(tetrahydrofuran-3-ylmethyl)cyclohexylamine 62
N-(4-Chloro-1-methyl-pyrazol-3-ylmethyl)-[trans-4- A 452.21 1.17
0.6 (2-phenylchroman-6-yloxy)]-cyclohexylamine 63
N-(Cyclohexylmethyl)-[trans-4-(2-phenylchroman- A 420.33 1.08 0.6
6-yloxy)]-cyclohexylamine 64 N-(3-Methylsulfanylbutyl)-[trans-4-(2-
A 426.28 1.05 0.5 phenylchroman-6-yloxy)]-cyclohexylamine 65
N-Isobutyl-[trans-4-(2-phenylchroman-6-yloxy)]- A 380.3 1.04 0.4
cyclohexylamine 66 N-(3-Methyl-1H-pyrazol-4-yl)methyl)-[trans-4-(2-
A 418.26 1.13 0.4 phenylchroman-6-yloxy)]-cyclohexylamine 67
N-(4-Methylthiazol-5-ylmethyl)-[trans-4-(2- A 435.23 1.14 0.4
phenylchroman-6-yloxy)]-cyclohexylamine 68
N-(1-Ethyl-3-methyl-pyrazol-4-ylmethyl)-[trans-4- A 446.29 1.15 0.3
(2-phenylchroman-6-yloxy)]-cyclohexylamine 69
N-(5-Chloro-thiophen-2-ylmethyl)-[trans-4-(2- A 454.15 1.20 1.3
phenylchroman-6-yloxy)]-cyclohexylamine 70
N-(2-methylbutyl)-[trans-4-(2-phenylchroman-6- A 394.31 1.06 0.5
yloxy)]-cyclohexylamine 71
(S)-2-(Methylamino)-N-[trans-4-(2-phenylchroman- B 409.27 3.66 0.6
6-yloxy)cyclohexyl]propanamide hydrochloride 72
(R)-2-Amino-N-[trans-4-(2-phenylchroman-6- A 395.22 1.00 0.3
yloxy)cyclohexyl]propanamide hydrochloride 73
N-[trans-4-((S)-2-Phenylchroman-6- A 473.18 1.36 30
yloxy)cyclohexyl]morpholine-4-sulfonamide 74
4-(2-Phenylchroman-6-yloxy)cyclohexanol A 325.24 1.33 0.3 75
N-[trans-4-((S)-2-Phenylchroman-6-yloxy)cyclo- A 493.21 1.21 1.0
hexyl]-2-(pyridin-4-yl)ethanesulfonamide 76
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-(2- A 432.28 1.15 1.0
phenylchroman-6-yloxy)-cyclohexylamine 77
4-(2-Phenylchroman-6-yloxy)cyclohexanone A 323.15 1.37 0.4 78
[4-(2-Phenylchroman-6-yloxy)cyclohexyl] acetate B 0.6 79
[trans-4-(2-Phenylchroman-6-yloxy)]-N,N- A 516.23 11
bis(thiophen-3-ylmethyl)cyclohexylamine 80
N,N-Bis(cyclopropylmethyl)-[trans-4-(2- A 432.34 1.07 0.5
phenylchroman-6-yloxy)]-cyclohexylamine 81
N,N-Bis(4-chloro-1-methyl-pyrazol-3-ylmethyl)- A 580.23 1.23 4.0
[trans-4-(2-phenylchroman-6-yloxy)]- cyclohexylamine 82
N,N-Bis(5-methylisoxazol-3-ylmethyl)-[trans-4-(2- A 514.3 1.43 3.8
phenylchroman-6-yloxy)]-cyclohexylamine 83
[trans-4-(2-Phenylchroman-6-yloxy)]-N,N- A 518.2 1.40 1.4
bis(thiazol-5-ylmethyl)cyclohexylamine 84
N,N-Bis(1-methylpyrazol-3-ylmethyl)-[trans-4-(2- B 512.26 3.86 0.8
phenylchroman-6-yloxy)]-cyclohexylamine 85
N,N-Bis(furan-3-ylmethyl)-[trans-4-(2- A 484.27 1.20 0.8
phenylchroman-6-yloxy)]-cyclohexylamine 86
N,N-Bis(2-methylthiazol-4-ylmethyl)-[trans-4-(2- B 546.17 0.8
phenylchroman-6-yloxy)]-cyclohexylamine 87
N,N-Bis(1,5-dimethylpyrazol-3-ylmethyl)-[trans-4- A 540.34 1.20 1.3
(2-phenylchroman-6-yloxy)]-cyclohexylamine 88
N,N-Bis(2-methylbutyl)-[trans-4-(2-phenylchroman- A 2.5
6-yloxy)]-cyclohexylamine 89 3-Fluoro-isonicotinic acid
4-(2-phenyl-chroman-6- A 448.26 1.46 0.4 yloxy)-cyclohexyl ester 90
4-(2-Phenylchroman-6-yloxy)-1-propyl- A 0.2 cyclohexanol 91 Methyl
2-{[cis-4-(2-phenylchroman-6- A 424.23 1.33 0.4
yloxy)cyclohexanecarbonyl]amino}acetate, stereoisomer 1 (2) 92
Methyl 2-[[cis-4-[2-phenylchroman-6- A 424.22 1.33 0.1
yloxy]cyclohexanecarbonyl]amino]acetate, stereoisomer 2 (2) 93
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-[cis-4-(2- A 460.32 1.34 0.3
phenylchroman-6-yloxy)]- cyclohexanecarboxamide, stereoisomer 1 (2)
94 N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-[cis-4-(2- A 460.3 1.34 1.6
phenylchroman-6-yloxy)]- cyclohexanecarboxamide, stereoisomer 2 (2)
95 N-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-[4-cis-(2- A 448.23
1.32 0.2 phenylchroman-6-yloxy)]- cyclohexanecarboxamide,
stereoisomer 1 (2) 96
N-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-[4-cis-(2- A 448.27 1.33
0.4 phenylchroman-6-yloxy)]- cyclohexanecarboxamide, stereoisomer 2
(2) 97 N-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-4-(2- B 420.28 3.63
0.5 phenylchroman-6-yloxy)-cyclohexylamine 98
N-Isopentyl-4-(2-phenylchroman-6-yloxy)- A 394.31 1.19 0.6
cyclohexylamine 99 N-(2-Hydroxyethyl)-4-((R)-2-phenylchroman-6- B
396.26 4.38 0.3 yloxy)-cyclohexanecarboxamide 100
2-{(2-Methylbutyl)-[4-(2-phenylchroman-6- A 438.34 1.18 1.4
yloxy)cyclohexyl]amino}ethanol 101
N-(2-Methylbutyl)-4-(2-phenylchroman-6-yloxy)- A 394.31 1.19 0.9
cyclohexylamine 102 N-(2-Hydroxyethyl)-4-((S)-2-phenylchroman-6- E
395.83 1.13 1.1 yloxy)-cyclohexanecarboxamide 103
N-(Furan-3-ylmethyl)-4-(2-phenylchroman-6- A 404.23 1.16 0.8
yloxy)-cyclohexylamine 104 4-(2-Phenylchroman-6-yloxy)-N-(1,3,5- A
446.3 1.15 0.8 trimethylpyrazol-4-ylmethyl)cyclohexylamine 105
N-Cyclohexyl-4-(2-phenylchroman-6-yloxy)- F 406.29 1.06 1.1
cyclohexylamine 106 N-(1-Methylbutyl)-4-(2-phenylchroman-6-yloxy)-
F 394.29 1.06 0.8 cyclohexylamine 107
N-Isohexyl-4-(2-phenylchroman-6-yloxy)- F 408.3 1.08 0.8
cyclohexylamine 108 N-Butyl-4-(2-phenylchroman-6-yloxy)- F 380.27
1.04 0.6 cyclohexylamine 109
N-(1,2-Dimethylpropyl)-4-(2-phenylchroman-6- F 394.29 1.05 1.0
yloxy)-cyclohexylamine 110 N-(2-Methoxy-1-methyl-ethyl)-4-(2- F
396.27 1.03 1.3 phenylchroman-6-yloxy)-cyclohexylamine 111
N-(2-Methylsulfanylethyl)-4-(2-phenylchroman-6- F 398.24 1.03 0.6
yloxy)-cyclohexylamine 112
N-(3-Ethoxypropyl)-4-(2-phenylchroman-6-yloxy)- F 410.29 1.05 0.9
cyclohexylamine 113 4-(2-Phenylchroman-6-yloxy)-N-propyl- F 366.25
1.02 0.5 cyclohexylamine 114
N-(3-Methylpentyl)-4-(2-phenylchroman-6-yloxy)- F 408.3 1.08 0.7
cyclohexylamine 115 N-(3-Methoxy-2,2-dimethyl-propyl)-4-(2- F
424.29 1.07 1.0 phenylchroman-6-yloxy)-cyclohexylamine 116
4-(2-Phenylchroman-6-yloxy)-N-(3- F 436.31 1.03 0.6
tetrahydrofuran-3-ylpropyl)cyclohexylamine 117
N-(2-Cyclohexylsulfanylethyl)-4-(2- F 466.3 1.11 3.7
phenylchroman-6-yloxy)-cyclohexylamine 118
N-(1-Isopropylpiperidin-4-ylmethyl)-4-(2- E 463.44 0.89 2.1
phenylchroman-6-yloxy)-cyclohexylamine 119
N-(2-Isopropylsulfanylethyl)-4-(2-phenylchroman- F 426.27 1.07 1.1
6-yloxy)-cyclohexylamine 120 4-(2-Phenylchroman-6-yloxy)-N-(2- F
436.31 1.03 0.8 tetrahydropyran-4-ylethyl)cyclohexylamine
121 N-(3-Methoxypropyl)-4-(2-phenylchroman-6-yloxy)- F 396.28 1.02
0.7 cyclohexylamine 122
N-(3-tert-Butoxypropyl)-4-(2-phenylchroman-6- F 438.32 1.08 1.2
yloxy)-cyclohexylamine 123
N-Cyclopropyl-4-(2-phenylchroman-6-yloxy)- F 364.25 1.02 1.0
cyclohexylamine 124 4-(2-Phenylchroman-6-yloxy)-N-(1- F 406.29 1.07
2.4 propylcyclopropyl)cyclohexylamine 125 N-[4-(2-Phenylchroman-6-
F 408.27 1.00 1.9 yloxy)cyclohexyl]tetrahydropyran-4-ylamine 126
N-[3-Cyclopentoxypropyl]-4-(2-phenylchroman-6- F 450.31 1.09 1.6
yloxy)-cyclohexylamine 127
N-(3,3-Dimethylbutyl)-4-(2-phenylchroman-6- F 408.31 1.08 1.1
yloxy)-cyclohexylamine 128 N1,N1-Dimethyl-N2-[4-(2-phenylchroman-6-
E 409.35 0.91 1.7 yloxy)cyclohexyl]propane-1,2-diamine 129
4-(2-Phenylchroman-6-yloxy)-N-(tetrahydrofuran- F 408.28 1.03 0.7
2-ylmethyl)cyclohexylamine 130
N-(3-Methylbutyl)-4-(2-phenylchroman-6-yloxy)- F 412.25 1.05 0.8
cyclohexylamine 131 N-(2-Ethylsulfanylethyl)-4-(2-phenylchroman-6-
F 382.26 1.01 0.6 yloxy)-cyclohexylamine 132
N-(2-Methoxyethyl)-4-(2-phenylchroman-6-yloxy)- F 410.29 1.05 0.7
cyclohexylamine 133 N-[1-(Methoxymethyl)propyl]-4-(2-phenylchroman-
F 424.3 1.06 1.0 6-yloxy)-cyclohexylamine 134
N-(3-Isopropoxypropyl)-4-(2-phenylchroman-6- F 424.31 1.06 1.1
yloxy)-cyclohexylamine 135
N-(2-tert-Butoxyethyl)-4-(2-phenylchroman-6- E 477.47 0.90 0.8
yloxy)-cyclohexylamine 136
N-[2-(1-Isopropylpiperidin-4-yl)ethyl]-4-(2- E 421.39 0.88 1.8
phenylchroman-6-yloxy)-cyclohexylamine 137
4-(2-Phenylchroman-6-yloxy)-N-(2-pyrrolidin-1- E 485.35 1.00 1.3
ylethyl)cyclohexylamine 138
N-[2-(1,1-Dioxo-thiomorpholin-4-yl)ethyl]-4-(2- E 453.35 0.99 0.6
phenylchroman-6-yloxy)-cyclohexylamine 139
4-(2-Phenylchroman-6-yloxy)-N-(2-thiomorpholin- F 396.27 1.03 1.0
4-ylethyl)cyclohexylamine 140
N-((S)-2-Methoxy-1-methyl-ethyl)-4-(2- F 408.31 1.08 1.4
phenylchroman-6-yloxy)-cyclohexylamine 141
N-(1,3-Dimethylbutyl)-4-(2-phenylchroman-6- F 378.26 1.03 1.0
yloxy)-cyclohexylamine 142
N-Cyclobutyl-4-(2-phenylchroman-6-yloxy)- F 392.28 1.04 0.6
cyclohexylamine 143 N-Cyclopentyl-4-(2-phenylchroman-6-yloxy)- F
394.29 1.07 0.8 cyclohexylamine 144
N-Pentyl-4-(2-phenylchroman-6-yloxy)- E 435.39 0.89 0.6
cyclohexylamine 145 4-(2-Phenylchroman-6-yloxy)-N-(2-piperidin-1- F
420.31 1.08 2.1 ylethyl)cyclohexylamine 146
(trans-4-Methyl-cyclohexyl)-[4-(2-phenyl-chroman- F 442.23 0.99 2.0
6-yloxy)-cyclohexyl]-amine 147 1,1-Dioxo-N-[4-(2-phenylchroman-6- F
378.27 1.04 0.7 yloxy)cyclohexyl]-tetrahydrothiophen-3-ylamine 148
N-But-3-enyl-4-(2-phenylchroman-6-yloxy)- F 366.26 1.02 0.9
cyclohexylamine 149 N-Isopropyl-4-(2-phenylchroman-6-yloxy)- B
364.32 3.68 1.4 cyclohexylamine 150
N-(3-Hydroxypropyl)-4-(2-phenylchroman-6-yloxy)- A 424.32 1.34 0.9
cyclohexanecarboxamide 151 N-(2-Hydroxy-1,1-dimethyl-ethyl)-4-(2- A
408.37 1.22 1.3 phenylchroman-6-yloxy)-cyclohexanecarboxamide 152
N-(3,3-Dimethylbutyl)-4-(2-phenylchroman-6- E 394.25 1.02 1.4
yloxy)-cyclohexylamine 153 N-{trans-4-[2-(o-Tolyl)chroman-6- E
460.31 1.22 1.2 yloxy]cyclohexyl}-3-pyrazol-1-yl-propanamide 154
(Tetrahydrofuran-3-ylmethyl)-[trans-4-(2-o-tolyl- E 422.33 1.02 2.2
chroman-6-yloxy)-cyclohexyl]-amine 155
Bis-(tetrahydrofuran-3-ylmethyl)-[trans-4-(2-o-tolyl- E 506.39 1.04
5.3 chroman-6-yloxy)-cyclohexyl]-amine 156
trans-4-[2-(o-Tolyl)chroman-6- E 338.32 0.99 0.6
yloxy]cyclohexylamine hydrochloride 157
N,N-Bis(2-hydroxyethyl)-4-(2-phenylchroman-6- A 2.0
yloxy)-cyclohexanecarboxamide 158
N-(Isoxazol-5-ylmethyl)-4-[2-(o-tolyl)chroman-6- E 447.28 1.22 0.4
yloxy]-cyclohexanecarboxamide 159
2-Amino-N-[trans-4-((S)-2-phenylchroman-6- A 381.35 1.12 0.2
yloxy)cyclohexyl]acetamide hydrochloride 160
2-Amino-N-[trans-4-((R)-2-phenylchroman-6- A 381.38 1.12 1.1
yloxy)cyclohexyl]acetamide hydrochloride 161
N-(2,2-Dimethylpropyl)-4-(2-phenylchroman-6- E 1.3
yloxy)-cyclohexylamine 162
N-(2,2-Dimethylpropyl)-4-(2-phenylchroman-6- B 2.3
yloxy)-cyclohexylamine 163 1-Methyl-4-(2-phenylchroman-6-yloxy)- B
677.57 4.84 0.6 cyclohexanol [2M + H].sup.+ 164
4-[2-(2,6-Dimethylphenyl)chroman-6-yloxy]-N- A 474.53 1.19 9.4
(1,3,5-trimethylpyrazol-4-ylmethyl)cyclohexylamine 165
4-[2-(2,6-Dimethylphenyl)chroman-6-yloxy]-N-(3- A 454.5 1.22 10
methylsulfanylbutyl)cyclohexylamine 166
4-[2-(2,6-Dimethylphenyl)chroman-6-yloxy]-N-(2- A 424.44 1.32 6.2
hydroxyethyl)cyclohexanecarboxamide 167
4-[2-(2,6-Dimethylphenyl)chroman-6-yloxy]-N- A 461.42 1.38 7.7
(isoxazol-5-ylmethyl)cyclohexanecarboxamide 168
trans-4-[2-(2,6-Dimethylphenyl)chroman-6- A 352.35 1.16 4.0
yloxy]cyclohexylamine hydrochloride 169
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(1,3,5- E 464.44 1.04 2.5
trimethylpyrazol-4-ylmethyl)cyclohexylamine 170
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(3- B 444.43 3.87 4.6
methylsulfanylbutyl)cyclohexylamine 171
trans-4-[2-(2,6-Dimethylphenyl)chroman-6-yloxy]- A 436.33 1.17 8.3
N-(tetrahydrofuran-3-ylmethyl)cyclohexylamine 172
N-[trans-4-[2-(2,6-Dimethylphenyl)chroman-6- A 474.31 1.37 7.1
yloxy]cyclohexyl]-3-pyrazol-1-yl-propanamide 173
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- A 414.23 1.27 0.7
hydroxyethyl)cyclohexanecarboxamide 174
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N- A 451.24 1.33 0.6
(isoxazol-5-ylmethyl)cyclohexanecarboxamide 175
N-(3-Methylsulfanylbutyl)-4-[2-(o-tolyl)chroman-6- B 440.46 4.06
3.5 yloxy]-cyclohexylamine 176
trans-4-[2-(2-Fluorophenyl)chroman-6- E 342.22 1.00 1.3
yloxy]cyclohexylamine hydrochloride 177
[4-(2-o-Tolyl-chroman-6-yloxy)-cyclohexyl]-(1,3,5- A 460.34 1.16
3.2 trimethylpyrazol-4-ylmethyl)-amine 178
trans-4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N- B 426.48 3.63 1.6
(tetrahydrofuran-3-ylmethyl)cyclohexylamine 179
N-[trans-4-[2-(2-Fluorophenyl)chroman-6- A 464.27 1.30 1.2
yloxy]cyclohexyl]-3-pyrazol-1-yl-propanamide 180
(S)--N-[trans-4-(2-Phenylchroman-6- A 421.3 1.14 0.8
yloxy)cyclohexyl]pyrrolidine-2-carboxamide hydrochloride 181
(S)-2-Amino-3-hydroxy-N-[trans-4-(2- A 411.27 1.11 0.3
phenylchroman-6-yloxy)cyclohexyl]propanamide hydrochloride 182
N-[trans-4-(2-Phenylchroman-6-yloxy)cyclohexyl]- A 435.29 1.14 0.3
2-pyrrolidin-1-yl-acetamide 183
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-[2-(2- A 478.34 1.32 10
fluorophenyl)chroman-6-yloxy]- cyclohexanecarboxamide 184
N-(2-Chloro-pyridin-4-ylmethyl)-4-[2-(2- A 495.3 1.35 1.3
fluorophenyl)chroman-6-yloxy]- cyclohexanecarboxamide 185
2-Amino-N-{cis-4-[2-(o-tolyl)chroman-6- A 409.26 1.15 0.6
yloxy]cyclohexylmethyl}acetamide hydrochloride 186
2-Amino-N-{trans-4-[2-(5-fluoro-2-methyl- A 413.26 1.14 0.4
phenyl)chroman-6-yloxy]cyclohexyl}acetamide 187
4-[2-(o-Tolyl)chroman-6-yloxy]-N-(tetrahydrofuran- E 422.34 1.05
99% 2-ylmethyl)cyclohexylamine (3) 188
N-(2-Methoxy-1-methyl-ethyl)-4-[2-(o- E 410.32 1.05 96%
tolyl)chroman-6-yloxy]-cyclohexylamine (3) 189
N-(2-Methoxyethyl)-4-[2-(o-tolyl)chroman-6-yloxy]- E 396.29 1.03
100% cyclohexylamine (3) 190
N-(3-Isopropoxypropyl)-4-[2-(o-tolyl)chroman-6- E 438.37 1.08 93%
yloxy]-cyclohexylamine (3) 191
N-(2-Ethylsulfanylethyl)-4-[2-(o-tolyl)chroman-6- E 426.3 1.07 95%
yloxy]-cyclohexylamine (3) 192
N-(2-Methylsulfanylethyl)-4-[2-(o-tolyl)chroman-6- E 412.28 1.05
98% yloxy]-cyclohexylamine (3) 193
N-(3-Methoxypropyl)-4-[2-(o-tolyl)chroman-6- E 410.31 1.04 99%
yloxy]-cyclohexylamine (3) 194
N-(2-Isopropylsulfanylethyl)-4-[2-(o-tolyl)chroman- E 440.33 1.08
85% 6-yloxy]-cyclohexylamine (3) 195
N-[1-(Methoxymethyl)propyl]-4-[2-(o-tolyl)chroman- E 424.36 1.06
96% 6-yloxy]-cyclohexylamine (3) 196
4-[2-(o-Tolyl)chroman-6-yloxy]-N-(2- E 450.39 1.05 97%
tetrahydropyran-4-ylethyl)cyclohexylamine (3) 197
N-{4-[2-(o-Tolyl)chroman-6- E 422.36 1.03 96%
yloxy]cyclohexyl}tetrahydropyran-4-ylamine (3) 198
4-[2-(o-Tolyl)chroman-6-yloxy]-N-(3- E 450.35 1.05 97%
tetrahydrofuran-3-ylpropyl)cyclohexylamine (3) 199
N-[3-Cyclopentoxypropyl]-4-[2-(o-tolyl)chroman-6- E 464.42 1.10 71%
yloxy]-cyclohexylamine (3) 200
N-(3-Methoxy-2,2-dimethyl-propyl)-4-[2-(o- E 438.46 1.08 94%
tolyl)chroman-6-yloxy]-cyclohexylamine (3) 201
N-(3-Ethoxypropyl)-4-[2-(o-tolyl)chroman-6-yloxy]- E 424.33 1.06
98% cyclohexylamine (3) 202
N-(2-Morpholin-4-ylethyl)-4-[2-(o-tolyl)chroman-6- E 451.36 1.00
1.9 yloxy]-cyclohexylamine 203
N-Cyclopropyl-4-[2-(o-tolyl)chroman-6-yloxy]- E 378.28 1.04 1.5
cyclohexylamine 204 N-Cyclopentyl-4-[2-(o-tolyl)chroman-6-yloxy]- E
406.33 1.06 1.9 cyclohexylamine 205
4-[2-(o-Tolyl)chroman-6-yloxy]-N-propyl- B 380.35 3.84 1.5
cyclohexylamine 206
N-[4-[2-(o-Tolyl)chroman-6-yloxy]cyclohexyl]-1,1- E 456.26 1.02 1.1
dioxo-tetrahydrothiophen-3-ylamine 207
N-((S)-2-Methoxy-1-methyl-ethyl)-4-[2-(o- E 410.32 1.05 1.5
tolyl)chroman-6-yloxy]-cyclohexylamine 208
4-[2-(o-Tolyl)chroman-6-yloxy]-N-(tetrahydropyran- E 436.33 1.03
3.0 4-ylmethyl)cyclohexylamine 209
4-[2-(o-Tolyl)chroman-6-yloxy]-N-(2-thiomorpholin- E 467.33 1.02
3.2 4-ylethyl)cyclohexylamine 210
N-{4-[2-(2-Fluorophenyl)chroman-6-yloxy]cyclo- E 460.2 1.00 1.1
hexyl}-1,1-dioxo-tetrahydrothiophen-3-ylamine 211
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(3- E 442.33 1.07 2.2
methoxy-2,2-dimethyl-propyl)cyclohexylamine 212
N-Cyclopropyl-4-[2-(2-fluorophenyl)chroman-6- E 382.23 1.02 1.7
yloxy]-cyclohexylamine 213
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-propyl- E 384.26 1.03 1.4
cyclohexylamine 214 4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E
400.24 1.02 1.6 methoxyethyl)cyclohexylamine 215
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(3- E 414.27 1.03 2.8
methoxypropyl)cyclohexylamine 216
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N- E 426.27 1.03 1.7
(tetrahydrofuran-2-ylmethyl)cyclohexylamine 217
N-(2-Ethylsulfanylethyl)-4-[2-(2- E 430.27 1.05 2.3
fluorophenyl)chroman-6-yloxy]-cyclohexylamine 218
N-Cyclopentyl-4-[2-(2-fluorophenyl)chroman-6- E 410.27 1.05 2.8
yloxy]-cyclohexylamine 219
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E 414.29 1.03 2.4
methoxy-1-methyl-ethyl)cyclohexylamine 220
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E 454.32 1.03 2.4
tetrahydropyran-4-ylethyl)cyclohexylamine 221
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-((S)-2- E 414.29 1.03 2.3
methoxy-1-methyl-ethyl)cyclohexylamine 222
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-[1- E 428.32 1.05 3.1
(methoxymethyl)propyl]cyclohexylamine 223
N-(3-Ethoxypropyl)-4-[2-(2-fluorophenyl)chroman- E 428.32 1.05 3.1
6-yloxy]-cyclohexylamine 224
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E 455.34 0.98 3.5
morpholin-4-ylethyl)cyclohexylamine 225
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(3- B 442.41 3.97 3.9
isopropoxypropyl)cyclohexylamine 226
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E 416.26 1.03 2.4
methylsulfanylethyl)cyclohexylamine 227
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E 471.3 1.00 4.3
thiomorpholin-4-ylethyl)cyclohexylamine 228
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(3- E 454.32 1.03 2.2
tetrahydrofuran-3-ylpropyl)cyclohexylamine 229
N-(3-Cyclopentoxypropyl)-4-[2-(2- E 468.35 1.09 6.0
fluorophenyl)chroman-6-yloxy]-cyclohexylamine 230
N-Butyl-4-[2-(2-fluorophenyl)chroman-6-yloxy]- E 398.29 1.05 2.9
cyclohexylamine 231 N-{4-[2-(2-Fluorophenyl)chroman-6- E 426.28
1.01 4.1 yloxy]cyclohexyl}tetrahydropyran-4-ylamine 232
4-[2-(2-Fluorophenyl)chroman-6-yloxy]-N-(2- E 444.29 1.07 5.9
isopropylsulfanylethyl)cyclohexylamine 233
2-(3,5-Dimethylpyrazol-1-yl)-N-{trans-4-[2-(2- E 478.32 1.23 30
fluorophenyl)chroman-6- yloxy]cyclohexyl}acetamide 234
3-(3,5-Dimethyl-1H-pyrazol-4-yl)-N-{trans-4-[2-(2- E 492.33 1.12
0.1 fluorophenyl)chroman-6- yloxy]cyclohexyl}propanamide 235
2-(3,5-Dimethyl-1H-pyrazol-4-yl)-N-{trans-4-[2-(2- E 478.3 1.14 1.5
fluorophenyl)chroman-6- yloxy]cyclohexyl}acetamide 236
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 450.29 1.20 0.1
yloxy]cyclohexyl}-2-pyrazol-1-yl-acetamide 237
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 465.29 1.15 0.2
yloxy]cyclohexyl}-3-([1,2,4]triazol-1- yl)propanamide 238
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 442.24 1.23 0.1
yloxy]cyclohexyl}-2-hydroxy-2-methyl-butanamide 239
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 410.25 1.23 0.1
yloxy]cyclohexyl}cyclopropanecarboxamide 240
3,3,3-Trifluoro-N-{trans-4-[2-(2-fluoro- E 452.21 1.25 0.1
phenyl)chroman-6-yloxy]cyclohexyl}propanamide 241
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 430.22 1.24 0.04
yloxy]cyclohexyl}-2-methylsulfanyl-acetamide 242
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 465.25 1.25 0.5
yloxy]cyclohexyl}-3,5-dimethyl-isoxazole-4- carboxamide 243
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 428.23 1.20 0.7
yloxy]cyclohexyl}-3-methoxy-propanamide 244
N-{[trans-4-[2-(2-Fluorophenyl)chroman-6- E 424.27 1.26 0.1
yloxy]cyclohexyl}cyclobutanecarboxamide 245
2-(2,5-Dimethylthiazol-4-yl)-N-{trans-4-[2-(2- E 495.37 1.25 0.3
fluorophenyl)chroman-6- yloxy]cyclohexyl}acetamide 246
3-Fluoro-N-{trans-4-[2-(2-fluorophenyl)chroman-6- E 465.25 1.24 0.1
yloxy]cyclohexyl}pyridine-4-carboxamide 247
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 467.25 1.28 0.3
yloxy]cyclohexyl}-2-methyl-thiazole-4-carboxamide 248
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 480.26 1.21 0.2
yloxy]cyclohexyl}-3-(3-methyl-[1,2,4]oxadiazol-5- yl)propanamide
249 N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 465.25 1.22 1.1
yloxy]cyclohexyl}-2-(3-methylisoxazol-5- yl)acetamide 250
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 464.3 1.22 0.8
yloxy]cyclohexyl}-2-(3-methylpyrazol-1- yl)acetamide 251
2,2-Difluoro-N-{trans-4-[2-(2- E 446.24 1.25 5.0
fluorophenyl)chroman-6- yloxy]cyclohexyl}cyclopropanecarboxamide
252 2-Cyclopropyl-N-{trans-4-[2-(2-fluoro- E 424.29 1.24 0.3
phenyl)chroman-6-yloxy]cyclohexyl}acetamide 253
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 464.3 1.20 0.3
yloxy]cyclohexyl}-3-pyrazol-1-yl-propanamide 254
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 506.34 1.17 0.3
yloxy]cyclohexyl}-3-(1,3,5-trimethylpyrazol-4- yl)propanamide 255
(R)--N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 428.27 1.24 0.2
yloxy]cyclohexyl}-2-methoxy-propanamide 256
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 451.27 1.16 0.1
yloxy]cyclohexyl}-2-([1,2,4]triazol-1-yl)acetamide 257
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 478.31 1.22 0.2
yloxy]cyclohexyl}-3-(5-methylpyrazol-1- yl)propanamide 258
3-(1,5-Dimethylpyrazol-4-yl)-N-{trans-4-[2-(2- B 492.38 4.64 0.2
fluorophenyl)chroman-6- yloxy]cyclohexyl}propanamide 259
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 476.21 1.17 0.1
yloxy]cyclohexyl}-3-methylsulfonyl-propanamide 260
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 484.2 1.28 0.4
yloxy]cyclohexyl}-2- (trifluoromethylsulfanyl)acetamide 261
N-{trans-4-[2-(2-Fluorophenyl)chroman-6- E 450.26 1.20 0.3
yloxy]cyclohexyl}-5-methyl-1H-pyrazole-3- carboxamide 262
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 428.18 1.29 0.2
N-(2-hydroxyethyl)cyclohexanecarboxamide 263
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 465.17 1.35 0.1
N-(isoxazol-5-ylmethyl)cyclohexanecarboxamide 264
N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-4-[2-(o- A 440.19 1.25 0.2
tolyl)chroman-6-yloxy]-cyclohexanecarboxamide 265
cis-4-[2-(o-Tolyl)chroman-6-yloxy]-N-(pyridin-2- A 443.2 1.38 0.4
yl)cyclohexanecarboxamide 266
trans-4-[2-(o-Tolyl)chroman-6-yloxy]-N-(pyridin-2- A 443.2 1.39 0.3
yl)cyclohexanecarboxamide 267
trans-4-((R)-2-o-tolyl-chroman-6-yloxy)- A 410.2 1.28 0.2
cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide 268
trans-4-((S)-2-o-tolyl-chroman-6-yloxy)- E 410.3 1.16 0.15
cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide 269
cis-4-(2-o-tolyl-chroman-6-yloxy)- A 410.2 1.28 0.4
cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, stereoisomer 1
(2) 270 cis-4-(2-o-tolyl-chroman-6-yloxy)- A 410.2 1.28 0.1
cyclohexanecarboxylic acid (2-hydroxy-ethyl)- amide, stereoisomer 2
(2) 271 2-{trans-4-[2-(o-Tolyl)chroman-6- A 396.17 1.17 0.8
yloxy]cyclohexylamino}acetic acid 272
N-Carbamoylmethyl-4-[2-(3-fluoro-2-methyl- A 441.16 1.27 0.4
phenyl)chroman-6-yloxy]- cyclohexanecarboxamide 273
N-Dimethylcarbamoylmethyl-4-[2-(3-fluoro-2- A 469.19 1.32 0.6
methyl-phenyl)chroman-6-yloxy]- cyclohexanecarboxamide 274
N-[2-(Dimethylsulfamoyl)ethyl]-4-[2-(3-fluoro-2- A 519.18 1.35 0.6
methyl-phenyl)chroman-6-yloxy]- cyclohexanecarboxamide 275
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 505.16 1.32 0.4
N-[2-(methylsulfamoyl)ethyl]cyclohexane- carboxamide 276
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 442.19 1.31 0.6
N-(2-hydroxypropyl)cyclohexanecarboxamide 277
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- D 505 4.42 0.3
N-[2-(methanesulfonamido)ethyl]cyclohexane- carboxamide 278
2-Hydroxy-N-[trans-4-(2-phenylchroman-6- A 382.18 1.26 0.2
yloxy)cyclohexyl]acetamide 279
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 468.24 1.34 0.7
N-(2-hydroxycyclopentyl)cyclohexane- carboxamide, stereoisomer 1
(2) 280 4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 512.36
1.37 0.1 N-(2-hydroxycyclopentyl)cyclohexane- [M - H +
HCO.sub.2H].sup.- carboxamide, stereoisomer 2 (2) 281
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- A 455.21 1.29 0.5
N-methylcarbamoylmethyl-cyclohexane- carboxamide 282
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- E 486.16 1.42 0.4
N-(3-methylsulfanylbutyl)cyclohexanecarboxamide 283
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-[2-(3-fluoro-2- E 492.19 1.36
0.6 methyl-phenyl)chroman-6-yloxy]-cyclohexane- carboxamide 284
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- E 496.19 1.39 0.8
N-{[(1S,2R)-2-hydroxycyclohexyl]methyl}cyclo- hexanecarboxamide 285
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- E 482.17 1.36 0.5
N-[(1S,2S)-2-hydroxycyclohexyl]cyclohexane- carboxamide,
stereoisomeric mixture 1 286
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- E 482.18 1.36 0.5
N-[(1S,2S)-2-hydroxycyclohexyl]cyclohexane- carboxamide,
stereoisomeric mixture 2 287
4-[2-(3-Fluoro-2-methyl-phenyl)chroman-6-yloxy]- E 482.18 1.38 0.1
N-[(1S,2S)-2-hydroxycyclohexyl]cyclohexane- carboxamide,
stereoisomeric mixture 3 288
N-(2-Hydroxyethyl)-4-[7-methyl-2-(o-tolyl)chroman- E 424.13 1.35
1.9 6-yloxy]-cyclohexanecarboxamide 289
N-(Isoxazol-5-ylmethyl)-4-[7-methyl-2-(o- E 461.12 1.41 1.3
tolyl)chroman-6-yloxy]-cyclohexanecarboxamide 290
N-[2-Ethyl-2H-pyrazol-3-ylmethyl]-4-[7-methyl-2-(o- E 488.17 1.41
1.5 tolyl)chroman-6-yloxy]-cyclohexanecarboxamide 291
4-(5-Chloro-2-phenyl-chroman-6-yloxy)-N-(2- E 430.09 1.30 1.1
hydroxyethyl)cyclohexanecarboxamide 292
4-(5-Chloro-2-phenyl-chroman-6-yloxy)-N- E 467.1 1.36 1.9
(isoxazol-5-ylmethyl)cyclohexanecarboxamide 293
4-(5-Chloro-2-phenyl-chroman-6-yloxy)-N-[(2- E 494.12 1.36 4.7
ethyl-2H-pyrazol-3- yl)methyl]cyclohexanecarboxamide 294
4-[2-(2-Fluoro-3-methoxy-phenyl)chroman-6- B 444.23 4.28 1.3
yloxy]-N-(2-hydroxyethyl)cyclohexanecarboxamide 295
4-[2-(2-Fluoro-3-methoxy-phenyl)chroman-6- B 481.18 4.68 1.1
yloxy]-N-(isoxazol-5- ylmethyl)cyclohexanecarboxamide 296
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-[2-(2-fluoro-3- E 508.2 1.30
0.9 methoxy-phenyl)chroman-6-yloxy]- cyclohexanecarboxamide 297
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-(3-methyl-2- E 474.22 1.34 0.5
phenyl-chroman-6-yloxy)- cyclohexanecarboxamide 298
N-(Isoxazol-5-ylmethyl)-4-(3-methyl-2-phenyl- E 447.15 1.34 1.4
chroman-6-yloxy)-cyclohexanecarboxamide 299
N-(2-Hydroxyethyl)-4-(3-methyl-2-phenyl-chroman- E 410.15 1.28 1.9
6-yloxy)-cyclohexanecarboxamide 300
N-(2-Ethyl-2H-pyrazol-3-ylmethyl)-4-[2-(3-fluoro-2- E 508.18 1.34
0.4 methoxy-phenyl)chroman-6-yloxy]- cyclohexanecarboxamide 301
4-[2-(3-Fluoro-2-methoxy-phenyl)chroman-6- E 481.12 1.33 0.2
yloxy]-N-(isoxazol-5- ylmethyl)cyclohexanecarboxamide 302
4-[2-(3-Fluoro-2-methoxy-phenyl)chroman-6- E 444.14 1.27 0.4
yloxy]-N-(2-hydroxyethyl)cyclohexanecarboxamide 303 Phosphoric acid
mono-(2-{[trans-4-((S)-2-o-tolyl- E 490.28 1.22 0.1
chroman-6-yloxy)-cyclohexanecarbonyl]-amino}- ethyl) ester disodium
salt 304 (1R,3R)-3-(2-Phenylchroman-6- A 310.18 0.96 0.6
yloxy)cyclopentylamine hydrochloride 305 [3-(2-Phenylchroman-6- E
323.97 0.98 1.5 yloxy)cyclopentylmethyl]amine hydrochloride 306
cis-3-(2-Phenylchroman-6-yloxy)cyclobutylamine E 296.3 0.96 1.6
hydrochloride
[0399] (1) Observed ion [M+H].sup.+, unless specified otherwise
[0400] (2) In case a compound has been obtained as stereoisomer 1
and stereoisomer 2, one of them has R configuration, and the other
S configuration, with respect to position 2 in the chroman ring
[0401] (3) Inhibition in % at 10 .mu.M; IC.sub.50 value not
determined
[0402] Exemplary NMR data of example compounds.
Example No. 156
[0403] .sup.1H-NMR (400 MHz): .delta. (ppm)=1.41 (4H, m), 1.98 (3H,
m), 2.11 (3H, m), 2.35 (3H, s), 2.75 (1H, m), 3.02 (2H, m), 4.12
(1H, m), 5.15 (1H, dd), 6.74 (3H, m), 7.24 (3H, m), 7.41 (1H,
m).
Example No. 158
[0404] .sup.1H-NMR (400 MHz): .delta. (ppm)=1.28 (2H, m), 1.54 (2H,
m), 1.88 (3H, m), 2.11 (3H, m), 2.22 (1H, m), 2.32 (3H, s), 2.75
(1H, m), 2.96 (1H, m), 4.12 (1H, m), 4.42 (2H, d), 5.17 (1H dd),
6.28 (1H, s), 6.72 (3H, m), 7.21 (3H, m), 7.43 (1H, m), 8.48 (2H,
m).
Example No. 159
[0405] .sup.1H-NMR: .delta. (ppm)=1.47 (4H, m), 1.90 (2H, m), 2.00
(3H, m), 2.15 (1H, m), 2.70 (1H, m), 2.95 (1H, m), 3.54 (2H, m),
3.67 (1H, m), 4.16 (1H, m), 5.05 (1H, dd), 6.72 (3H, m), 7.38 (1H,
m), 7.41 (4H, m), 8.48 (1H, d).
Example No. 177
[0406] .sup.1H-NMR: .delta. (ppm)=1.40 (1H, m), 1.58 (2H, m), 1.78,
(1H, m), 1.98 (3H, m), 2.18 (7H, m), 2.25 (3H, s), 2.35 (3H, s),
2.77 (1H, m), 3.03 (1H, m), 3.19, (1H, m), 3.97 (2H, m), 4.13
(0.5H, m), 4.48 (0.5H, m), 5.17 (1H, dd), 6.73 (3H, m), 7.22 (3H,
m), 7.40 (1H, m).
Example No. 180
[0407] .sup.1H-NMR: .delta. (ppm)=1.48 (4H, m), 1.95 (8H, m), 2.15
(1H, m), 2.28 (1H, m), 2.70 (1H, m), 2.93 (1H, m), 3.22 (1H, m),
3.51 (2H, m), 3.65 (1H, m), 4.10 (1H, t), 4.18 (1H, m), 5.05 (1H,
dd), 6.73 (3H, m), 7.42 (1H, m), 7.40 (4H, m) 8.45 (1H, d).
Example No. 268
[0408] .sup.1H-NMR (400 MHz): .delta. (ppm)=1.28 (2H, m), 1.48 (2H,
m), 1.74 (2H, m), 1.88 (1H, m), 2.11 (4H, m), 2.32 (3H, s), 2.38
(1H, m), 2.73 (1H, dd), 2.96 (1H, m), 3.12 (2H, dt), 3.38 (4H, m),
4.12 (1H, m), 4.68 (1H, t), 5.17 (1H, dd), 6.72 (3H), 7.21 (3H),
7.43 (1H), 7.79 (1H, t).
Example No. 303
[0409] .sup.1H-NMR (400 MHz, D.sub.2O): .delta. (ppm)=1.45 (4H, m),
1.93 (2H, m), 2.08 (1H, m), 2.18 (3H, m) 2.30 (1H, m) 2.81 (1H, m),
3.02 (1H, m), 3.35 (2H, t), 3.80 (2H, m), 4.42 (1H, m), 5, 30 (1H,
dd), 6.81 (2H, m), 6.90 (1H, m), 7.29 (3H, m), 7.48 (1H, m).
Pharmacological Examples
[0410] A) Assay Method for Determining the NCX1 Inhibitory
Activity
[0411] The sodium/calcium exchanger NCX1 can transport calcium ions
and sodium ions through the cell membrane. The transport is an
exchange of Ca.sup.2+ and Na.sup.+ in two directions depending on
membrane potential and ion gradients. At the first direction, named
"forward mode" or "calcium export mode", Ca.sup.2+ is transported
out of the cell and Na.sup.+ is transported into the cell. At the
other direction, named "reverse mode" or "calcium import mode", the
transport directions are vice versa. The effect of the compounds of
the invention on NCX1 was determined in CHO cells stably expressing
human NCX1 (gene symbol SLC8A1; cf. WO 2009/115238). The assay is
based on the monitoring of intracellular Ca.sup.2+ concentrations
using a calcium-sensitive fluorescence dye which is detected by
means of a FLIPR device (Fluorimetric Imaging Plate Reader,
Molecular Devices).
Assay Technology--Reverse Mode
[0412] The assay is based on the monitoring of intracellular
Ca.sup.2+ concentrations using the calcium-sensitive dye Fluo-4.
CHO cells expressing NCX1 were loaded with the dye by means of the
acetoxymethyl ester Fluo-4 AM (Invitrogen, F14202), which is
cleaved intracellularly by esterase activity to yield the charged
species of free Fluo-4. After an preincubation period with the test
compound, Gramicidine (Sigma, G5002) was added. Gramicidine is an
ionophor for Na.sup.+ ions mediating an increase of intracellular
Na.sup.+ ions. Consequently, intracellular Na.sup.+ ions are
exchanged against extracellular Ca.sup.2+ ions (Ca.sup.+ influx,
reverse mode). The intracellular elevation of Ca.sup.2+ ions was
detected by measuring the fluorescence of Fluo-4 at a wavelength of
520 nm by a FLIPR device.
[0413] Briefly, for the reverse mode transport assay 18000 cells
per well were seeded into a 96 well microplate (Corning COSTAR
3904) and incubated overnight in culture medium (1.times. Nut Mix
F12 (Ham) (Gibco, 21765-029); 10% (v/v) fetal calf serum (PAA Gold,
A15-649); 450 .mu.g/ml Geneticin (Gibco, 10131-027)). A total
volume of 100 .mu.l medium per well was used. For the preparation
of the FLIPR assay, the culture medium was removed from the plates
and 100 .mu.l of dye solution (2 .mu.M Fluo-4 AM; 0.02% (v/v)
Pluronic F-127 (20%, Invitrogen, P3000MP); 0.1% (v/v) bovine
albumin solution (30% (v/v), Sigma, A9205) in assay buffer (133.8
mM NaCl (Sigma, S5886); 4.7 mM KCl (Sigma, P3911); 1.25 mM
MgCl.sub.2 (Merck, 1.05833.0250); 3.5 mM CaCl.sub.2 (Merck,
1.02083.0250); 5 mM glucose (Sigma, G7021); 10 mM Hepes (Sigma,
H4034); 0.01% (v/v) Pluronic F-127 (5%, Sigma, P2443); 2.5 mM
Probenecid (Maybridge, SB00915EB); pH 7.4)) were added into each
well. The plates were incubated in the dark at room temperature for
80 min. After the incubation period, the dye solution was removed
and the wells were washed with 100 .mu.l of assay buffer. Then 80
.mu.l of a solution of the test compound in assay buffer in
different concentrations were added into the wells. The plates were
incubated at 16.degree. C. for 45 min. Meanwhile a 60 .mu.M
solution of Gramicidine in assay buffer (4.degree. C.) was prepared
and stored in the wells of a 96 well microplate (96 well
microplate, polypropylene, U-shape (Greiner Bio-One, 650201)) at
4.degree. C. until measurement was started. The fluorescence
monitoring was performed at 240 measuring points with measurement
intervals of 2 sec. After the fifth measuring point, 40 .mu.l of
the Gramicidine solution were added to each well of the assay
plates to give a final Gramicidine concentration of 20 .mu.M. For
the determination of the IC.sub.50 values the minimal fluorescence
value was subtracted from the maximal fluorescence value for all
measuring points. The calculation of the IC.sub.50 values via the
percentage inhibitions of Ca.sup.2+ influx into cells (reverse
mode) effected by the test compound was performed in Biost@t Speed
2.0. Results obtained with compounds of the invention are given in
Table 1.
Assay Technology--Forward Mode
[0414] The assay is based on the monitoring of intracellular
Ca.sup.2+ concentrations using the PBX Calcium Assay Kit from BD
(Becton, Dickinson and Company) with calcium indicator dye
51-9000177BKa (BD, 640177). CHO cells expressing NCX1 were loaded
with the dye, and after a preincubation period with the test
compound, lonomycin (Calbiochem, 407950) was added. Ionomycin is an
ionophor for Ca.sup.2+ ions mediating an increase of intracellular
Ca.sup.2+ ions. Consequently, intracellular Ca.sup.2+ ions are
exchanged against extracellular Na.sup.+ ions (Ca.sup.2+ efflux,
forward mode). The decrease of intracellular Ca.sup.2+ ions was
detected by measuring the fluorescence of the calcium indicator dye
at a wavelength of 520 nm by a FLIPR device.
[0415] Briefly, similarly as for the reverse mode, for the forward
mode transport assay 18000 cells per well were seeded into a 96
well microplate (Corning COSTAR 3904) and incubated overnight in
culture medium (cf. above). A total volume of 100 .mu.l medium per
well was used. For the preparation of the FLIPR assay, the culture
medium was removed from the plates and 100 .mu.l of assay buffer
(133.8 mM NaCl (Sigma, 55886); 4.7 mM KCl (Sigma, P3911); 1.25 mM
MgCl.sub.2 (Merck, 1.05833.0250); 3.5 mM CaCl.sub.2 (Merck,
1.02083.0250); 5 mM glucose (Sigma, G7021); 10 mM Hepes (Sigma,
H4034); pH 7.4)) were added to each well in a washing step. Assay
buffer was removed, and 100 .mu.l of a solution of the test
compound in assay buffer in different concentrations were added
into the wells. Further, 100 .mu.l of dye solution (0.09% (v/v)
calcium indicator dye, 9.1% (v/v) signal enhancer (from PBX Calcium
Assay Kit); in assay buffer) were added into each well. The plates
were incubated in the dark at room temperature for 60 min.
Meanwhile a 10 .mu.M solution of lonomycin in assay buffer
(additionally containing 0.05% fetal calf serum (cf. above);
4.degree. C.) was prepared and stored in the wells of a 96 well
microplate (96 well microplate, polypropylene. U-shape (Greiner
Bio-One, 650201)). The fluorescence monitoring was performed at 60
measuring points with measurement intervals of 2 sec. After the
fifth measuring point, 50 .mu.l of the lonomycin solution were
added to each well of the assay plate to give a final lonomycin
concentration of 2 .mu.M. For the determination of the IC.sub.50
values the minimal fluorescence value was subtracted from the
maximal fluorescence value for the fifteenth to fifty-fifth
measuring points. The calculation of the IC.sub.50 values via the
percentage inhibitions of Ca.sup.2+ efflux out of cells (forward
mode) effected by the test compound was performed in Biost@t Speed
2.0. Results obtained with compounds of the invention are given in
Table 2. "NCX1fw IC.sub.50" in Table 2 means the IC.sub.50 value
(in .mu.M (micromol/liter)) for inhibition of NCX1 in forward
mode.
TABLE-US-00002 TABLE 2 IC.sub.50 values for inhibition of the NCX1
in forward mode by example compounds Example NCX1fw number
IC.sub.50 156 1.5 158 2.2 159 2.5 177 0.2 180 10 267 4.4 268 0.5
269 3.1 270 1.0 303 2.5
B) In Vivo Method for Determining the Effect on Heart
Contractility
[0416] Adult male Sprague-Dawley rats (Harlan Winkelmann, Borchen,
Germany) weighing 340 to 370 g were anesthetized with pentobarbital
(100 mg/kg i.p.) and ventilated with a mixture of oxygen (40%) and
room air (60%) at a tidal volume of 1 ml/100 g at 60 breaths/min.
Body temperature was maintained at 36.5.+-.0.3.degree. C. with a
heating lamp and was monitored with a rectal thermo sensor.
Systemic blood pressure was measured in the left carotid artery
using a pressure transducer (Combitrans; B. Braun Melsungen AG,
Melsungen, Germany) connected to a DC-bridge-amplifier (PLUGSYS/ADC
Type 663; Harvard Apparatus GmbH, March-Hugstetten, Germany). The
electrocardiogram was measured as lead II via subcutaneously placed
electrodes connected to a Heart-Rate-Module (PLUGSYS/HRM Type 669;
Harvard Apparatus GmbH, March-Hugstetten, Germany). A micro-tip
catheter (2 French, SPR-320; Millar Instruments, Houston, Tex.,
USA) was placed via the right carotid artery into the left
ventricle, and the left ventricular pressure (LVP) and the
enddiastolic pressure (EDP) were continuously measured.
Registration of the hemodynamic data was performed via an analog
digital converter by a personal computer using Notocord software
(HEM version 3.5). Left ventricular contractility (dp/dt.sub.max)
and relaxation (dp/dt.sub.min) were calculated from the LVP signal.
For intravenous administration of the test compounds, the left
jugular vein was prepared and a PP-50 catheter was inserted. Test
compounds were administered either by intravenous bolus injection
or by intravenous infusion by means of an infusion pump (Unita; B.
Braun Melsungen AG, Melsungen, Germany). Test compounds were
dissolved in a mixture of Glycofurol (75%) and Cremophor (25%), and
the solution was further diluted with distilled water (1:4). In a
typical experiment, several dosages of the test compound were
administered subsequently at increasing doses. Statistical
significance of the data obtained with drug vs control experiments,
in which solvent was administered, was evaluated with the 2-sided
ANOVA test (program Everstat). Increases in left ventricular
contractility (percent increase) by example compounds are given in
Table 3 in comparison to control experiments in which solvent was
administered.
TABLE-US-00003 TABLE 3 Increase in left ventricular contractility
by example compounds Dose Contractility Example (mg per kg of
increase number body weight) (%) 156 0.1 mg/kg 44% 0.3 mg/kg 110%
1.0 mg/kg 171% 158 0.1 mg/kg 106% 0.3 mg/kg 139% 1.0 mg/kg 146% 159
0.1 mg/kg 46% 0.3 mg/kg 104% 1.0 mg/kg 140% 177 0.1 mg/kg 29% 0.3
mg/kg 81% 1.0 mg/kg 134% 180 0.1 mg/kg 26% 0.3 mg/kg 66% 1.0 mg/kg
99% 268 0.1 mg/kg 108% 0.3 mg/kg 154% 1.0 mg/kg 179% 303 0.1 mg/kg
69% 0.3 mg/kg 114% 1.0 mg/kg 172%
* * * * *